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Abstract——In mammalian cells, the process of malig-
nant transformation is characterized by the loss or
down-regulation of tumor-suppressor genes and/or the
mutation or overexpression of proto-oncogenes, whose
products promote dysregulated proliferation of cells
and extend their life span. Deregulation in intracellular
transduction pathways generates mitogenic signals that
promote abnormal cell growth and the acquisition of an
undifferentiated phenotype. Genetic abnormalities in
cancer have been widely studied to identify those fac-
tors predictive of tumor progression, survival, and re-
sponse to chemotherapeutic agents. Pharmacogenetics
has been founded as a science to examine the genetic
basis of interindividual variation in drug metabolism,
drug targets, and transporters, which result in differ-
ences in the efficacy and safety of many therapeutic
agents. The traditional pharmacogenetic approach re-
lies on studying sequence variations in candidate genes
suspected of affecting drug response. However, these
studies have yielded contradictory results because of
the small number of molecular determinants of drug
response examined, and in several cases this approach
was revealed to be reductionistic. This limitation is now
being overcome by the use of novel techniques, i.e., high-
density DNA and protein arrays, which allow genome-
and proteome-wide tumor profiling. Pharmacogenomics
represents the natural evolution of pharmacogenetics
since it addresses, on a genome-wide basis, the effect of
the sum of genetic variants on drug responses of indi-
viduals. Development of pharmacogenomics as a new
field has accelerated the progress in drug discovery by
the identification of novel therapeutic targets by expres-
sion profiling at the genomic or proteomic levels. In
addition to this, pharmacogenetics and pharmacog-
enomics provide an important opportunity to select pa-
tients who may benefit from the administration of spe-
cific agents that best match the genetic profile of the
disease, thus allowing maximum activity.
I. Introduction
The aim of this review is to examine the current
understanding of the influence that the genetic profile of
non-small cell lung cancer, the most frequent cause of
cancer death in humans in the Western world, may have
on the effect of chemotherapeutic agents. The applica-
tion of the principles of pharmacogenetics by the use of
novel techniques may lead to increasing predictability of
drug response of the disease, with the aim of targeted
therapeutic intervention.
II. Clinical Relevance and Management of Non-
Small Cell Lung Cancer
Lung cancer is a leading cause of mortality among
men and women in the Western world, with 170,000
deaths per year. This exceeds the sum of the next three
leading causes of death due to breast, colon, and prostate
cancer. There are over one million deaths worldwide due
to malignant tumors of the lung, making it an epidemic
disease (Jemal et al., 2002). Lung cancer is a deadly
illness because of the low proportion of subjects (15%)
that are still alive 5 years after the initial diagnosis.
Patients with stage I disease (T1–2, N0, M0) may be
cured by optimal treatment, and 70% of them may
achieve a 5-year survival; unfortunately, most subjects
present with advanced disease, and this condition ad-
versely affects survival (Cortes-Funes, 2002; Ferreira et
al., 2002).
From a histological point of view, lung cancer is clas-
sified into non-small cell (NSCLC1) and small cell lung
cancer (SCLC); 80% are NSCLCs, including adenocarci-
nomas, squamous cell (epidermoid), and large cell carci-
nomas, and 20% are SCLCs (Rom et al., 2000).
1 NSCLC, non-small cell lung cancer; ABC, ATP-binding cassette;
Akt, AKR mouse T-cell lymphoma; ANA, abundant in neuroepithe-
lium area; APC/MCC, adenomatous polyposis coli/mutated in colon
cancer; BAT-26, mononucleotide microsatellite containing a 26-re-
peat adenine tract; CAAX, cysteine, aliphatic amino acid and any
amino acid; cdc2, cell division control kinase 2; cdc25B, cell division
control kinase 25B; CDK, cyclin-dependent kinase; CDKN2A, cyclin-
dependent kinase inhibitor 2A; CGH, comparative genomic hybrid-
ization; cM, centimorgan; Cox-2, type-2 inducible isoform of cycloox-
ygenase; CpG, cytidine phosphate guanosine; DAPK, death-
associated protein kinase; DMs, double minute chromosomes; DNA-
MTase, DNA-methyltransferase; EGF, epidermal growth factor;
EGFR, epidermal growth factor receptor; EMAST, elevated micro-
satellite alterations at selected tetranucleotide repeats; ERCC1, ex-
cision repair cross-complementing 1 gene, ERK, extracellular signal-
regulated kinase; FHIT, fragile histidine triad; FISH, fluorescence in
situ hybridization; GML, glycosyl-phosphatidyl-inositol-anchored
molecule-like protein; GSTP1, glutathione S-transferase P1 isoform;
GDP/GTP, guanosine diphosphate/triphosphate; HDAC, histone
deacetylase; hMLH1, human MutL homolog-1; hMSH3, human
MutS homolog-3; HSRs, homogeneously staining regions; hTERT,
human telomerase reverse transcriptase; IC50, 50% inhibitory con-
centration; IC80, 80% inhibitory concentration; ICE, interleukin-1-
converting enzyme; LOH, loss of heterozygosity; LRP, vault-trans-
porter lung resistance protein; LRP-DIT, lipoprotein receptor-related
protein-deleted in tumors; MALDI-TOF, matrix-assisted laser de-
sorption/ionization time-of-flight; MAPK, mitogen-activated protein
kinase; MDM2, mouse double minute 2; MDR1, multidrug resistance
1 gene; MEK, mitogen-activated protein kinase/extracellular signal-
regulated kinase kinase; MGMT, O6-methylguanine-DNA methyl-
transferase; MMP, matrix metalloproteinase; MRP, multidrug resis-
tance-associated protein; NER, nucleotide excision repair; PCNA,
proliferating cell nuclear antigen; P-gp, P-glycoprotein; PI3K; phos-
phatidylinositol 3-kinase; PKB, protein kinase B; PTEN/MMAC1,
phosphatase and tensin homolog deleted on chromosome 10/mutated
in multiple advanced cancers 1; RAR, retinoic acid receptor;
RASSF1, RAS effector homolog 1; RB, retinoblastoma tumor sup-
pressor gene; RER, replication-error-type instability; RPL14, ribo-
somal protein L14 gene; RT-PCR, reverse-transcriptase polymerase
chain reaction; RXR, retinoid X receptor; SCLC, small cell lung
cancer; SELDI-TOF, surface-enhanced laser desorption/ionization
time-of-flight; SNP, single nucleotide polymorphism; SROs, short
regions of the overlap of the deletions; TGF-, transforming growth
factor-; TGF-, transforming growth factor-; TGF-RII, trans-
forming growth factor- type II receptor; TNM, tumor, lymph node,
metastasis staging system; TRAIL-R2, tumor necrosis factor-related
apoptosis-inducing ligand receptor 2; TSLC1, tumor suppressor lung
cancer 1;VEGF, vascular endothelial growth factor; VNTR, variable
number of tandem repeats.
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Surgery is the recommended treatment; chemother-
apy and radiotherapy have a role either as a part of a
treatment strategy to cure locally advanced disease or as
a palliative therapy for metastatic tumors. In patients
with stages I and II NSCLC (T1–2, N1, M0) who cannot
be treated by surgery because of nontumor-related co-
morbidity, radiotherapy is the therapeutic approach of
choice. With standard radiotherapy, the survival at 3
and 5 years of patients with stage I disease is about 30
to 40% and 10 to 30%, respectively (Bonnet et al., 2001;
Jeremic et al., 2002), while the 2-year survival is 20% for
stage II disease. The prognosis of stage IIIA (T3, N0–1,
M0 or T1–3, N2, M0) and IIIB (any T4 or any N3, M0)
NSCLC is dismal, although still curable in some cases.
Survival at 5 years is about 5% in patients with N2
disease (involvement of ipsilateral or subcarinal medi-
astinal lymph nodes or ipsilateral supraclavicular
lymph nodes), and 50% in patients with T3 disease (tu-
mor involving the pleura, chest wall, diaphragm, or peri-
cardium) without lymph node involvement. Patients
with N3 (contralateral mediastinal hilar or supraclavic-
ular lymph node involvement) or T4 tumors (invasion of
mediastinal organs, malignant pleural effusion) are
treated with palliative intent (Malayeri et al., 2001).
Postoperative mediastinal radiation therapy has been
shown to significantly reduce the risk of local relapse
with no or little impact on survival (PORT Meta-analy-
sis Trialists Group, 1998), while adjuvant chemotherapy
is ineffective (Souquet and Geriniere, 2001). Preopera-
tive chemotherapy followed by surgery and postopera-
tive radiation therapy, in the case of incomplete resec-
tion, seems to be able to prolong disease-free and overall
survivals in comparison with surgery alone (Rosell et al.,
1994; Roth et al., 1994; Gandara et al., 2001; Rinaldi and
Crino`, 2001). Combined chemo-radiotherapy has a
strong rationale due to its potential synergistic effects,
although the results for locally advanced inoperable dis-
ease are still controversial and its feasibility before sur-
gery has been proven only in phase II trials, many of
them including stage IIIA-B patients (Lau et al., 2001).
The median survival of patients with metastatic
NSCLC treated with chemotherapy is in the range of 8
to 10 months. Standard chemotherapy consists of com-
bination regimens containing cisplatin, carboplatin, pac-
litaxel, docetaxel, gemcitabine, vinorelbine, ifosfamide,
and etoposide. However, recent randomized studies on
more than 2200 patients failed to show major differences
in response rates and survival among the combination of
cisplatin  gemcitabine, cisplatin  vinorelbine, and
cisplatin or carboplatin  paclitaxel or docetaxel (Table
1). According to the results reported, a response rate
exceeding 40% cannot be expected, irrespective of what
drug combination is administered; in addition to this,
the survival rate of patients older than 70 years of age
who are treated with chemotherapy not containing cis-
platin is similar to that of younger patients (Alberola et
al., 2001; Gridelli et al., 2001, 2002; Rodriguez et al.,
2001; Scagliotti et al., 2001; Van Meerbeeck et al., 2001)
(Table 1).
Chemotherapy has a role in the treatment of locally
advanced and metastatic NSCLC, either as a part of a
curative strategy or with palliative intent, although clin-
ical response to chemotherapy is still unsatisfactory,
particularly with respect to the complete response rate,
which is still low. Therefore, a better selection of pa-
tients and the identification of predictive factors of sen-
sitivity to chemotherapeutic agents are warranted.
Concerning locally advanced disease (stage IIIA-B),
resectability criteria are not uniformly accepted; thus,
the distinction between patients with resectable and
unresectable tumor may be difficult. Preoperative induc-
tion chemotherapy provides a response rate of approxi-
mately 60% and a downstaging to resectable disease in
44 to 65% of subjects (Felip and Rosell, 2002). Surgically
treated patients achieve a median survival of approxi-
mately 20 months and a long-term survival of 20 to 25%.
TABLE 1
Summary of selected randomized trials in advanced NSCLC
Authors Patients Chemotherapy ResponseRate
Median
Survival
1-Year
Survival
2-Year
Survival
% months % %
Rodriguez et al., 2001 408 Cisplatin  docetaxel 10.9 47 21
406 Carboplatin  docetaxel 9.1 38 16
404 Cisplatin  vinorelbine 10 42 14
Scagliotti et al., 2001 201 Cisplatin  vinorelbine 30 9.5 37
201 Carboplatin  paclitaxel 32 9.9 43
205 Cisplatin  gemcitabine 30 9.8 37
Van Meerbeeck et al., 2001 161 Paclitaxel  gemcitabine 27 6.9 26.5
160 Cisplatin  gemcitabine 26 8.8 33
159 Cisplatin  paclitaxel 31 8.1 36
Alberola et al., 2001 166 Cisplatin  gemcitabine 43 8.7 35
176 Cisplatin  gemcitabine  vinorelbine 39 7.9 31
175 Gemcitabine  vinorelbine 3 ifosfamide  vinorelbinea 26 8.1 35
Gridelli et al., 2001b 233 Vinorelbine 18.5 8.8 41
233 Gemcitabine 17.3 6.6 26
232 Gemcitabine  vinorelbine 20 7.6 31
a Sequential treatment with two regimens.
b Patients older than 70 years.
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Pathologically complete remissions are low and about
10% of patients will progress under induction chemo-
therapy (Rosell et al., 1994; Roth et al., 1994; Kumar et
al., 1996; Rinaldi and Crino`, 2001). Induction chemo-
therapy followed by full-dose radiotherapy is suitable for
patients with good performance status (Pottgen et al.,
2002), and preoperative radio-chemotherapy is suitable
for selected patients because of up to 10% morbidity and
mortality (Thomas et al., 1999). In patients with incom-
plete resection, postoperative radiotherapy may be ad-
ministered (Grossi et al., 2001; Pitz et al., 2002).
Radiotherapy is considered the standard treatment
for unresectable tumors; a total dose of at least 60 Gy
results in a survival of about 30% and 7% at 1 and 3
years, respectively (Cox et al., 1991; Baumann et al.,
2001). A meta-analysis study showed that the addition of
chemotherapy to radiotherapy has a marginal impact on
survival, with a hazard ratio of 0.94 and a 2% absolute
benefit at 2 and 5 years (Non-Small Cell Lung Cancer
Collaborative Group, 1995). An RTOG trial provided
evidence in support of simultaneous chemotherapy and
radiotherapy compared to sequential treatment (median
survival 17 versus 14.6 months), although the overall
results cannot be considered satisfactory (Werner-Wasik
et al., 2000). Finally, patient with stage IIIB disease
may be administered chemotherapy for palliative intent.
The vast majority of patients with metastatic NSCLC
(stage IV) die from disseminated cancer within two
years of follow-up. Since the survival benefit is small
and the prognosis is poor, the role of chemotherapy is
doubtful and it is not recommended as a standard treat-
ment in subjects in poor general condition (Non-Small
Cell Lung Cancer Collaborative Group, 1995; Socinski et
al., 2002). Standard chemotherapy mainly consists of
combination regimens containing cisplatin; a 27% reduc-
tion in the risk of death has been reported, equivalent to
an absolute improvement in survival of 10% or an in-
creased median survival of 1.5 months, and a lower
incidence of disease-related complications has been ob-
served (Non-Small Cell Lung Cancer Collaborative
Group, 1995; Manegold, 2001). Isolated symptomatic le-
sions, including bone metastases and spinal cord com-
pression, are treated with radiotherapy. Second-line
chemotherapy may be effective in some patients; do-
cetaxel produces good results in cisplatin-treated pa-
tients (Fossella et al., 1995; Kim et al., 2002), while
cisplatin-based chemotherapy after paclitaxel and gem-
citabine has been reported to be effective only in 20% of
those patients responsive to the first-line treatment and
in none with refractory disease (De Pas et al., 2001).
The assessment of the prognosis of patients with lung
cancer is essential for the choice of the best therapeutic
option. The major clinical prognostic determinant in
NSCLC is tumor extension; patients with advanced, un-
resectable NSCLC have a poor prognosis, with very few
5-year survivors and a median survival of less than 1
year. However, a large variability of clinical outcome
characterizes this subset of patients, some of them sur-
viving only a few weeks and some others several years.
Many prognostic factors have been recognized and are
currently being evaluated to support therapeutic deci-
sions. In patients with surgically resected stage I
NSCLC, the prognostic significance of a panel of tumor
markers, including ErbB-1/epidermal growth factor re-
ceptor (EGFR), HER-2/neu (ErbB-2), Bcl-2, p53, and
angiogenesis was evaluated. Statistical analysis demon-
strated that tumor extension represented the most pow-
erful prognostic factor for survival and time to recur-
rence, while increased EGFR expression was
significantly associated with a poorer survival (P 
0.02); none of the other immunocytochemical markers
was an independent predictive factor for survival (Pas-
torino et al., 1997). Furthermore, the immunohisto-
chemical analysis of protein expression profiles of 216
patients with NSCLC demonstrated that the expression
of nuclear oncoproteins fos and jun and of cyclin A were
decreased in carcinomas of patients with long-term sur-
vival (Volm et al., 2002).
The subgroup of patients with metastatic NSCLC is
heterogeneous, and the differentiation between patients
with single or multiple metastases has prognostic rele-
vance. Patients with a single metastasis, particularly in
the absence of mediastinal lymph node involvement,
have a better prognosis than patients with multiple
distant sites of disease. When a single brain metastasis
is the only site of first recurrence in patients free of
extracranial disease, a surgical approach with brain tu-
mor resection or stereotactic radiosurgery improves the
quality of life and offers a chance of long-term survival,
with a median survival of up to 27 months (Arbit et al.,
1995; Granone et al., 2001). Together with pretreatment
stage, performance status and weight loss are important
prognostic factors in advanced NSCLC (Paesmans et al.,
1995; Buccheri and Ferrigno, 2001). This reflects the
tumor biological profile, which in turn translates into
the aggressiveness of the disease. Moreover, patients
with poor performance status and severe weight loss are
unsuitable candidates for antitumor treatment and are
more susceptible to severe medical complications. Other
factors have a prognostic role in patients with NSCLC,
although not always confirmed in retrospective analy-
ses: among the others, it seems to be relevant to the
male gender, the presence of clinical symptoms (i.e.,
cough and hemoptysis), and elevated neutrophil count
(Paesmans et al., 1995; Martins and Pereira, 1999).
Stages I–IIIA NSCLC are potentially resectable; how-
ever, patients belonging to these groups are highly het-
erogeneous with respect to their prognosis, since the
5-year survival rate is about 80% for stage I and 20 to
30% for stage IIIA. For stage I, important independent
prognostic factors are the volume of primary tumor and
pretreatment serum lactate dehydrogenase (Feld et al.,
1997). Mediastinal lymph node involvement is an impor-
tant adverse prognostic factor, and the strongest predic-
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tor of long-term survival after surgery is the absence of
mediastinal neoplastic spread. Patients with metastatic
ipsilateral or subcarinal mediastinal lymph nodes or
ipsilateral supraclavicular lymph nodes (N2) are none-
theless a heterogeneous subgroup. Moreover, N2 lymph
node involvement has a different prognostic value if
clinically or pathologically detected. Patients with pre-
operative evidence of N2 disease have a worse prognosis
than patients with clinically undetectable involvement
(Andre et al., 2000). Moreover, the number of metastatic
mediastinal lymph nodes proved to be an independent
prognostic factor and was related to a significant differ-
ence in overall survival of surgically treated stage IIIA
NSCLC (Andre et al., 2000). Patients with single lymph
node metastasis showed a longer median survival than
patients with multiple lymph node involvement.
The spreading of tumor cells in the bone marrow of
patients with clinically localized NSCLC may be de-
tected by immunohistochemical analysis, and it is asso-
ciated with a poor prognosis (Pantel et al., 1996; Osaki et
al., 2002). Finally, histopathology has no prognostic
value and the importance of tumor cell differentiation is
controversial, while a poor prognosis is correlated with
lymphatic and vascular invasion and the expression of
mucin and a high mitotic index of cancer cells (Komaki
et al., 1998).
III. Genetic Instability and Gene Dysfunction in
Non-Small Cell Lung Cancer
Tumor evolution is a multistep process characterized
by the loss of function of cellular mechanisms that con-
trol normal proliferation and differentiation. It is esti-
mated that 10 to 20 genetic events, including the alter-
ation of oncogenes and tumor-suppressor genes, will
have occurred by the time a lung tumor becomes clini-
cally evident (Tran et al., 1998). Genetic instability is
the hallmark of cancer as a disease. It may be indicated
by a variety of cellular features at the chromosomal and
DNA levels. Evidence of DNA instability is represented
by the incidence of point mutations, deletions/insertions,
recombination, gene amplification, and microsatellite
instability, while at the chromosomal level it consists of
aneuploidy, translocations, deletions, sister chromatid
recombinations, fragile sites, homogeneously stained re-
gions, and double minute chromosomes (Sherbet and
Lakshmi, 1997).
A. Gene Amplification
Oncogene amplification is frequently detected in hu-
man cancer and it is characteristic of solid tumors, in-
cluding NSCLC. DNA amplification does not occur in
normal cells and it is maintained in cancer cells as a
result of selection. DNA amplification is observed with
cytogenetic methods as double minute chromosomes
(DMs) or homogeneously staining regions (HSRs), but
more recent technologies, including fluorescence in situ
hybridization (FISH) and comparative genomic hybrid-
ization (CGH), have substantially increased the ability
to detect such alterations (Imreh et al., 1997; Grompe et
al., 1998). DMs are episomal forms of amplified DNA
that generally lack centromeres and are unequally dis-
tributed between daughter cells at mitosis. In contrast,
HSRs are chromosomally integrated forms of amplified
DNA. They represent either the replacement of the nor-
mal chromosome banding pattern with an extended re-
gion of homogeneous staining or the insertion of such a
region into an otherwise normally banded chromosome
(Grompe et al., 1998). DMs and HSRs tend to be mutu-
ally exclusive and are potentially interchangeable man-
ifestations of amplified DNA; therefore, DMs can poten-
tially integrate into distant chromosomal sites to
generate heritable HSRs. DMs, and less frequently
HSRs or a combination of both, are found in approxi-
mately 17% of NSCLC (Imreh et al., 1997).
The vast majority of oncogene amplifications found in
human cancers affect the myc family; among them, c-
myc is amplified in 50% of NSCLC and it correlates
with the extent of lymph node metastasis (Kubokura et
al., 2001; Salgia and Skarin, 1998). Less frequent gene
amplification involves the cdc25B gene (40%) (Wu et al.,
1998), cyclin D1 (5%), and the EGFR gene (5.9%) (Re-
issmann et al., 1999), and HER-2/neu (2%) (Cox et al.,
2001).
B. Gene Mutation
Mutations are DNA sequence alterations that may
result in the disruption or abnormal activity of a gene or
the encoded protein. These include gene rearrange-
ments, deletions, insertions, and single-base changes.
Nonsense mutations result in the appearance of a stop
codon and premature termination during protein syn-
thesis, missense mutations are single-base substitutions
causing incorporation of an inappropriate amino acid
into a protein, and frameshift mutations shift the read-
ing frame of triplet codons in a gene during mRNA
translation (Grompe et al., 1998). Mutations that cause
the synthesis of structurally aberrant proteins usually
occur within the coding region of the gene, while those
that result in the production of abnormal amounts of the
protein may affect the 1) transcriptional machinery, 2)
regulatory regions (i.e., gene promoter), 3) RNA process-
ing (i.e., splicing alterations in the 5 untranslated re-
gion or 3 adenylation signals), or 4) translational ma-
chinery that controls initiation, elongation, and
termination of polypeptide chains (Grompe et al., 1998).
At variance with a mutation, a DNA polymorphism is a
sequence alteration stably expressed and found at a
frequency of 1% in a given population. The simplest
type is the single nucleotide polymorphism (SNP), a
single base difference between genome sequences that
occurs approximately every 1 kb in the human genome
(Grompe et al., 1998; Danesi et al., 2001). Additional
types of polymorphism are represented by the variable
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number of tandem repeats (VNTR, minisatellites), mul-
tiple copies of short repeats of DNA sequences (0.1–10
kb) distributed along the human genome, and the mic-
rosatellite repeats, a simpler but more common variant
of minisatellites, in which up to tetranucleotide repeats
are reiterated in multiple copies (Grompe et al., 1998).
Although point mutations are more commonly associ-
ated with loss of function (i.e., the TP53 gene), there are
notable examples of activating point mutations in a cel-
lular proto-oncogene; indeed, in approximately 30% of
human NSCLCs, the K-ras oncogene is mutated (Noda
et al., 2001). Mutations affecting the tumor-suppressor
gene TP53 may be associated with deregulation in te-
lomerase activity, which in turn may be important in the
process of lung tumorigenesis and low-grade differenti-
ation in NSCLC (Maniwa et al., 2001). The simultaneous
occurrence of TP53 gene mutation and high telomerase
activity may be relevant to the grade of malignancy in
lung tumors (Maniwa et al., 2001). In NSCLC, inactiva-
tion by point mutation of the CDKN2A (cyclin-depen-
dent kinase inhibitor 2A) gene, which encodes p16INK4a
(p16 inhibitor of kinase 4a), is observed in smokers,
whereas CDKN2A is inactivated in nonsmokers through
promoter hypermethylation (Sanchez-Cespedes et al.,
2001). Additional mutations observed in NSCLC involve
the tumor necrosis factor-related apoptosis-inducing li-
gand-receptor 2 (TRAIL-R2) gene (10.6% mutations),
mapped to chromosome 8p21–22 and encoding a cell-
surface receptor involved in cell death signaling (Lee et
al., 1999a), and the lipoprotein receptor-related protein-
deleted in tumors (LRP-DIT), a tumor-suppressor gene
that is inactivated by homozygous deletion or mutation
in at least 40% of NSCLC cell lines and thus may play an
important role in lung tumorigenesis (Liu et al., 2000).
C. Promoter Hypermethylation
Neoplastic cells simultaneously harbor diffuse
genomic hypomethylation, more regional areas of hyper-
methylation, and increased DNA-methyltransferase
(DNA-MTase) activity. Each component of this methyl-
ation imbalance may contribute to tumor progression.
Main targets of the regional hypermethylation are the
normally unmethylated CpG (cytidine phosphate
guanosine) islands located in gene promoter regions. In
particular, methylation of normally unmethylated sites
in the promoter regions of tumor-suppressor and DNA-
repair genes is correlated with loss of expression of these
genes in cancer cell lines and primary tumors (Baylin
and Herman, 2000). Methylation of the CpG islands in
the O6-methylguanine-DNA methyltransferase (MGMT)
prevents gene transcription, and cells cannot repair the
alkylation of O6-methylguanine (Qian and Brent, 1997;
Watts et al., 1997; Esteller et al., 1999a; Danam et al.,
1999). Furthermore, in vitro treatment with demethyl-
ating drugs restores the expression of MGMT (Qian and
Brent, 1997; Esteller et al., 2000).
DNA hypermethylation is associated with transcrip-
tional repression and represents an alternative to coding
region mutations for inactivation of tumor-suppressor
genes, including CDKN2A (p16INK4a). The hypermethyl-
ation of a promoter is an epigenetic phenomenon that
leads to its inactivation or down-regulation of gene tran-
scription (Baylin et al., 1998). CpG sequences are located
in the promoter regions of about 50% of all human genes;
in normal cells, unmethylated CpG islands are protected
from methylation on flanking regions, while in neoplas-
tic cells this protection is lost (Baylin et al., 1998;
Wistuba et al., 2001). Promoter hypermethylation has
relevance in the development of cancer, as it occurs at
the level of tumor-suppressor genes (Costello et al.,
2000; Wistuba et al., 2001). Promoter hypermethylation
is frequently detected in NSCLC, and the number of
CpG sequences that are methylated may be very large
(up to 4500) (Costello et al., 2000). The hypermethyl-
ation of promoter regions of CDKN2A (p16INK4a), death-
associated protein kinase (DAPK), GSTP1 (glutathione
S-transferase P1 isoform), and MGMT has been detected
in 68% of NSCLC, but not in surrounding normal tis-
sues. Moreover, 73% of patients with abnormal methyl-
ation patterns at the level of promoters also showed
circulating DNA with abnormal patterns of methylation,
while patients without methylation abnormalities did
not show the same alterations in circulating DNA, thus
suggesting that this finding is specific and may allow
genetic testing that may be useful for treatment selec-
tion and diagnosis of disease recurrence (Esteller et al.,
1999b). DAPK promoter hypermethylation is observed
in 44% of patients with stage I NSCLC; this genetic
abnormality predicts an adverse prognosis, as the 5-year
survival after surgical resection is significantly poorer
with respect to those patients without DAPK promoter
hypermethylation (Tang et al., 2000). Aberrant methyl-
ation of the CDKN2A (p16INK4a) tumor-suppressor gene
has been detected in the early stage of NSCLC. CDKN2A
(p16INK4a) has a relevant role in NSCLC carcinogenesis,
and its silencing has been detected at high frequency in
invasive and in situ tumors. In particular, CDKN2A
(p16INK4a) methylation is detected in 17% of basal cell
hyperplasia, in 24% of squamous metaplasia, and in 50%
of in situ carcinomas; this proportion further increases
(75%) in in situ carcinoma adjacent to invasive squa-
mous cell cancer (Belinsky et al., 1998). The RAS effector
homolog (RASSF1) gene has a putative role as a tumor-
suppressor gene in lung cancer; RASSF1 shows pro-
moter methylation at the CpG islands in 40% of NSCLC,
and loss of gene expression (Burbee et al., 2001). Finally,
promoter methylation also affects the retinoic acid re-
ceptor system, which plays an important role in cell
differentiation and lung development. Retinoids can
suppress carcinogenesis in preneoplastic bronchial le-
sions and their effects are mediated by nuclear recep-
tors, i.e., the retinoic acid receptors (RAR, RAR, and
RAR) and the retinoid X receptors (RXR, RXR, and
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RXR). Several reports indicate that loss of RAR ex-
pression, because of promoter hypermethylation, is as-
sociated with increased susceptibility to lung cancer.
The RAR gene promoter is hypermethylated in 41% of
NSCLC and is almost always unmethylated in control
normal samples (Virmani et al., 2001b). Loss of pro-
moter methylation in cell lines by in vitro treatment
with 5-aza-2-deoxycytidine restored RAR gene expres-
sion and cell growth (Virmani et al., 2001b).
D. Histone Deacetylation
Another mechanism of gene silencing is represented
by histone deacetylation. At variance with hypermeth-
ylation of gene promoter regions, histone deacetylation
modulates higher-order chromatin structure. The addi-
tion of an acetyl group on lysines is catalyzed by histone
acetyltransferase, while histone deacetylases remove
the acetyl groups. Steady-state histone acetylation is
controlled by the balance of both enzymatic activities;
hypoacetylated histones increase their positive charge,
condense the chromatin, and prevent gene transcription.
Conversely, hyperacetylated histones neutralize the
electrostatic charge and de-condense chromatin, thus
allowing gene transcription to proceed. Transcription
repressors, such as pRB, are associated with histone
deacetylases. Recent studies have revealed several en-
zyme isoforms in mammalian cells encoded by histone
deacetylase (HDAC) genes: HDAC1, HDAC2, HDAC3,
h-HDAC4, h-HDAC5, h-HDAC6, h-HDAC7, and HDAC8
(Hu et al., 2000). There is potential synergy between
inhibition of DNA methylation and histone deacetylase
activity in restoring silenced gene expression. Indeed,
depsipeptide, an inhibitor of histone deacetylase, acts
synergistically with 5-aza-2-deoxycytidine, a hypom-
ethylating agent inhibitor of DNA-MTase, in restoring
the expression of CDKN2A (p16INK4a) (Zhu et al., 2001a)
and inducing apoptosis in lung cancer cells (Zhu et al.,
2001b). Apoptosis represents a naturally occurring
mechanism of cell number regulation by deletion rather
than by inhibition of cell division; abnormally triggered
apoptosis also occurs after treatment with drugs that
induce irreversible cell damage, such as cytotoxic
agents, and also after withdrawal of hormones or growth
factors or treatment with selected cytokines (Sloviter,
2002). Transforming growth factor (TGF)- strongly in-
hibits epithelial cell proliferation through interaction
with the TGF- type II receptor (TGF-RII). Most
NSCLC cell lines have lost the growth-inhibitory re-
sponse to TGF- because of the loss of TGF-RII expres-
sion, which is dependent, at least in part, on histone
deacetylation (Osada et al., 2001). Finally, in vitro treat-
ment of cells with the demethylating agent 5-aza-2-
deoxycytidine and the histone deacetylase inhibitor tri-
chostatin A induces the cells to express hTERT (human
telomerase reverse transcriptase), suggesting a poten-
tial role for DNA methylation and/or histone deacetyla-
tion in negative regulation of hTERT (Devereux et al.,
1999). Agents that inhibit histone deacetylase in vitro
include hybrid polar compounds (Richon et al., 1998),
phenylacetate and phenylbutyrate (Samid et al., 1997),
and MS-27-275 (Saito et al., 1999). These agents induce
terminal differentiation in vitro as well as cell cycle
arrest and partial reversion of the malignant phenotype
in a variety of neoplasms, including NSCLC. For these
reasons, inhibitors of histone deacetylase have been de-
veloped and clinically tested. The administration of the
investigational agent CI-994 induced a partial response
lasting over 2 years in one patient with heavily pre-
treated adenocarcinoma of the lung and a stable disease
in an additional subject. Thrombocytopenia was the
dose-limiting toxicity at the maximum tolerated dose of
8 mg/m2/day for 8 weeks. Other toxicities included fa-
tigue and gastrointestinal effects such as nausea, vom-
iting, diarrhea, constipation, and mucositis (Prakash et
al., 2001).
E. Loss of Heterozygosity
Deletions of specific genes may occur during the de-
velopment of tumors. This mechanisms of tumorigene-
sis, called loss of heterozygosity (LOH) or allelic imbal-
ance, consists of the loss of an allele at a specific locus,
and it is of obvious importance if this deletion involves a
tumor-suppressor gene. Since the deletion involving
only one allele may be silent, a second somatic mutation
may consist of the loss of the entire chromosome, carry-
ing the residual normal allele, or a large portion of it, or
in the elimination of the normal gene by recombination
events that duplicate the mutant allele (Black, 1997). In
situations in which these events can be traced at the
DNA level, for example by monitoring restriction frag-
ment length or a cytidine-adenine repeat-type of poly-
morphism, the outcome is that the tumor appears to be
homozygous or hemizygous for markers in or close to the
relevant tumor-suppressor gene. The LOH is part of the
two-hit model of carcinogenesis (Knudson, 1971; Black,
1997). Cells containing a pair of chromosomes in which
a marker gene (e.g., retinoblastoma [RB]) is either ho-
mozygous wild-type or heterozygous have the same nor-
mal phenotype, demonstrating the recessive nature of
the mutant allele. Tumorigenesis will only ensue if both
copies of the gene are mutated (nonfunctioning) or de-
leted. In an individual who inherits a mutant copy from
one parent, only a single somatic mutation is needed to
lead to tumorigenesis. In subjects carrying two wild-type
alleles, both copies must sustain independent somatic
mutations (Black, 1997). The investigation of clinical
implications of allelic deletions at three common sites of
LOH in regions 5q21, 11p15.5, and 11p13 in 86 patients
with NSCLC demonstrated that LOH frequency at 5q21
was 20%, whereas LOH frequencies in 11p15.5 and
11p13 were 31% and 19%, respectively (Sanchez-Ces-
pedes et al., 1997). There was a significant correlation
between 5q21 LOH and mediastinal lymph node in-
volvement (P  0.03); however, no significant differ-
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ences were observed in median survival times in pa-
tients with 5q21 LOH as compared to the remainder (26
versus 37 months, P 0.33) or in patients with 11p LOH
(38 versus 32 months, P  0.72) (Sanchez-Cespedes et
al., 1997).
LOH for a locus on human chromosome 11q22–23
containing a putative tumor-suppressor gene is observed
at high frequency in patients with NSCLC (Pletcher et
al., 2001). LOH at the adenomatous polyposis coli/mu-
tated in colonic cancer (APC/MCC) locus, a tumor-sup-
pressor gene associated with both familial and sporadic
cancer, was observed in 83% of NSCLC cell lines (Vir-
mani et al., 2001a). It has been previously reported that
the incidence of LOH on chromosomes 2q, 9p, 18q, and
22q in advanced-stage NSCLC was significantly higher
than that in early stages (Shiseki et al., 1994, 1996).
These results indicate that tumor-suppressor genes on
chromosomes 2q, 9p, 18q, and 22q play an important
role in the acquisition of malignant phenotype in
NSCLC. However, the clinical implications and prognos-
tic impact of 2q, 9p, 18q, and 22q LOH have not been
established.
Transfer of chromosome 11 into the human A549
NSCLC cell line suppresses tumorigenesis, indicating
that LOH may be responsible, at least in part, for the
malignant phenotype and suggesting that multiple tu-
mor-suppressor genes are located in this chromosome. A
region of 700 kb on 11q23.2 of A549 cells also contains a
single gene, TSLC1 (tumor-suppressor lung cancer 1),
whose expression is reduced or absent in A549 and sev-
eral other NSCLC cell lines (Kuramochi et al., 2001).
Hypermethylation of the TSLC1 promoter would repre-
sent the second hit in NSCLC with LOH (Kuramochi et
al., 2001). A highly significant association between TP53
mutations and deletions on 3p, 5q, 9p, 11p, and 17p is
found in lung cancer (Zienolddiny et al., 2001). Further-
more, 86% of the tumors with concordant deletions in
the four most involved loci (3p21, 5q11–13, 9p21, and
17p13) had TP53 mutations as compared to only 8% of
the tumors without deletions at the corresponding loci
(Zienolddiny et al., 2001). The frequency of deletions was
significantly higher among smokers as compared to non-
smokers. This difference was significant for the 3p21.3
(human MutL homolog-1 [hMLH1] locus), 3p14.2 (frag-
ile histidine triad [FHIT] locus), 5q11–13 (human MutS
homolog-3 [hMSH3] locus), and 9p21 (D9S157 locus).
Deletions were more common in squamous cell carcino-
mas than in adenocarcinomas. Covariate analysis re-
vealed that histological type and TP53 mutations were
significant and independent parameters for predicting
LOH status at several loci (Zienolddiny et al., 2001). In
a study designed to identify the major tumor-suppressor
gene loci involved in the pathogenesis of lung cancer, 22
different regions with more than 60% LOH were identi-
fied: 1) 13 regions with a preference for SCLC, 2) 7
regions with a preference for NSCLC, 3) 2 regions af-
fecting both SCLC and NSCLC (Girard et al., 2000). The
chromosomal arms with the most frequent LOH were
1p, 3p, 4p, 4q, 5q, 8p, 9p (p16), 9q, 10p, 10q, 13q (RB),
15q, 17p (TP53), 18q, 19p, Xp, and Xq (Girard et al.,
2000). In addition, new homozygous deletions were
found at 2p23, 8q24, 18q11, and Xq22. On average, 36%
of markers showed allele loss in individual NSCLC tu-
mors, with an average size of subchromosomal region of
loss of five to six markers. SCLC and NSCLC had dif-
ferent regions of frequent LOH (hot spots), and NSCLC
had more of these regions (n  22) than SCLC (n  17)
(Girard et al., 2000). Finally, in lung cancer cell lines, at
least 17 to 22 chromosomal regions with frequent allele
loss are involved, suggesting that the same number of
putative tumor-suppressor genes is inactivated. In addi-
tion to this, SCLC and NSCLC frequently undergo dif-
ferent specific genetic alterations, and clusters of tumor-
suppressor genes are likely to be inactivated together
(Girard et al., 2000). Lung metaplastic and alveolar hy-
perplastic lesions with atypia show genetic alterations,
including LOH of 3p, 9p, and mutations of the TP53
gene. The analysis of microsatellite markers showed
that 5 of 35 cases of squamous cell carcinoma and 3 of 26
cases of adenocarcinoma showed LOH in both preneo-
plastic lesions and synchronous cancers (Kohno et al.,
1999). Nine patients (25.7%) with squamous cell carci-
noma and 6 patients (23.1%) with adenocarcinoma had
mutations involving TP53; in 2 patients with squamous
cell carcinoma, the same mutation was observed in both
dysplasia and squamous cell carcinoma (Kohno et al.,
1999). These findings suggest that several genetic alter-
ations may occur in preneoplastic lesions or in the early
stage of squamous cell carcinoma of the lung, whereas
they occur relatively late in the pathogenesis of adeno-
carcinoma (Kohno et al., 1999).
The analysis of surgically resected NSCLC specimens
for LOH at 3p25–26, 3p21, 3p14, 5q, 11p, 17q, and 18q
demonstrated that, with respect to pRB, p16INK4a, and
p53, the tumors could be grouped into four categories:
normal for all three proteins (21%); abnormal for pRB or
p16INK4a and normal for p53 (30%); normal for pRB and
p16INK4a and abnormal for p53 (20%); and abnormal for
all three proteins (28%) (Geradts et al., 1999). An aber-
rant expression of pRB, p16INK4a, p53, and 3p LOH,
either individually or in combination, was not associated
with survival differences or any other clinical parame-
ters, with the exception that pRB and p16INK4a abnor-
malities were more common in older patients. pRB and
p16INK4a expression showed a strong inverse correla-
tion, whereas there was no relationship between the
expression of pRB, p16INK4a, and p53 (Geradts et al.,
1999). An abnormal expression of any of the three genes
inversely correlated with K-ras mutations at codon 12
(P  0.004), but not with LOH at 3p or at other loci.
Therefore, NSCLCs show distinct patterns of tumor-
suppressor gene inactivation, but no clear clinical corre-
lates exist either alone or in combination for pRB,
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p16INK4a, p53, and 3p abnormalities (Geradts et al.,
1999).
In an effort to identify regions containing novel cancer
genes, chromosome 18p11 was examined for LOH in
matched normal and NSCLC tumor samples by using
18p11 and 18q12.3 polymorphic markers (Tran et al.,
1998). This analysis revealed two regions of LOH in
18p11 in up to 38% of the tumor samples examined. The
regions of LOH identified included a region between
D18S59 and D18S476 markers, and a more proximal
region of intermediate frequency between D18S452 and
D18S453 (Tran et al., 1998). These results provide evi-
dence for the presence of one or more tumor-suppressor
genes on the short arm of chromosome 18, which may be
involved in NSCLC (Tran et al., 1998). Deletions in the
5q14 region have been described in a variety of neo-
plasms, including lung cancer. The high frequency of
allelic losses observed in this region implies the presence
of putative tumor-suppressor genes. In a series of 56
NSCLCs the allelic imbalance within the 5q14 region
and its relationship with p53 abnormalities, kinetic pa-
rameters, proliferation and apoptotic index, and the
ploidy status of tumors revealed that an allelic imbal-
ance at D5S644 was found at a frequency of 51.2%
(Gorgoulis et al., 2000). LOH at 5q14 was associated
with a low apoptotic index, suggesting the presence of
putative tumor-suppressor genes. Simultaneous alter-
ations of both p53 and D5S644 loci were the most fre-
quent pattern observed (37.5%) (Gorgoulis et al., 2000).
These findings imply a synergistic mechanism of coop-
eration between different tumor-suppressor genes. How-
ever, proliferation activity was dependent only on p53
status, leading to the assumption that the putative tu-
mor-suppressor genes present at 5q14 may be involved
in apoptotic pathways (Gorgoulis et al., 2000). The use of
microsatellite markers at 3p14, 9p21, and 10q24 to an-
alyze tumor samples from 91 patients with pathological
stage I NSCLC demonstrated that LOH at any single
locus was not significantly associated with survival
(Zhou et al., 2000). The analysis of LOH on a panel of
102 NSCLC samples with 20 polymorphic markers evi-
denced two short regions of the overlap of the deletions
(SROs): SRO2a (D1S417-D1S57) and SRO2b (D1S450-
D1S243). Allelic losses at either region located on 1p32-
pter correlated independently with an advanced stage of
disease and with postoperative metastasis and relapse,
suggesting that crucial genes in these regions are in-
volved in NSCLC progression (Chizhikov et al., 2001).
The short arm of chromosome 3 is thought to harbor an
oncogenic locus that is important in lung carcinogenesis
because of its sensitivity to loss by the action of carcin-
ogens and evidence of frequent deletion in lung cancer.
Of 219 lung cancers, 44.2% of squamous cell carcinomas
and 30.2% of adenocarcinomas showed 3p21 LOH, its
prevalence being higher in p53 mutated cases (Hirao et
al., 2001). The analysis for LOH at chromosome 3p24 in
samples of normal and tumor tissues from the lungs of
76 patients with NSCLC revealed that RXR, RAR,
and RAR gene expression was decreased in 18%, 63%,
and 41% of tumor specimens (Picard et al., 1999). LOH
at 3p24 was observed in 41% of tumor samples and in
20% of non-neoplastic lesions. Therefore, a large per-
centage of tumors shows a marked decrease in the ex-
pression of RXR, RAR, and RAR, and a high fre-
quency of LOH at 3p24, which is also observed in non-
neoplastic lesions (Picard et al., 1999). These data
suggest that altered retinoid receptor expression may
play a role in lung carcinogenesis (Picard et al., 1999).
LOH at chromosome 3p24, which hosts RAR, was ob-
served in 100% (13 of 13) of SCLC cell lines and 67% (12
of 18) of NSCLC cell lines, and the difference was sta-
tistically significant (Virmani et al., 2001b). Abnormal-
ities of FHIT, the tumor-suppressor gene located at
3p14.2, have been found in NSCLC. Analysis of a subset
of 76 specimens of stage I NSCLC, in which microsatel-
lite analysis at the FHIT locus was performed, did not
show a strong association between LOH at 3p14.2 and
pFHIT expression, suggesting the presence of complex
mechanisms of gene inactivation (Tseng et al., 1999).
However, loss of FHIT was significantly higher in bron-
chial metaplastic lesions (47%) than in histologically
normal bronchial epithelium (20%), and pFHIT expres-
sion was significantly reduced in a substantial number
of early-stage NSCLC and preneoplastic lesions in
chronic smokers (Tseng et al., 1999).
In stage I NSCLC, allelic imbalance is observed on 2q,
9p, 18q, and 22q in 22, 38, 29, and 15% of cases, respec-
tively, whereas p53 is mutated in 41% of stage I
NSCLCs (Tomizawa et al., 1999). Allelic imbalance on
9p and 22q, and p53 mutations, were significantly asso-
ciated with shortened survival of the patients (Tomi-
zawa et al., 1999). These results indicate that clinical
aggressiveness of early-stage NSCLC is associated, at
least in part, with the presence of allelic imbalance on
chromosome 9p, which could be a clinically useful prog-
nostic indicator (Tomizawa et al., 1999). Allelotyping
studies suggest that allelic losses at one or both arms of
chromosome 4 are frequent in several tumor types. The
analysis of clinical specimens and NSCLC cell lines by
using 16 polymorphic microsatellite markers showed
LOH at three nonoverlapping regions: 1) 4q33–34 (R1),
2) 4q25–26 (R2), and 3) 4p15.1–15.3 (R3) in about 20 to
30%, with no differences between tumors and cell lines,
the loss of R3 alone being the most frequent pattern
(Shivapurkar et al., 1999). LOH may occur in 83% of
NSCLCs with chromosomal duplication, suggesting that
the duplicated chromosome is homozygous; these find-
ings imply that LOH occurs before chromosomal dupli-
cation during lung carcinogenesis (Varella-Garcia et al.,
1998). LOH on chromosome 11q23 is observed at high
frequency in NSCLC, suggesting the presence of a tu-
mor-suppressor gene (Murakami et al., 1998). Allelotyp-
ing of NSCLC and SCLC cell lines demonstrated signif-
icant differences in LOH frequencies between NSCLC
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and SCLC at 13 regions on 8 chromosome arms (3p, 5q,
6q, 9p, 10q, 11p, 13q, and 19p). Eight homozygous dele-
tions were present in seven cell lines at four regions,
3p12, 3p14.2, 9p21, and 10q23–25. In addition to this,
there was LOH at 6p21.3 and 13q12.3 in NSCLC (Vir-
mani et al., 1998). The frequent occurrence of 21q dele-
tions in human NSCLC indicates the presence of a tu-
mor-suppressor gene on this chromosome arm. The ANA
(abundant in neuroepithelium area) gene, a member of
an antiproliferative gene family, is mapped to 21q11.2-
q21.1 and was homozygously deleted in the human
Ma17 NSCLC cell line. LOH at this locus was detected
in 24 of 47 (51.1%) NSCLCs, and the frequency of LOH
in brain metastases was significantly higher than that
in stage I–II primary tumors. These data suggest that
the homozygously deleted region harbors a novel tumor-
suppressor gene involved in NSCLC progression (Kohno
et al., 1998). The PTEN/MMAC1 (phosphatase and ten-
sin homolog deleted on chromosome 10/mutated in mul-
tiple advanced cancers) is a candidate tumor-suppressor
gene recently identified at chromosomal band 10q23.
Microsatellite analysis revealed LOH at markers near
the gene in 50% of 42 primary NSCLCs. These results
suggest that PTEN/MMAC1 gene inactivation plays a
role in the genesis of some tumor types (Okami et al.,
1998). In a cohort of 87 NSCLCs, LOH was investigated
by using dinucleotide repeat sequences from chromo-
somal locations 1p, 3p, 5q, 8p, 9p, 10p, 11p, 13q, and 17q.
In 28% (24 of 87) of NSCLCs, LOH in at least one locus
was detected. The frequency of LOH differed between
the various cell types of NSCLC. The highest frequency
was seen in large cell carcinoma (3 of 6, 50%) followed by
squamous cell carcinoma (16 of 43, 37%) and adenocar-
cinoma (5 of 35, 14%), and the most common site of LOH
was 3p (Pylkkanen et al., 1997). The TGF-RII gene has
been mapped to chromosome 3p, on which LOH was
frequently detected in NSCLC; however, TGF-RII mu-
tations were not found in NSCLC with LOH on chromo-
some 3p (Tani et al., 1997). Deletions involving the chro-
mosome 9p21 region, which also harbors the tumor-
suppressor locus CDKN2A, have been reported as
frequent events in NSCLC. LOH at a marker proximal
to the CDKN2A locus was found most frequently (52%),
while LOH at a marker closest (5 kb) to the CDKN2A
gene was seen in only 17% of tumors (Mead et al., 1997).
A homozygous loss of markers close to CDKN2A was,
however, detected in 2 of 3 cell lines and one accompa-
nying tumor sample. Therefore, a tumor-suppressor
gene in the region of deletion proximal to the CDKN2A
gene within 9p21 may play a significant role in the
pathogenesis and progression of NSCLC (Mead et al.,
1997). LOH in the TP53 locus was found in 9 of 38
(23.6%) cases. A trend was found between p53-positive
immunostaining and a history of heavy smoking, and
was inversely correlated with LOH at the TP53 locus
(Liloglou et al., 1997). High LOH on chromosome arms
3p, 9p, and 17p is a common event in NSCLC. LOH was
observed at a frequency of 38% on 3p, 58% on 9p, and
38% on 17p. Polarization of the LOH on chromosome
arms 3p, 9p, and 17p was observed such that 80%
showed loss on 3p, 80% on 9p, and 73% on 17p (Field et
al., 1996). LOH on chromosome arms 3p, 13q, and 17p
was detected frequently (60%) in both stage I primary
lung tumors and brain metastases, whereas the inci-
dence of LOH on chromosome arms 2q, 5q, 9p, 12q, 18q,
and 22q was higher than 60% only in brain metastases.
In particular, the incidence of LOH on chromosome arms
2q, 9p, 18q, and 22q in brain metastases was signifi-
cantly higher than that in stage I primary lung tumors
(Shiseki et al., 1996). These results indicate that tumor-
suppressor genes on chromosome arms 3p, 13q, and 17p
are involved in the genesis of NSCLC, whereas those on
several chromosome arms, especially on 2q, 9p, 18q, and
22q, play an important role in the progression of NSCLC
(Shiseki et al., 1996). High-density polymorphic marker
analysis throughout 11p15.5 confirmed the presence of
two distinct regions of LOH for NSCLC in 11p15.5. In 9
of 13 (69%) tumors with LOH, allelic deletion was re-
stricted to 11p15.5, indicating that whole chromosome
11 loss is not a common event in NSCLC and suggesting
that chromosome band 11p15.5 harbors a minimum of
three separate loci (Tran and Newsham, 1996).
3p21 Loss appears, so far, to be the most frequent and
the earliest genetic alteration described in NSCLC, but
it does not seem to carry significant prognostic informa-
tion in invasive tumors (Thiberville et al., 1995). The
short arm of chromosome 17, which contains the p53
gene, is frequently affected by LOH in lung cancer. The
frequency of LOH at 17q is 42%, approaching that at 17p
(54%), and two distinct 17q regions are implicated. LOH
at D17S4 on 17q is more frequent in adenocarcinomas
than in squamous cell carcinomas, whereas squamous
cell carcinomas had more LOH at 17p than at 17q,
indicating a molecular genetic heterogeneity between
the major NSCLC subtypes. In addition, LOH at 17q
correlates with higher tumor stages and a significantly
worse prognosis. In comparison, 25% of cases have mu-
tations at TP53 exons 5–8, but these are not associated
with tumor stage or survival (Fong et al., 1995a). LOH
at the APC/MCC gene cluster at chromosome 5q21 oc-
curs frequently in NSCLC; it affects 29% of NSCLC and
it is significantly correlated with worse survival. Fur-
thermore, in squamous cell carcinoma, LOH at 5q not
only correlated with a short survival, but also with tu-
mor involvement of the mediastinal and/or hilar lymph
nodes (Fong et al., 1995b). In contrast, LOH at chromo-
some 18q was far less frequent, occurring in 14% of
NSCLC cases, and it was not associated with advanced
stage or adverse prognosis. These data suggest that
LOH at 5q has a role in determining tumor progression
and survival in NSCLC, and may prove to be a clinically
useful prognostic indicator (Fong et al., 1995b).
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F. Microsatellite Alteration
Microsatellites are repetitive nucleotide sequences of
varying lengths, which occur in the human genome,
between and within genes (Eshleman et al., 1996; Sher-
bet and Lakshmi, 1997). Microsatellite sequences (also
called microsatellite markers) are unstable because of
variations that can occur in repetitive sequence units,
resulting in the expansion or shortening of them. The
instability of microsatellite loci contributes to the muta-
tor phenotype of cancer and provides an explanation of
the high incidence of mutations compared to normal
cells (Loeb, 1994). The instability of microsatellites can
affect nonrepetitive sequences of the DNA, and the di-
rect consequence is the generation of a ladder-like motif
that replaces the normal allele pattern of the human
genome (Wistuba et al., 2001). A majority of microsatel-
lite repeats occur outside the coding regions of genes;
therefore, microsatellite instability may not directly
lead to carcinogenesis, but could destabilize DNA se-
quences inside and outside the microsatellite repeats
and make the genome hypermutable. As a corollary, one
should consider the possibility that microsatellite insta-
bility might be engendered by exposure to carcinogens.
Microsatellite instability was found in about one-third of
NSCLC, with a substantial difference between meta-
static lesions (55%) and primary disease (12%) (Adachi
et al., 1995), thus suggesting a possible direct relation-
ship between microsatellite instability and cancer pro-
gression. It has been recently observed, however, that
microsatellite instability, defined as the change in the
number of short-tandem DNA repeats, is not common in
NSCLC, while the microsatellite alteration, where a sin-
gle band of altered size is found, has been described in 2
to 49% of NSCLC (Sekido et al., 1998; Wistuba et al.,
2001). By using 16 markers on chromosomes 3p and 9p,
microsatellite alteration is found in 7 of 20 histologically
normal lung tissue specimens at a frequency similar to
that observed in NSCLC tumor tissue (8 of 20). Five
cases showed microsatellite alteration in both normal
lung tissue and the corresponding tumor (Park et al.,
2000). In 2 of 12 patients microsatellite alteration was
detected in normal lung tissue while the tumor was
negative. These results indicate that genetic alterations
are widely distributed in the lung tissue of patients with
lung cancer (Park et al., 2000).
The short arm of chromosome 3 is thought to harbor
an oncogenic locus involved in the pathogenesis of
NSCLC. The region at 3p21 is believed to contain a
distinct locus that is sensitive to loss from the action of
tobacco smoke carcinogens, and has been reported to be
specifically targeted for deletion in lung cancer. A recent
study examined the LOH on chromosome 3 at 3p21 in
NSCLC and the microsatellite alteration at the BAT-26
locus because the mismatch DNA repair gene, hMLH1,
is found at 3p21 (Hirao et al., 2001). Instability of
BAT-26 was not found, while LOH at 3p21 was detected
in 44.2% of squamous cell carcinomas and 30.2% of
adenocarcinomas and was frequently associated with
TP53 mutations (Hirao et al., 2001). Using a panel of 12
markers, microsatellite instability was detected in 24 of
47 (51%) NSCLC and 10 of 18 (56%) head and neck
cancers, but was only observed in 8 of 38 (21%) bladder
and 3 of 25 (12%) kidney cancers (Xu et al., 2001). The
results of this study suggest that about 50% of respira-
tory tract cancers exhibit microsatellite instability, pre-
dominantly at AAAG sequences. This distinct type of
instability is termed EMAST (elevated microsatellite
alterations at selected tetranucleotide repeats) and the
identification of markers with EMAST may prove useful
for the molecular detection of respiratory tract cancers
(Xu et al., 2001). Microsatellite instability was observed
in 5 of 7 NSCLC cell lines and 3 of 21 NSCLC tissues
(Kim et al., 2000). Microsatellite instability was highly
associated with TGF-RII frameshift mutations (75%),
thus supporting the hypothesis that TGF-RII plays an
important role in NSCLC carcinogenesis (Kim et al.,
2000). Among 91 patients with stage I NSCLC, 32% of
subjects whose tumors had microsatellite instability at
10q24 died of the disease within 5 years after surgery,
compared with 16% without microsatellite instability at
10q24 (Zhou et al., 2000). Seventy-one percent of pa-
tients with lung adenocarcinoma and microsatellite in-
stability at 10q24 died because of disease progression,
compared with 12% without microsatellite instability,
indicating the presence of distinct mechanisms in tu-
morigenesis among different subtypes of lung cancer
(Zhou et al., 2000). Of 23 patients who had microsatellite
instability at 10q24 and 3p14, 39% died of the disease
within 5 years as compared with 15% of the patients
without such a profile (Zhou et al., 2000). Furthermore,
among the 22 patients with no alteration at any loci
tested, none died of lung cancer within 5 years after
surgery, whereas 28% of the patients outside these pro-
files died of the disease (Zhou et al., 2000). These results
support the hypothesis that microsatellite alterations
can be used as biomarkers for the genetic classification
of stage I NSCLC, which may in turn influence treat-
ment decisions (Zhou et al., 2000). Microsatellite alter-
ation may also be detected in the DNA of cells in bron-
choalveolar lavage fluid from patients with resectable
NSCLC; indeed, microsatellite instability was observed
in NSCLC tissue in approximately 50% of patients; the
identical alteration was shown in the bronchoalveolar
lavage fluid of 14% of the corresponding patients (Ahr-
endt et al., 1999).
Chromosome 3p is consistently deleted in lung cancer,
and it is believed to contain several tumor-suppressor
genes. The role of chromosome 3 in tumor suppression
has been confirmed by isolation of the human homolog of
the ribosomal protein L14 gene (RPL14) located at
3p21.3 (Shriver et al., 1998). The RPL14 sequence con-
tains a highly polymorphic trinucleotide repeat that en-
codes a variable-length polyalanine tract (Shriver et al.,
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1998). Genotype analysis of RPL14 shows that this locus
is 68% heterozygous in the normal population compared
with 25% in NSCLC cell lines. Cell cultures derived from
normal bronchial epithelium show a 65% level of het-
erozygosity, reflecting that of the normal population
(Shriver et al., 1998). In additional studies, microsatel-
lite instability at one or more loci was observed in 13
(36%) of 36 cases of resected NSCLC (19 cases of squa-
mous cell carcinoma, 15 of adenocarcinoma, and 2 of
large cell carcinoma) (Kim et al., 1998a). Six tumors
showed instability in a single microsatellite, three tu-
mors had alterations in three of four tested microsatel-
lites, and the microsatellite that showed instability most
frequently in these tumors was D3S1340 (31%) (Kim et
al., 1998a). Furthermore, microsatellite instability was
found in 24% of 17 cancers at stage I, in 17% of 6 tumors
at stage II, in 73% of 11 tumors at stage IIIA, and in
none at stage IIIB; overall, microsatellite instability was
observed in at least one-third of NSCLC (Kim et al.,
1998a). A set of 11 microsatellite loci spanning 1p was
used to examine the frequency of allelic imbalance in a
panel of 58 tumors; 87.9% of 58 cases had somatic allelic
loss at one or more loci tested. Two SROs have been
identified: SRO1 at 1p13.1 and SRO2 at 1p32-pter
(Gasparian et al., 1998). Allelic losses at these regions
have been compared among adenocarcinomas and squa-
mous cell carcinomas, and no difference has been found.
On the contrary, SRO2 deletions significantly correlated
with advanced stage of the disease and postoperative
disease recurrence (Gasparian et al., 1998). These data
may suggest that SRO1 and SRO2 harbor tumor-sup-
pressor genes involved in different stages of NSCLC
development (Gasparian et al., 1998). The comparison of
DNA from human tumor and normal bronchial mucosa
with respect to microsatellite instability and LOH on
chromosome 17p, 17q, 9p, and 9q, using 10 polymorphic
markers, was performed on biopsies and tissue speci-
mens obtained from the tumor and paired normal bron-
chial mucosa in 20 patients with NSCLC (Froudarakis
et al., 1998). Sixteen of 20 tumors (80%) displayed ge-
netic alterations; 30% of tumors exhibited microsatellite
instability, 25% exhibited LOH, and 25% of tumors
showed microsatellite instability and LOH (Froudarakis
et al., 1998). No relationship was found between LOH or
microsatellite instability and the histologic subtype of
NSCLC or disease stage. These results suggest that
genetic alterations have a role in carcinogenesis as they
exist in all stages and histologic subtypes of NSCLC
(Froudarakis et al., 1998). In a cohort of 379 women with
NSCLC, microsatellite instability was observed more
frequently in patients with three or more relatives with
cancer (6 of 9, 67%) than in control patients (5 of 28,
18%; P  0.011) (Suzuki et al., 1998). Thus, a signifi-
cantly higher rate of microsatellite instability is associ-
ated with familial clustering of malignancy (Suzuki et
al., 1998). The replication-error-type instability (RER)
is a frequent genetic alteration in stage I NSCLC. RER
at one or both chromosomes 2p and 3p was identified in
24 of 35 patients; 9 patients showed LOH (Rosell et al.,
1997). A statistically significant correlation was found
between RER and poor prognosis; furthermore, RER
proved to be an independent factor that predicted de-
creased survival (Rosell et al., 1997). These data suggest
that RER is common in NSCLC, and it may provide
important prognostic information in stage I NSCLC
(Rosell et al., 1997).
G. Protein Phosphorylation
Reversible protein phosphorylation has emerged as
the predominant mechanism of control of protein activ-
ity in eukaryotic cells in response to environmental sig-
nals, mainly related to cell proliferation. The phosphor-
ylation of specific proteins, which is under the control of
two families of enzymes known as protein kinases and
phosphatases, provides signal amplification. Since more
than 10% of proteins in a normal mammalian cell are
thought to be regulated through phosphorylation, this
aspect of proteomics is gaining significant interest. Ab-
normal protein phosphorylation is the basis for or the
result of major diseases, including cancer. Mutations in
protein kinases and phosphatases or in regulatory genes
result in a number of hereditary disorders, including
leukemias and lymphomas (Shapiro et al., 1995). Exces-
sive activity of kinases under the control of growth-
promoting genes is the apparent mechanism responsible
for inactivation of tumor-suppressor gene products, in-
cluding pRB. Indeed, cyclin-dependent kinase (cdk)4-
mediated phosphorylation of pRB is stimulated by cyclin
D1, an oncogene, and inhibited by p16INK4a, the product
of the tumor-suppressor gene CDKN2A (Shapiro et al.,
1995). NSCLC is predominantly pRB-positive and most
tumor specimens and cell lines overexpress cyclin D1,
indicating that cyclin D1 overexpression and RB inacti-
vation coexist (Shapiro et al., 1995). Furthermore, pRB-
positive NSCLC cell lines have absent or low p16INK4a,
and in primary lung resection specimens p16INK4a was
undetectable in 18 of 27 NSCLC samples. These data
confirm the dependence of pRB inactivation on p16INK4a
expression (Shapiro et al., 1995).
To evaluate the role of Akt/PKB (AKR mouse T-cell
lymphoma/protein kinase B) in the survival of patients
with NSCLC, a panel of NSCLC cell lines that differed
with respect to tumor histology and p53, pRB, and p21K-
ras status were examined. Constitutive Akt/PKB activ-
ity was demonstrated in 16 of 17 cell lines (Brognard et
al., 2001). Akt/PKB activation was dependent on phos-
phatidylinositol 3-kinase (PI3K) and promoted survival
because wortmannin, a PI3K inhibitor, suppressed Akt/
PKB phosphorylation and increased apoptosis only in
cells with activated Akt/PKB (Brognard et al., 2001). To
test whether Akt/PKB is involved in drug resistance,
tumor cells were exposed to conventional anticancer
agents in combination with the phosphatidyl-inositol
3-kinase inhibitor LY294002. LY294002 potentiated
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chemotherapy-induced apoptosis in cells with high Akt/
PKB levels, but was ineffective in cells with low Akt/
PKB levels (Brognard et al., 2001). Transfecting consti-
tutively active Akt/PKB into cells with low Akt/PKB
activity attenuated chemotherapy- and radiation-in-
duced apoptosis (Brognard et al., 2001). Thus, Akt/PKB
is a constitutively active kinase that promotes survival
of NSCLC cells, and modulation of its activity by phar-
macological or genetic approaches alters the cellular
sensitivity to chemotherapeutic agents used to treat pa-
tients with NSCLC (Brognard et al., 2001).
IV. Genetic Abnormalities in Non-Small Cell
Lung Cancer
Multistep tumorigenesis is the process by which ge-
netic events accumulate over time and result in malig-
nant transformation. It is estimated that approximately
10 to 20 alterations of tumor-suppressor genes and/or
proto-oncogenes are required for lung tumorigenesis.
Numerous alterations have been identified that occur
frequently in NSCLC. These include RAS proto-onco-
gene mutations, TP53 gene mutations, inactivation of
the RB gene, and alterations in CDKN2A, HER-2/neu,
MYC, Bcl-2, and FHIT (Table 2).
A. RAS
The product of the RAS gene (p21ras) regulates trans-
duction of growth-proliferative signals from the mem-
brane to the nucleus, and mutationally activated RAS is
found in 25 to 48% of NSCLC. The p21ras proteins bind
to and hydrolyze GTP by means of their intrinsic GT-
Pase activity. Point mutations in p21ras impair its GT-
Pase activity and the constitutive presence of the active,
GTP-bound form of p21ras (p21rasGTP) leads to deregu-
lated growth and cellular transformation (MacDonald
and McCormick, 1997). To perform its function in cell
signaling, p21ras must be farnesylated on the CAAX
motif (Cysteine, Aliphatic amino acid, and any amino
acid [X]) at the carboxyl terminus of p21ras protein, a
reaction mediated by farnesyl protein transferase (Di
Paolo et al., 2001). Intracellular effectors of p21ras in-
clude raf-1, MEK (mitogen-activated protein kinase
[MAPK]/extracellular signal-regulated kinase [ERK] ki-
nase), and MAPKs, which are needed for RAS-mediated
DNA synthesis, gene transcription, and eventually ma-
lignant transformation (MacDonald and McCormick,
1997). Although this represents the prevalent hypothe-
sis for p21ras signal transduction, recent studies failed
to substantiate it (Ramakrishna et al., 2000). In partic-
ular, lung tumors do not have more total p21K-ras or
p21K-rasGTP than normal lung tissue, nor are higher
levels of these proteins found in tumors with mutant
K-RAS. Activated p21K-rasGTP levels did not correlate
with proliferating cell nuclear antigen (PCNA) staining.
Furthermore, tumors with mutant K-RAS displayed
smaller size compared with tumors lacking this muta-
tion (Ramakrishna et al., 2000). In nontransformed lung
epithelial cells in culture both total and activated p21K-
ras increased markedly at confluence, but not after se-
rum stimulation, and mRNA analysis indicated an in-
crease in K-RAS expression in confluent cells. These
findings indicate that normal p21K-ras activity is asso-
ciated with growth arrest of normal lung epithelial cells
and that the exact contribution of mutated p21K-ras to
tumor development is still undetermined (Ramakrishna
et al., 2000). To evaluate the association of K-RAS ab-
normalities with the incidence of NSCLC, 410 surgically
resected specimens were analyzed for K-RAS mutations
in codons 12, 13, and 61; mutations were found in 33
patients (8%) and all were smokers or ex-smokers (Noda
et al., 2001). There were no significant differences in
tumor stage between wild-type and mutant K-RAS. The
most frequently identified mutation was a GT trans-
version (75.8%) that resulted in the substitution of a
glycine for a cysteine or a valine (Noda et al., 2001). This
study provides evidence of a clear correlation between
smoking and GT transversions affecting the K-RAS
gene (Noda et al., 2001). Survival is strongly associated
with K-RAS gene mutations in NSCLC (Rosell et al.,
1996). The analysis of the relationship between tumor
aggressiveness and K-RAS point mutations at codons 12
and 61 was evaluated in 275 consecutively treated stage
I–IV NSCLCs. In stage I disease, median survival was
27 versus 41.5 months in patients with or without K-
RAS mutations at codon 12, respectively (Rosell et al.,
1996). Furthermore, in patients with stage IIIA disease,
median survival time was 7 months in those with K-RAS
mutations at codon 12 (aspartic acid to serine) and 15
months for those with other K-RAS mutations (P 0.01)
(Rosell et al., 1996). In a multivariate analysis, point
mutation at codon 12 of K-RAS was a strong predictive
factor for death (hazard ratio, 2.06; P  0.02) after
adjustment for other factors, including stage and histol-
ogy. Therefore, in patients with NSCLC specific K-RAS
point mutations are associated with a significantly in-
creased risk of recurrence and death, independently of
tumor stage and histology (Rosell et al., 1996).
Intron 1 of the human H-RAS gene possesses a unique
polymorphism consisting of GGGCCT repeats. Analysis
of this locus in matched tumor versus normal samples
from 38 patients with NSCLC revealed 6.6% LOH and
10.5% hexanucleotide instability (Kotsinas et al., 2001).
TABLE 2
Summary of genes involved in lung tumorigenesis
Gene Protein Function ChromosomalLocation
K-RAS Signal transduction 11p14.1
TP53 DNA repair checkpoint 17p13
RB Cell cycle checkpoint 13q14
CDKN2A CDK inhibitor 9p21
MYC Transcription factor 8q24
Bcl-2 Inhibitor of apoptosis 18q21
FHIT Tumor suppressor 3p14.2
HER-2/neu Signal transduction 17p21
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The same pattern of alterations was also detected in
tissues adjacent to lung adenocarcinomas and dyspla-
sias contiguous to squamous cell carcinomas (7.7% LOH,
5.9% hexanucleotide instability), implying that abnor-
malities at this locus may be early events in lung carci-
nogenesis (Kotsinas et al., 2001). In view of reports
showing that elements in intron 1 of the H-RAS gene
potentially influence its transcriptional regulation, the
hexanucleotide locus could be an element with possible
involvement in expressional regulation of H-RAS (Kotsi-
nas et al., 2001).
B. TP53
The product of the TP53 tumor-suppressor gene is
p53, a DNA-binding, sequence-specific transcription fac-
tor that activates the expression of genes engaged in
promoting growth arrest in the G1 phase or cell death in
response to genotoxic stress. Also, p53 prevents cells
from undergoing mitosis when they enter the G2 phase
with damaged DNA (Taylor and Stark, 2001). Part of the
mechanism by which p53 blocks cells at the G2 check-
point involves inhibition of cdc2, the cyclin-dependent
kinase required to enter mitosis. Binding of cdc2 to
cyclin B1 is required for its activity, and repression of
the cyclin B1 gene by p53 also contributes to blocking
entry into mitosis (Taylor and Stark, 2001). The transfer
of the wild-type TP53 gene into the p53-null human
NSCLC NCI-H358 cells results in a typical senescence-
like phenotype, characterized by reduction in cell
growth, enlarged and flat cell morphology, cell cycle
arrest in the G1 phase, down-regulation of cyclin B1 and
cdc2 expression, and suppression of DNA synthesis
(Ling et al., 2000). The ability of p53 to inhibit cellular
proliferation or to induce cell death is suppressed by the
product of the mouse double minute 2 (MDM2) gene.
This property underlies the oncogenic potential of
MDM2, which is overexpressed in various human tu-
mors. Similar to other oncogenes, surveillance pathways
might counteract the deleterious effects of deregulated
MDM2 expression (Daujat et al., 2001). The GML gene
(glycosyl-phosphatidyl-inositol-anchored molecule-like
protein gene) is a novel gene specifically induced by
wild-type p53, which may participate in cell cycle control
and the apoptotic pathway (Higashiyama et al., 2000).
Loss of function of the TP53 tumor-suppressor gene,
because of missense mutations that cause single residue
changes in the DNA binding core domain of the protein,
occurs early in lung tumorigenesis in about 50% of cases
(Rom et al., 2000). This mutation confers a growth ad-
vantage to the cells, allowing them to clonally expand
due to loss of the p53-controlled G1 checkpoint and ap-
optosis. Genetic instability due to the impaired ability of
p53 to regulate DNA damage repair further facilitates
the occurrence of new genetic abnormalities, leading to
malignant progression. The cell cycle control is further
compromised in NSCLC by alterations in the G1/S tran-
sition control genes, either loss of the CDKN2A or RB
genes or amplification of the cyclin D gene (Sherbet and
Lakshmi, 1997). Not only TP53 mutations result in the
abrogation of wild-type p53 activity, but the expressed
p53 mutant proteins also tend to gain oncogenic func-
tions, such as interference with wild-type p53-indepen-
dent apoptosis (Sigal and Rotter, 2000). Because mu-
tated p53 is expressed in cancer cells and not in normal
cells, its reactivation to wild-type function by gene trans-
duction may eliminate cancer by restoring apoptosis or
other p53-dependent mechanisms of growth suppression
(Sigal and Rotter, 2000). However, mutants with more
extensive structural changes in the DNA binding core
domain may be refractory to reactivation to the wild-
type p53 phenotype. Therefore, understanding the struc-
ture and functions of p53 mutants may lead to effective
reactivation modalities or to the ability to eliminate
mutant p53 (Sigal and Rotter, 2000).
The development of p53 gene abnormalities, which
result in gross aneuploidy and multiple structural chro-
mosomal changes, commonly occurs at the interface be-
tween severe dysplasia and invasive tumor (Shackney
and Shankey, 1997). To date, the characteristics of TP53
gene mutations in lung cancer have been extensively
investigated. However, current estimates of TP53 alter-
ations are inaccurate, since most studies have limited
their analyses to exons 5 to 8 of the TP53 gene. The
examination of mutations in the entire coding region of
TP53, from exons 2 to 11, in 52 lung carcinoma cell lines
and 106 primary NSCLCs revealed that the prevalence
of mutations was high (80%) in NSCLC cell lines, and
9 of 45 mutations (20%) were detected outside the region
of exons 5 to 8 (Fujita et al., 1999). The frequency of
mutations in primary NSCLC was 48% and was signif-
icantly different between adenocarcinomas (39%) and
squamous cell carcinomas (67%). AG transitions (14%)
and GT transversions (26%) were frequently detected
in smoking patients (Fujita et al., 1999).
The DNA repair protein MGMT removes mutagenic
adducts from the O6 position of guanine, thereby pro-
tecting the genome against GA transitions (Wolf et al.,
2001). The MGMT gene is inactivated by promoter hy-
permethylation in many human cancers and has been
associated with GA mutations in K-RAS. In addition to
this, experimental data have been provided in support of
the hypothesis that hypermethylation of the MGMT pro-
moter is associated with an increase in GA transitions
in the TP53 gene in NSCLC (Wolf et al., 2001). Methyl-
ation of the promoter region of the MGMT gene is de-
tected in 29% of NSCLC primary tumors collected at
surgery; hypermethylation of the MGMT promoter was
more common in adenocarcinoma than in other histolog-
ical types of NSCLC and was also more common in
poorly differentiated tumors (Wolf et al., 2001). MGMT
promoter hypermethylation occurred significantly more
often (64%) in tumors with a GA mutation in TP53
than in tumors with other types of TP53 mutations
(27%) or in tumors with wild-type TP53 (18%) (Wolf et
70 DANESI ET AL.
al., 2001). The shift in the TP53 mutational status ob-
served in methylated tumors suggests that MGMT pro-
moter hypermethylation precedes the mutation of the
TP53 gene. Because GA mutations account for more
than 40% of the TP53 mutations in human cancer, it is
likely that, in most cases, MGMT inactivation play a
major role (Wolf et al., 2001).
C. RB
The RB tumor-suppressor gene is located on chromo-
some 13q14. Cytogenetic abnormalities of chromosome
13 and LOH at the RB locus have been reported in a
variety of human cancers, including NSCLCs, and the
frequency of RB abnormalities detected by immunohis-
tochemistry in NSCLCs is up to 30% (Wistuba et al.,
2001). Furthermore, functional pRB protein is absent in
90% of SCLCs, and in up to 30% of NSCLC primary
lesions and cell lines (Rom et al., 2000). pRB is a pocket
protein that cooperates with p53 in the regulation of cell
cycle progression and controls, at the transcriptional
level, the balance between cell differentiation and pro-
liferation (Sherbet and Lakshmi, 1997). In the cell cycle,
the transition from the G1 to the S phase is of crucial
importance. Indeed, it is only before this checkpoint that
cells can be oriented toward the differentiation pathway;
beyond, cells progress into the cycle in an autonomous
manner. The transcription factor E2F controls the ex-
pression of a group of checkpoint genes whose products
are required either for the G1/S transition or DNA rep-
lication (e.g., DNA polymerase-, thymidylate synthase,
thymidine kinase, and dihydrofolate reductase). E2F ac-
tivity is repressed in growth-arrested cells and in early
G1, and is activated at mid-to-late G1. pRB represses
E2F by binding to it and by activating chromatin remod-
eling factors, including histone deacetylases, DNA-
MTase, and histone methyltransferase (Ferreira et al.,
2001; Nevins, 2001). The molecular events that lead to
deregulated tumor cell growth include sustained activity
of cyclin-dependent kinases (CDK2, CDK4, and CDK6);
as a result of loss of CDK inhibitors, such as p16INK4a;
and persistent up-regulation of several cyclins (cyclin
D1, cyclin A, and cyclin E), the positive regulators of
CDKs. CDKs inactivate pRB by phosphorylation, which
is followed by the release of E2F from an inactive com-
plex with pRB, and the constitutively high E2F activity
induces continuous expression of target genes whose
products promote cell cycle progression (La Thangue,
1997; Sherbet and Lakshmi, 1997). Therefore, sustained
hyperphosphorylation and inactivation of pRB contrib-
ute to the transformation of normal bronchial epithe-
lium to autonomously growing cancer cells. Additional
mechanisms of pRB inactivation include RB point mu-
tations and chromosomal deletions (La Thangue, 1997;
Sherbet and Lakshmi, 1997). Although RB plays an
important role in lung tumorigenesis, in cooperation
with other genetic abnormalities pRB status does not
represent a prognostic factor in NSCLCs. Indeed, among
90 patients with lung adenocarcinoma, 56.7% have re-
duced expression of the RB gene; however, there were no
statistical differences among pRB, TP53 mutations, and
clinico-pathological status. The 5-year survival rate in
patients with normal versus reduced pRB expression
was 55.1 versus 73%, the difference being nonsignificant
(Sugio et al., 2001). Furthermore, in tumor specimens
obtained from 207 surgically resected primary NSCLCs,
p53 or pRB were detected in 55.6 and 65.7% of lung
tumors, respectively; p53 had a positive correlation with
regional lymph node metastasis and advanced tumor
stage, while an inverse correlation between the expres-
sion of pRB and p53 was found. By multivariate analy-
sis, p53 expression and pathological stage were indepen-
dent prognostic factors, while pRB status did not
represent a prognostic marker (Lee et al., 1999b).
D. CDKN2A (p16INK4a)
Members of the INK4 protein family inhibit cdk4 and
cdk6-mediated phosphorylation of pRB; inactivation of
p16INK4a in tumors expressing wild-type pRB is required
for malignant cells to enter the S phase or escape senes-
cence (Shapiro et al., 1998). The occurrence of p16INK4a
lesions is second only to p53 abnormalities in human
cancer and is a frequent event in premalignant lesions of
the upper digestive tract (Wong et al., 2001). The
CDKN2A gene is inactivated by a two-hit mechanism
that can involve CpG island methylation, 9p21 LOH,
mutation, or homozygous deletion (Pines, 1997; Sherbet
and Lakshmi, 1997). CDKN2A is a tumor-suppressor
gene that regulates cell-cycle progression through a G1/S
restriction point by inhibiting CDK4 and CDK6/cyclin
D-mediated phosphorylation of pRB. The CDKN2A locus
on chromosome 9p21 encodes two proteins translated by
alternative splicing of mRNA; the -transcript,
p16INK4a, which inhibits phosphorylation of pRB
through cyclin D1/CDK4; and the -transcript, p14ARF,
the binding of which to MDM2 stabilizes it and increases
the availability of wild-type p53 (Pines, 1997; Sherbet
and Lakshmi, 1997). Homozygous deletion of p16INK4a
and the less frequent promoter hypermethylation dis-
rupt the pathway of pRB/cyclin D1/CDK4, whereas ho-
mozygous deletion and hypermethylation of p14ARF per-
mit degradation of p53 exported by MDM2 no longer
sequestered in the nucleus. In addition to this, amplifi-
cation of MDM2 is an alternative way of inactivating
p53 (Pines, 1997; Sherbet and Lakshmi, 1997). The anal-
ysis of p16INK4a, p14ARF, and p53 in 38 primary NSCLC
specimens (19 adenocarcinomas and 19 squamous carci-
nomas) showed that p16INK4a was inactivated in 58% of
tumors by homozygous deletions, promoter hypermeth-
ylation, and point mutation in exon 2 (Sanchez-Cespedes
et al., 1999). Fourteen tumors had simultaneous
p16INK4a and p14ARF inactivation, most frequently be-
cause of homozygous deletions extending into the
INK4a/ARF locus (Sanchez-Cespedes et al., 1999). Addi-
tional studies demonstrated abnormal p16INK4a expres-
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sion in 46% of NSCLCs examined. No relationship was
observed between p16INK4a abnormal staining and var-
ious clinico-pathological parameters (Spanakis et al.,
1999). Deletions of CDKN2A may represent a predomi-
nant mechanism of gene inactivation. LOH was also
observed at the D9S162 (35%) and D9S126 (38%) loci,
which lie 6 cM and 4 cM, respectively, from the area that
encodes p16INK4a, implying that other tumor-suppressor
genes may reside in this region (Spanakis et al., 1999). A
study provided evidence that aberrant expression of
p16INK4a and pRB was observed in 33 (49%) and 27
(40%) of 68 NSCLCs, respectively. Molecular analysis
revealed that deletions and transcriptional silencing by
methylation were the main mechanisms of CDKN2/
p16INK4a inactivation in NSCLCs (Gorgoulis et al.,
1998). Multiple genetic abnormalities are frequently ob-
served in NSCLCs, including overexpression of p53 and
MDM2, abnormal pRB expression, and elevated levels of
MDM2 and p53 (Gorgoulis et al., 1998). Moreover, de-
regulated expression of p16INK4a, pRB, p53, and MDM2
occurred in a large proportion (43%) of NSCLCs. This
finding was not related to the clinical stage of the tu-
mors, suggesting that abnormalities of this network oc-
cur early in the development of a subset of NSCLCs
(Gorgoulis et al., 1998). Finally, smoking was associated
with LOH and microsatellite instability at the 9p21–22
locus as well as with aberrant expression of p16INK4a/
pRB and overexpression of p53/MDM2 (Gorgoulis et al.,
1998).
E. MYC
Overexpression of dominant oncogenes plays a role in
tumor progression and it appears to be a late event in
lung cancer pathogenesis. The MYC family of oncogenes
produces proteins that, when expressed in the nucleus,
lead to cell proliferation. MYC overexpression occurs in
the vast majority of SCLCs but is rare in NSCLCs (Sal-
gia and Skarin, 1998; Bunn et al., 2000). The c-MYC
gene encodes a transcription factor that heterodimerizes
with a partner protein, termed Max, to regulate gene
expression by binding to specific DNA sequences. Max
also heterodimerizes with the Mad family of proteins to
repress transcription, antagonize c-MYC, and promote
cellular differentiation (Grandori et al., 2000; Amati et
al., 2001). These DNA-bound heterodimers recruit coac-
tivator or corepressor complexes that generate alter-
ations in chromatin structure, which in turn modulate
transcription. Initial identification of target genes sug-
gests that the network regulates loci involved in the cell
cycle, growth, life span, and cell morphology. Because
c-MYC and Mad proteins are expressed in response to
diverse signaling pathways, the network can be viewed
as a functional module that acts to convert environmen-
tal signals into specific gene-regulatory programs (Gran-
dori et al., 2000; Amati et al., 2001). The most frequent
genetic alteration that affects c-MYC is gene amplifica-
tion, which is found in 8 to 20% of NSCLCs (Salgia and
Skarin, 1998; Wistuba et al., 2001).
F. Bcl-2
The Bcl-2 gene was identified as an oncogene in fol-
licular lymphoma associated with the chromosomal
translocation between chromosomes 18 and 14. The
Bcl-2 gene is located on chromosome 18q21 and the Bcl-2
protein is associated with the inner and outer mitochon-
drial membranes, as well as with the nuclear membrane
and endoplasmic reticulum. Bcl-2 extends cell survival
and inhibits drug-induced apoptosis (for review, see Loni
et al., 2001) by multiple mechanisms, including inhibi-
tion of p53-dependent apoptosis triggered by Bax; how-
ever, its protective effect may be lost if the protein is
phosphorylated. In some tumor cells expressing high
levels of wild-type p53, the pro-apoptotic protein Bax is
up-regulated, while Bcl-2 is down-regulated (Miyashita
et al., 1994).
Abnormal expression of the Bcl-2 gene product has
been found in a wide variety of tumors, including
NSCLC. The analysis of 116 tumor specimens from sur-
gically resected NSCLC revealed that 34% of them
showed Bcl-2 expression, which was found more fre-
quently in males than females, and in smokers (Dosaka-
Akita et al., 1999). Bcl-2 expression is observed more
frequently in squamous cell carcinomas (53%) than in
adenocarcinomas (22%) and, among squamous cell car-
cinomas, in pathological stage I tumors (85%) than in
stage II and III cancers (42%). Bcl-2 expression did not
correlate with p53 protein status and tumors metastatic
to regional lymph nodes were most frequently Bcl-2-
negative (Dosaka-Akita et al., 1999). Bcl-2 status ap-
pears not to influence the 5-year survival, since patients
with Bcl-2-positive or -negative tumors had a similar
survival rate; these data indicate that Bcl-2 expression
is frequently observed in squamous cell carcinomas at
an early stage, and that it does not predict the prognosis
of patients with NSCLC (Dosaka-Akita et al., 1999). The
immunohistochemical examination of apoptosis-regulat-
ing proteins, including Bcl-2, Mcl-1, Bax, Bak, and p53,
revealed that tumor specimens positive for the anti-
apoptotic proteins Bcl-2 and Mcl-1 were 31% and 58% of
the cases evaluated, respectively, whereas the pro-apop-
totic proteins Bax and Bak were found in 47% and 58%
of the samples (Borner et al., 1999). The immunoposi-
tivity of p53 was detected in 61% of the samples; the
expression of Bcl-2 and p53, and that of Mcl-1 and Bax,
showed a significant positive association, whereas the
expression of Bax was inversely related to p53. The
expression of Bcl-2 had a negative influence on relapse-
free survival in this population of resected NSCLC pa-
tients, but only subjects with p53-positive tumors devel-
oped metastases during follow-up (Borner et al., 1999).
The combination of Bcl-2-positivity/p53-negativity in
NSCLCs was associated with the worst survival rate
(Dingemans et al., 1999), and a comparison of long-term
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versus short-term survivors after surgical resection of
stage III squamous cell carcinomas demonstrated that
factors involved in apoptosis, including p53 and Bcl-2,
were up-regulated in subjects belonging to the long sur-
vival group (Mattern et al., 2002). In another study of
238 cases of NSCLC (203 squamous cell carcinomas and
35 adenocarcinomas), p185HER-2/neu and Bcl-2 were ex-
pressed at high levels in 42 and 71.8% of NSCLCs,
respectively. Univariate analysis demonstrated that
Bcl-2 expression was significantly associated with a poor
prognosis, as it was the coexpression of Bcl-2 with
p185HER-2/neu, p53, and p21ras. However, only the com-
bination of Bcl-2/p185HER-2/neu expression was an inde-
pendent marker of poor prognosis on multivariate anal-
ysis (hazard ratio  1.91) (Kim et al., 1998b). A recent
study of 102 patients with NSCLC demonstrated Bcl-2
protein overexpression in 48% of tissue specimens, with
no statistical association with p53 overexpression or mu-
tation (Laudanski et al., 2001). This study also con-
firmed that, in a multivariate analysis, only TP53 gene
mutations seem to have a strong and independent effect
on prognosis (Laudanski et al., 2001). Bronchial biopsies
from 60 lung cancer patients were found p53- (43.3%),
p21Waf1/Cip1- (60%), and Bcl-2- (33.3%) positive. While
single-protein expression was not associated with progno-
sis, the combined immunophenotype p53()/p21Waf1/Cip1
()/Bcl-2 () predicted longer survival (P  0.03). The
authors concluded that p53 and Bcl-2 alterations may
happen early in bronchial carcinogenesis and that the
absence of these alterations in combination with
p21Waf1/Cip1 overexpression may be associated with a
less aggressive tumor behavior (Kalomenidis et al.,
2001). In surgical samples of NSCLC, detectable Bcl-2
was shown by immunohistochemistry in 20 of 107 (19%)
cases and this finding was associated with squamous
cell histology. An inverse relationship was found be-
tween Bcl-2/vascular grade and Bcl-2/p185HER-2/neu,
while no relationships were found between p53 and
EGFR expression and Bcl-2, p185HER-2/neu, or vascular
grade. The improved prognosis of Bcl-2-positive NSCLC
may be related to low tumor vascularization; since nor-
mal lung epithelium expresses Bcl-2, tumor progression
may involve the loss of Bcl-2 followed by activation of
HER-2/neu or increase in tumor vascularization (Kouk-
ourakis et al., 1997). The immunohistochemical analysis
of 216 NSCLC specimens from T1–2 and N0–1 patients
confirmed the inverse relationship between Bcl-2 and
HER-2/neu and demonstrated that high thymidine phos-
phorylase and vascular endothelial growth factor
(VEGF) reactivity was statistically related to loss of
Bcl-2 expression (P  0.01). Thus, this study provided
additional evidence that the Bcl-2 gene has a suppres-
sive function on genes involved in angiogenesis (VEGF
and thymidine phosphorylase) and cell proliferation
(HER-2/neu) in NSCLC (Koukourakis et al., 1999). Ad-
ditional data in line with these findings were provided in
a later study (Boldrini et al., 2000).
G. FHIT
FHIT is a tumor-suppressor gene located at 3p14.2, a
region frequently lost in multiple tumor types, and ab-
normalities of FHIT have been found frequently in
NSCLC. To investigate whether FHIT inactivation plays
a role in early lung tumorigenesis, pFHIT immunohis-
tochemistry was performed in tumors from 87 patients
with stage I NSCLC and in 372 bronchial biopsy speci-
mens from 86 chronic smokers without evidence of ma-
lignancy (Tseng et al., 1999). It was found that 49% of
NSCLC specimens demonstrated significantly de-
creased or lack of staining for pFHIT. However, pFHIT
expression status was not significantly associated with
disease-free or overall survivals (Tseng et al., 1999). The
analysis of a subset of 76 specimens on which microsat-
ellite analysis at the FHIT locus was performed did not
show a strong association between LOH at FHIT and
protein levels, suggesting the presence of complex mech-
anisms of FHIT inactivation (Tseng et al., 1999). Of 372
bronchial biopsies from chronic smokers, 86 biopsies
(23%) exhibited decreased or lack of pFHIT expression.
Loss of pFHIT was significantly higher in bronchial
metaplastic lesions (47%) than in histologically normal
bronchial epithelium (20%; P  0.001) (Tseng et al.,
1999). Smokers with a metaplasia index of 15% had a
higher frequency of loss of pFHIT expression than those
with a metaplasia index of 15% (P  0.015). These
data indicate that pFHIT expression is significantly re-
duced in a substantial number of early-stage NSCLC
and preneoplastic lesions in chronic smokers. The asso-
ciation between cigarette smoking and pFHIT expres-
sion suggests a role for FHIT in the initiation of smok-
ing-related lung tumorigenesis (Tseng et al., 1999).
H. Epidermal Growth Factor Receptors
Epidermal growth factor (EGF) was one of the first
growth factors to be discovered and is the prototype of a
large family of closely related peptides that includes
TGF-, amphiregulin, heparin-binding EGF, and -cel-
lulin (Heldin and Ro¨nnstrand, 1997; Sherbet and Lak-
shmi, 1997; Ciardiello and Tortora, 2001). Among these
growth factors, TGF- has been identified as a key mod-
ulator in the process of cell proliferation in both normal
and malignant epithelial cells. TGF- binds to its spe-
cific cell membrane receptor, the EGFR, leading to the
activation of the EGFR tyrosine kinase enzymatic activ-
ity that triggers the intracellular signaling pathway.
The EGFR is part of a subfamily of four closely related
proteins: EGFR (also called ErbB-1), HER-2/neu (ErbB-
2), HER-3 (ErbB-3), and HER-4 (ErbB-4) (Heldin and
Ro¨nnstrand, 1997; Sherbet and Lakshmi, 1997;
Ciardiello and Tortora, 2001). The HER-2/neu gene is
located on chromosome 17p21; it codes for a 185-kDa
transmembrane glycoprotein (p185HER-2/neu) related to
EGFR. HER-2/neu is activated by a point mutation that
results in the change of amino acid residue 664 from
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valine to glutamic acid, and this change is associated
with its ability to transform cells. Alterations and am-
plifications of this gene have been reported in a variety
of human cancers such as NSCLC (Heldin and
Ro¨nnstrand, 1997; Sherbet and Lakshmi, 1997;
Ciardiello and Tortora, 2001). The receptors exist as
inactive monomers, which dimerize after ligand activa-
tion. This causes homodimerization or heterodimeriza-
tion between EGFR and other members of the Erb re-
ceptor family. After ligand-binding the tyrosine kinase
intracellular domain of the receptor is activated and
undergoes autophosphorylation, which initiates a cas-
cade of intracellular events. The signaling pathway in-
volves activation of p21ras and MAPK, which activate,
in turn, several nuclear proteins, including cyclin D1.
EGFR signaling is not only critical for cell proliferation;
indeed, several studies have demonstrated that EGFR-
mediated signals also contribute to other processes that
are crucial to cancer progression, including angiogene-
sis, metastasis, and inhibition of apoptosis (Heldin and
Ro¨nnstrand, 1997; Sherbet and Lakshmi, 1997;
Ciardiello and Tortora, 2001). These effects may be ex-
plained, at least in part, by the evidence that clinical
specimens of NSCLCs overexpressing both EGFR and
p185HER-2/neu also have higher levels of the inducible
isoform of cyclooxygenase (Cox-2) than those without
concomitant overexpression of these proteins (Niki et al.,
2002). Furthermore, Cox-2 mRNA levels correlate with
both p185HER-2/neu expression and a phosphorylated
form of MAPK/ERK in lung cancer cell lines, and the
addition of TGF- increased Cox-2 mRNA levels in cells.
These results suggest that EGFR signaling is involved
in the enhanced expression of Cox-2 in lung adenocarci-
nomas (Niki et al., 2002). The 11p15 mucin genes
(MUC2, MUC5AC, MUC5B, and MUC6) possess a cell-
specific pattern of expression in normal lung that is
altered during neoplastic transformation. Studies on the
mucoepidermoid NCI-H292 lung cancer cell line demon-
strated that treatment with EGF and TGF- resulted in
a strong increase of MUC2 and MUC5AC mRNAs levels,
promoter activity, and apomucin expression. Up-regula-
tion of MUC2 and MUC5AC genes was associated with
activation of the EGFR/Ras/Raf/MEK signaling pathway
leading to cell proliferation (Perrais et al., 2002). Abnor-
mal activation of autocrine pathways mediated by EGFR
in cancer cells may be attributed to several mechanisms,
such as overexpression of EGFR, increased availability
of ligands, decreased receptor turnover, decreased phos-
phatase activity, and aberrant receptors, including
EGFR gene alterations. In this context, the most com-
mon EGFR mutant found in human cancer is EGFRvIII.
The rearranged EGFRvIII gene is often amplified, thus
resulting in tumor cells overexpressing EGFRvIII pro-
tein, a truncated EGFR that lacks domains I and II of
the extracellular domain, and is not capable of ligand
binding (Heldin and Ro¨nnstrand, 1997; Sherbet and
Lakshmi, 1997; Ciardiello and Tortora, 2001). However,
it has a constitutively activated tyrosine kinase domain
that stimulates cell proliferation independently of li-
gand interaction.
EGFR is overexpressed in NSCLC, in which it is gen-
erally associated with advanced disease and poor prog-
nosis. EGFR overexpression has been associated with
resistance to cytotoxic agents, including cisplatin (Chen
et al., 2000), and the ErbB receptor tyrosine kinase
network stimulates cytoprotective p70 S6 kinase and
Akt activity in response to clinically relevant doses of
ionizing radiation (Contessa et al., 2002). The combined
HER-2/neu and EGFR overexpression in the same ane-
uploid cells defines a genetic evolutionary sequence that
is common to NSCLC; later steps in this sequence in-
clude RAS and c-MYC overexpression (Shackney and
Shankey, 1997). The immunohistochemical analysis of 408
stage I NSCLC specimens for p53, Bcl-2, p185HER-2/neu,
KI-67, pRB, and EGFR demonstrated that among men,
the molecular marker associated with decreased cancer-
specific survival is p185HER-2/neu, while among women,
these are p53 and pRB (D’Amico et al., 2000). The study
of the association between EGFR and HER-2/neu gene
expression and survival in primary tumor and matching
nonmalignant tissues from 83 patients with NSCLC
demonstrated that EGFR and HER-2/neu mRNA were
detectable in all specimens analyzed (Brabender et al.,
2001). High HER-2/neu and EGFR expression was de-
tected in 29 (34.9%) and 28 (33.7%) patients, respec-
tively, while high HER-2/neu and EGFR coexpression
was detectable in 14 (16.9%) subjects. HER-2/neu up-
regulation was associated with shorter survival (P 
0.004), whereas high EGFR expression showed a trend
toward reduced survival (Brabender et al., 2001). Mul-
tivariate analysis demonstrated that high expression of
HER-2/neu and combined EGFR-HER-2/neu were sig-
nificant and independent unfavorable prognostic fac-
tors, thus indicating that HER-2/neu and EGFR play a
crucial role in the biological behavior of NSCLCs (Bra-
bender et al., 2001). A recent study provided additional
evidence that coexpression of EGFR and matrix metal-
loproteinase-9 (MMP-9), microvessel density, and Bcl-2
were independent prognostic variables that allowed pre-
diction of patient outcome independent of surgical stage
(O’Byrne et al., 2001).
I. Multidrug Resistance Proteins
NSCLC is considered to be a chemotherapy-refractory
malignancy because of the lack of clinical efficacy of
single-agent therapy. Chemoresistance thus remains
the major obstacle to successful therapy of NSCLC, and
one of the reasons for such a biological profile is the
expression in tumor tissue of three protein families in-
volved in multidrug resistance: 1) P-glycoprotein (P-gp),
a 170-kDa protein encoded by the MDR1 gene; 2) the
multidrug resistance-associated protein (MRP) family, a
group of at least six members, the best characterized of
which is a 190-kDa protein (ABCC1, MRP); and 3) the
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vault-transporter lung resistance protein (LRP), a 110-
kDa protein encoded by the LRP gene (Borst et al., 1999;
Scheffer et al., 2000; Tan et al., 2000; Young et al., 2001).
Both P-gp and MRP are membrane-associated transport
proteins belonging to the large and ancient ATP-binding
cassette (ABC) superfamily; P-gp contains two multi-
spanning transmembrane domains compared with the
three that are present in MRP, which requires reduced
glutathione for its function (Scheffer et al., 2000; Tan et
al., 2000). LRP is located intracellularly and appears to
be involved in the resistance to cisplatin (Berger et al.,
2000). P-gp and MRP are most involved in the transport
of taxanes, anthracyclines, vinca alkaloids, and epipodo-
phyllotoxins to the outside of the membrane (Tan et al.,
2000), while MRP is also involved in cisplatin resistance
(Young et al., 2001).
The expression of drug-resistant proteins is expected
to be highly variable, depending on treatment status
and the type of drug administered in combination regi-
mens. Unfortunately, there are few studies published in
the literature addressing this point. In 15 cell lines
unselected with respect to chemotherapeutic agents,
MRP was constitutively expressed, with markedly vary-
ing intensity (Berger et al., 1997). Two cell lines ex-
pressed high MRP protein levels without amplification
of the MRP gene and a significant correlation between
MRP expression and chemoresistance toward doxorubi-
cin, etoposide, and vinblastine was observed (Berger et
al., 1997). The immunohistochemical analysis of paraf-
fin-embedded tissue from 27 cases of untreated NSCLC
showed the presence of P-gp in 5% of cells in only 3 of
27 cases, and MRP in 5 of 27 tumors (Kreisholt et al.,
1998). A study of surgical tissue samples from 84 un-
treated NSCLCs analyzed the levels of MDR1 mRNA
and demonstrated that 15% of tumors were positive for
the MDR1 gene, but the level was low in all samples
except for one adenocarcinoma, which expressed high
levels of MDR1. Gene expression in these tumors was
unrelated to pathologic factors such as histologic type,
pathologic stage, and tumor size (Oka et al., 1997).
Among 36 samples of surgically resected NSCLC squa-
mous cell and adenocarcinomas had higher LRP expres-
sion than large cell undifferentiated and mixed tumors,
while MRP expression was detected in few specimens
(Dingemans et al., 1996). Contrasting results were ob-
tained in studies aimed at establishing a relationship
between drug sensitivity and expression of proteins in-
volved in drug resistance. Using a large panel of uns-
elected cell lines, MRP mRNA expression was a poor
predictor of drug sensitivity, at variance with MDR1,
suggesting that other factors, including conjugating en-
zymes, glutathione levels, or other transporters, con-
found the MRP effect (Alvarez et al., 1998). In another
study conducted on unselected NSCLC cell lines, the
mRNA levels of MRP correlated with resistance to vin-
cristine, etoposide, and cisplatin, thus implying that
MRP may contribute to the drug resistance phenotype of
lung cancer cells (Young et al., 1999). Detectable levels
of MRP in most of the tumor mass was found in 87% of
samples of untreated NSCLC. In a substantial propor-
tion of adenocarcinomas (55%) and squamous cell carci-
nomas (28%), immunoreactivity approached that ob-
tained with the highly multidrug-resistant cell line
H69AR, from which the MRP was originally cloned
(Wright et al., 1998). No potentially confounding corre-
lation independent of its possible role in drug resistance
was observed between MRP expression in untreated
NSCLC and any clinicopathological parameter exam-
ined, including overall survival (Wright et al., 1998). The
predictive value of MRP and LRP expression in NSCLC
tumor biopsies with respect to treatment response was
evaluated in 38 patients who had been subsequently
treated with cisplatin/paclitaxel, cisplatin/teniposide or
etoposide, or carboplatin/etoposide/ifosfamide. The
study demonstrated that none of the investigated mark-
ers was related to overall response rate (Dingemans et
al., 2001). In a study on NSCLC the frequency of expres-
sion of LRP, MRP, and P-gp in tumor tissue was 74.2%,
80.3%, and 37.9%, respectively, and was unrelated to
cell differentiation and tumor staging. At variance with
previous studies, there was lower expression of both
LRP and MRP in chemo-responsive adenocarcinomas
compared with unresponsive tumors; in squamous cell
carcinomas, however, this was applicable to LRP expres-
sion only. Finally, coexpression of drug resistance-re-
lated genes adversely affected median survival of
NSCLC patients (Wang et al., 2000).
V. Potential Role of Pharmacogenetics in
Rational Therapeutic Decision
Pharmacogenetics is the study of how the responses of
patients to drugs are affected by their genetic profile
(Evans and Relling, 1999; Roses, 2000). The ability to
select patients on the basis of the likelihood of response
to a specific chemotherapeutic agent would avoid the
empiricism dependent on the inability to match the most
appropriate drug with the specific genetic profile of the
tumor. Our increasing knowledge of the mechanisms of
drug action, the identification of new drug targets, and
the understanding of genetic factors that determine the
response of individual patients may allow the design of
drug treatments that are specifically targeted toward
particular populations or that avoid genetic variability
in therapeutic response.
The extent of genetic polymorphism in the human
population indicates that pharmacogenetic variability is
likely to be an important issue for most drugs (Danesi et
al., 2001). The current application of pharmacogenetics
to the treatment of cancer patients is still at the inves-
tigational stage and is mostly concerned with the screen-
ing of individuals for genetically determined defects in
drug metabolism that are associated with severe, poten-
tially life-threatening adverse drug reactions (Danesi et
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al., 2001). Indeed, genetic polymorphism has been rec-
ognized as a major cause of unexpected toxicity after the
administration of analogs of pyrimidines (5-fluoroura-
cil), purines (6-mercaptopurine), and folic acids (metho-
trexate) as well as a number of natural products, includ-
ing inhibitors of topoisomerase I and II (anthracyclines
and camptothecins) (Danesi et al., 2001). Genes involved
in biotransformation and detoxification of the above-
mentioned anticancer agents include dihydropyrimidine
dehydrogenase, thiopurine methyltransferase, and
UDP-glucuronosyl-transferase, while other enzymes are
the targets of drug action (e.g., methylene-tetrahydrofo-
late reductase). The following chapters report on the
available data from the scientific literature concerning
the influence of genes that play a role in NSCLC tumor
progression, including RAS, TP53, RB, p16INK4a, MYC,
FHIT, Bcl-2, EGFR, and multidrug-resistant superfami-
lies; on the chemotherapeutic activity of drugs currently
used for the medical management of NSCLC, including
platinum compounds (cisplatin and carboplatin), tax-
anes (paclitaxel and docetaxel), gemcitabine, epipodo-
phyllotoxins (etoposide), vinca alkaloids (vinorelbine),
alkylating agents (ifosfamide and cyclophosphamide);
and new agents, including camptothecin analogs (topo-
tecan and irinotecan), inhibitors of EGFR, and novel
folic acid analogs. An overview of the best-characterized
interactions between genes and anticancer drugs in
NSCLC is reported in Fig. 1.
VI. Influence of Genetic Profile of Non-Small Cell
Lung Cancer on Drug Activity
A. Platinum Compounds
Cisplatin and carboplatin (Fig. 2) are alkylating
agents widely used in cancer chemotherapy. Response to
cisplatin is mainly mediated through a p53-dependent
apoptotic pathway. Most studies have reported that lung
cancer cells having wild-type p53 are more sensitive to
cisplatin than cells having either mutant or null p53.
The overexpression of p53 induced by cisplatin may trig-
ger apoptotic pathways via transactivation of the Bax
gene (Yoon et al., 2001). A study examined the introduc-
tion of a mutant p53 gene into the NCI-H460 cell line,
which carries a wild-type p53 gene, and the wild-type
p53 gene into NCI-H1437, NCI-H727, NCI-H441, and
NCI-H1299 cells which, in turn, bear a mutant p53 gene
(Lai et al., 2000). The NCI-H1437 cell line transfected
with a wild-type p53 gene showed a dramatic increase in
susceptibility to cisplatin compared to untransfected
NCI-H1437 cells. An increase in chemosensitivity was
also observed in wild-type p53 transfectants of NCI-
H727, NCI-H441, and NCI-H1299 cells (Lai et al., 2000).
In contrast, loss of chemosensitivity and lack of p53-
mediated DNA apoptotic degradation in response to an-
ticancer agents were observed in NCI-H460 cells trans-
fected with mutant p53. These observations suggest that
p53 gene status modulates the extent of chemosensitiv-
ity and the occurrence of apoptosis by cisplatin (Lai et
al., 2000). The infection of recombinant adenovirus ex-
pressing wild-type p53 to lung cancer cells that harbor a
mutant p53 gene improves their response to cisplatin
(Horio et al., 2000). Experimental studies on the effects
of wild-type p53 gene transfer in combination with var-
ious anticancer agents on the human pulmonary squa-
mous cell carcinoma cell line NCI-H157 and the human
pulmonary large cell carcinoma cell line NCI-H1299 pro-
vided evidence that cisplatin showed a high degree of
effectiveness and an additive effect with p53 transduc-
tion on NCI-H157 and NCI-H1299 cells (Osaki et al.,
FIG 1. Schematic representation of interactions between genes involved in lung tumorigenesis and NSCLC progression and anticancer agents
commonly used for the medical management of NSCLC. 1, overexpression; 2, downregulation; Mut, mutation; Del, deletion; WT, wild-type; VNR,
vinorelbine; VP-16, etoposide; SN-38, 7-ethyl-10-hydroxycamptothecin; MTX, methotrexate; GEM, gemcitabine; CPT, camptothecin; CDDP, cisplatin;
CBDCA, carboplatin; CTX, cyclophosphamide; , data from in vitro studies; , data from in vivo studies.
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2000). These results indicate that cisplatin would be a
candidate drug for the combination of chemotherapy and
gene therapy for NSCLC (Osaki et al., 2000). Since it
appears well established that p53 and DNA-damaging
agents such as cisplatin work synergistically to induce
apoptosis in cancer cells (Roth et al., 1999), patients
with NSCLC in complete or partial remission were com-
pared with those with stable or progressive disease with
respect to TP53 genotype and overall survival. Muta-
tions in the TP53 gene were detected by sequencing of
exons 2–11 (Kandioler-Eckersberger et al., 1999). A nor-
mal TP53 genotype proved to be significantly associated
with major response to chemotherapy (P  0.001). How-
ever, no association was found between p53 protein ex-
pression and TP53 genotype (Kandioler-Eckersberger et
al., 1999). A normal TP53 genotype was found to be
highly sensitive in predicting response to treatment,
whereas a mutant TP53 predicted lack of response. The
difference in overall survival was significant comparing
patients with a normal TP53, and responding to chemo-
therapy, with patients showing mutant TP53 with a
disease resistant to chemotherapy (Kandioler-Eckers-
berger et al., 1999). Therefore, a direct link between
wild-type TP53 and response to cisplatin-based induc-
tion treatment and between mutant genotype and resis-
tance to treatment was found, whereas the p53 immu-
nohistochemical result was predictive of neither
(Kandioler-Eckersberger et al., 1999). These data are
partially in contrast with another study, in which im-
munohistochemical analysis demonstrated a 70% con-
cordance between overexpression of p53 protein and mu-
tation in TP53 (Brattstrom et al., 1998). Indeed, tumor
specimens from 52 patients with stage IIIA NSCLC who
were enrolled in a prospective clinical trial of cisplatin-
based induction chemotherapy followed by surgical re-
section were examined for p53 expression which, in turn,
was correlated with clinical and pathological response
(Rusch et al., 1995). No relationship was established
between p53 expression and activity of the treatment
because 47 of 52 patients had a major response (Rusch et
al., 1995). However, a significant association was ob-
served between aberrant p53 expression and resistance
to chemotherapy as assessed by pathological response.
Only 3 of 20 patients whose tumors exhibited a high
level of p53 staining experienced a major pathological
response to chemotherapy, while just 7 of 52 cases ex-
amined before and after cisplatin-based chemotherapy
exhibited a change in the level of p53 expression (Rusch
et al., 1995). These results indicate that cisplatin alters
p53 expression infrequently and suggest a direct link
between aberrant p53 expression and resistance to cis-
platin-based chemotherapy in NSCLC (Rusch et al.,
1995). Additional clinical studies provided evidence that
wild-type p53 expression in tumors correlates with both
FIG 2. Chemical structures of currently used agents for the treatment of NSCLC.
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good response to cisplatin-based chemotherapy and bet-
ter survival of patients with advanced NSCLC (Oshita et
al., 2000). Resected tumors from 18 patients with recur-
rent NSCLC who had undergone complete resection and
received chemotherapy after the initial tumor recur-
rence were subjected to p53 immunostaining. Histolog-
ical examination of the resected tumors revealed 11 ad-
enocarcinomas, 6 squamous cell carcinomas, and 1
adenosquamous cell carcinoma. Group 1 displayed
50% (n  9) and group 2 50% (n  9) p53-immunopo-
sitive tumor tissues, and all patients received cisplatin-
based chemotherapy after recurrence (Oshita et al.,
2000). None of the patients in group 1 achieved response
to chemotherapy, whereas five subjects in group 2
achieved a complete and/or partial response (56%), re-
spectively (Oshita et al., 2000). The time to recurrence
after tumor resection of group 2 was significantly better
than that of group 1 (log-rank P  0.019; Wilcoxon P 
0.042), and survival of group 2 after chemotherapy was
also significantly longer than that of group 1 (log-rank
P  0.023; Wilcoxon P  0.034) (Oshita et al., 2000). It
is suggested that high p53 expression levels in tumors
correlate with both good response to cisplatin-based che-
motherapy and better survival of patients with ad-
vanced NSCLC (Oshita et al., 2000). The gene encoding
glycosyl-phosphatidyl-inositol-anchored molecule-like
protein (GML) is induced by wild-type p53 and the anal-
ysis of 30 surgically resected NSCLC specimens revealed
that GML expression was detectable in nine samples
(30%), and its incidence was significantly higher in p53-
negative or wild-type p53 tissues examined by immuno-
histochemistry (Higashiyama et al., 2000). In particular,
among p53-negative tumors, those with GML gene ex-
pression showed a significantly better sensitivity to cis-
platin; furthermore, a good response to cisplatin-based
chemotherapy in NSCLC patients with tumor residue or
recurrence was observed only in those with p53-negative
tissue with detectable GML gene expression (Higash-
iyama et al., 2000). It appears that in p53-negative
NSCLCs GML is generally expressed and it is associated
with good sensitivity to cisplatin, thus representing a
predictor of response (Higashiyama et al., 2000). On the
basis of the role of p53 in the chemosensitivity to anti-
cancer agents, recombinant adenovirus-mediated trans-
fer of the wild-type p53 gene was devised as a potentially
useful strategy for gene therapy; indeed, gene transfer
into monolayer cultures or multicellular tumor sphe-
roids of the human NSCLC cell line NCI-H358, which
has homozygous deletion of p53, markedly increased the
cellular sensitivity of these cells to the chemotherapeu-
tic effect of cisplatin (Fujiwara et al., 1994). Treated cells
underwent apoptosis, and direct injection of the p53-
adenovirus construct into H358 tumors implanted s.c.
into athymic nu/nu mice, followed by i.p. administration
of cisplatin, induced massive apoptotic death of the tu-
mors (Fujiwara et al., 1994). These results provide sup-
port for the clinical application of regimens combining
gene replacement with replication-deficient wild-type
p53 adenovirus and DNA-damaging drugs for the treat-
ment of NSCLC (Fujiwara et al., 1994). In a clinical
study aimed at determining the safety and activity of
adenovirus-mediated TP53 gene transfer in tumor tis-
sue followed by cisplatin administration in patients with
advanced NSCLC and abnormal p53 function, subjects
were administered intravenous cisplatin 80 mg/m2 on
day 1 and adenoviral vector carrying wild-type TP53 on
day 4 every 4 weeks, for a total of up to six courses
(Nemunaitis et al., 2000). Transient fever related to p53
vector administration developed in 8 of 24 patients. The
combination of gene transduction with chemotherapy
proved to be clinically active, since 17 patients achieved
stable disease, 2 patients had partial response, 4 pa-
tients had progressive disease, and 1 patient was not
assessable (Nemunaitis et al., 2000). However, in a fol-
lowing study, the clinical application of intratumoral
adenoviral TP53 gene therapy failed to provide addi-
tional benefit in patients treated with an effective first-
line chemotherapy for advanced NSCLC (Schuler et al.,
2001). Indeed, TP53 gene therapy was examined in 25
patients undergoing first-line chemotherapy for ad-
vanced NSCLC, including carboplatin at AUC6 plus pac-
litaxel 175 mg/m2 (day 1) or cisplatin 100 mg/m2 (day 1)
plus vinorelbine 25 mg/m2 (days 1, 8, 15, and 22), in
combination with intratumoral injection on day 1 of
7.5  1012 particles of SCH 58500, a recombinant ade-
novirus carrying wild-type TP53. No difference was ob-
served between the response rate of lesions treated with
TP53 gene therapy in addition to chemotherapy (52%
objective responses) and tumors treated with chemo-
therapy alone (48% objective responses) (Schuler et al.,
2001). Subgroup analysis according to the chemotherapy
regimens revealed evidence for increased mean local
tumor regressions in response to TP53 gene therapy in
patients receiving cisplatin plus vinorelbine, but not in
patients receiving carboplatin plus paclitaxel (Schuler et
al., 2001). There was no survival difference between the
two chemotherapy regimens, and the median survival of
the cohort was 10.5 months (1-year survival, 44%)
(Schuler et al., 2001). Furthermore, in 27 NSCLC pa-
tients treated with concomitant daily low-dose cisplatin
and radiotherapy, p53 expression showed no relation-
ship with outcome (Van de Vaart et al., 2000).
The study of pRB expression in 171 cell lines derived
from patients with lung malignancies, including
NSCLC, revealed absent or aberrant pRB protein ex-
pression in 12 of 80 NSCLCs. A stable, hypophosphory-
lated mutant pRB was detected in 3 NSCLC samples
(Shimizu et al., 1994). Analysis of the matched clinical
data showed no associations between RB status and age,
sex, extent of disease, performance status, smoking his-
tory, and previous treatment. In addition, retrospective
analysis showed no consistent correlation of pRB with
best clinical response, overall survival, or in vitro che-
motherapeutic drug sensitivity (Shimizu et al., 1994). A
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further investigation of the correlation of pRB expres-
sion levels and chemosensitivity of a panel of NSCLC
cell lines bearing a wild-type RB provided evidence of a
significant correlation between chemosensitivity and
high levels of RB protein (Yamamoto et al., 1998).
The relationship between chemoresistance and the
presence of RAS point mutations was investigated using
a panel of 20 NSCLC cell lines established from un-
treated patients. The 50% inhibitory concentration
(IC50) values for cisplatin were not significantly differ-
ent in the cell lines with or without mutated p21ras
(Tsai et al., 1993). The same finding was observed in
NCI-H82 human SCLC cells transduced with the v-H-
RAS oncogene, which resulted in the conversion of the
SCLC cellular phenotype into an NSCLC phenotype of
the NCI-H82Hras; p21ras expression was not associated
with significant changes in cisplatin sensitivity (Kauf-
mann et al., 1995). Nonetheless, the farnesyltransferase
inhibitor FTI-2153 was highly effective at suppressing
post-translational activation of oncogenic p21ras as well
as the constitutive activation of MAPK and human tu-
mor cell proliferation in soft agar. In addition to this, the
farnesyltransferase inhibitor FTI-2148 markedly inhib-
ited the growth of the human lung adenocarcinoma
A549 cells in nude mice in a dose-dependent manner,
and the combination therapy of FTI-2148 with cisplatin
resulted in a greater antitumor efficacy than mono-
therapy (Sun et al., 1999), possibly by interference with
biologic activation of p21ras. Finally, the combination of
the farnesyltransferase inhibitor SCH66336 with cispla-
tin produced antiproliferative effects that were additive
or synergistic over a broad range of clinically achievable
concentrations in A549 NSCLC cells (Adjei et al., 2001).
Examination of the effect of various drug sequences in
A549 cells revealed synergism when cells were exposed
to SCH66336 and then cisplatin, and antagonism when
drugs were administered in the opposite order. The ad-
ditive and synergistic effects resulted in enhanced apo-
ptosis with the SCH66336/cisplatin combination (Adjei
et al., 2001). SCH66336 was ineffective in the formation
or removal of cisplatin-DNA adducts, raising the possi-
bility that SCH66336 affected survival of cisplatin-
treated cells downstream of the DNA lesions (Adjei et
al., 2001). Therefore, although RAS mutations have a
modest effect on drug response of cancer cells, inhibition
of p21ras activity significantly enhances the effect of
cytotoxic agents administered in combination. In the
clinical setting, to determine whether the course of the
disease and the response to chemotherapy of patients
with advanced adenocarcinoma of the lung is affected by
K-RAS mutation, patients received chemotherapy with
mesna, ifosfamide, carboplatin, and etoposide (Roden-
huis et al., 1997). The presence of K-RAS mutations
could be established in 69 of 83 patients (83%). Patients
with a K-RAS mutation in their tumor were more likely
to have a close relative with lung cancer, but other
clinical characteristics, such as pattern of metastases,
response, and survival, were unrelated to the K-RAS
genotype (Rodenhuis et al., 1997). Therefore, patients
with advanced lung adenocarcinoma who harbor a RAS
mutation may have major responses to chemotherapy
and have similar progression-free and overall survival
as patients with RAS mutation-negative tumors (Roden-
huis et al., 1997). Finally, the prognostic value of K-RAS
mutations at codon 12 was evaluated in paraffin-embed-
ded specimens of 40 patients with stage III NSCLC who
underwent tumor resection after neoadjuvant treatment
with two cycles of ifosfamide, carboplatin, and etoposide,
and subsequent twice-daily radiotherapy with concur-
rent carboplatin and vindesine. A K-RAS codon 12-point
mutation was found in 13 of 28 resection specimens
(46%). Even after complete resection, the presence of a
K-RAS mutation was a significant predictor for a poor
progression-free survival (Broermann et al., 2002).
To study the interaction of genetic profile and muta-
tional status of key tumor-suppressor genes with anti-
cancer agents commonly used in NSCLC, the cytotoxic-
ity induced by carboplatin alone and in combination
with gemcitabine and paclitaxel was tested on the hu-
man cancer cell lines A549 (p16INK4a deleted, p53 wild-
type, and pRB wild-type); Calu-1 (p16INK4a deleted, p53
deleted, and pRB wild-type); and NCI-H596 (p16INK4a
wild-type, p53 mutated, and pRB deleted) (Edelman et
al., 2001). The IC50 of carboplatin was similar on A549
and Calu-1 cell lines (27 and 36 M), albeit it was much
lower on the NCI-H596 cell line (2.9 M). Although this
study did not evaluate the statistical relevance of these
findings and their possible link with the genetic pattern
of cell lines, the findings suggest a possible influence of
p16INK4a status on the chemosensitivity of cells that
were less sensitive to carboplatin if p16INK4a was de-
leted. Carboplatin was synergistic with gemcitabine in
all three cell lines, and the synergy was most pro-
nounced in the A549 cells when gemcitabine preceded
carboplatin (Edelman et al., 2001). Since the G2 check-
point has a key role in the response to DNA damage, a
flow cytometry study investigated the expression of cy-
clin B1, cdc2, cdc25c, and DNA content in two lung
cancer cell lines treated with cisplatin. In these cells, the
G2 arrest was associated with cdc2, cdc25c, cyclin B1,
and p16INK4a increase; however, G2 arrest after cisplatin
treatment was associated with deregulation of cyclin B1,
while other checkpoint proteins were not involved
(Links et al., 1998). Calu-1 NSCLC cells, which bear a
wild-type pRB and lack p53, do not arrest in G1 phase
following DNA damage; however, p16INK4a transduction
restores the G1 checkpoint arrest in response to treat-
ment with cisplatin (Shapiro et al., 1998). This finding
suggests that during tumor progression loss of p16INK4A
expression may be necessary for cells with wild-type
pRB to bypass the G1 arrest and attain a fully trans-
formed phenotype (Shapiro et al., 1998). In addition to
this, the replacement of p16INK4a into the p16INK4a-
negative, pRB-positive bladder cancer cell line EJ
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caused a profound inhibition of cell proliferation medi-
ated by arrest in the G1 phase of the cell cycle. In
contrast, the p16INK4a-positive, pRB-negative cell line
J82 was unaffected by gene transduction (Grim et al.,
1997). However, when adenovirally mediated p16INK4a
replacement was followed by cisplatin treatment, a
marked chemoresistance was observed in genetically
modified cells (Grim et al., 1997).
The exposure of the human lung carcinoma cell line
DLKP-SQ to clinically achievable concentrations of
doxorubicin generated a resistant variant, DLKP-SQ/
10p, which was found to be cross-resistant to P-gp- and
MRP-transportable drugs, but slightly sensitized to car-
boplatin (NicAmhlaoibh et al., 1999). Analysis of mRNA
levels in the resistant variant revealed overexpression of
the anti-apoptotic Bcl-xL transcript and the pro-apop-
totic Bax mRNA, but no alterations in Bcl-2 or Bag-1
mRNA levels (NicAmhlaoibh et al., 1999). Overexpres-
sion of the pro-apoptotic Bcl-xS gene in the DLKP-SQ/
10p line may explain the increase in sensitivity to car-
boplatin, and indicates that the relative expression of
different members of the Bcl-2 family of apoptosis-regu-
latory proteins may be important in determining sensi-
tivity to drug-induced apoptosis (NicAmhlaoibh et al.,
1999). After prolonged exposure of NCI-H460 NSCLC
cells to increasing concentrations of cisplatin, a resistant
subline was isolated (NCI-H460CIS); these cells exhib-
ited cross-resistance to other DNA damaging agents
such as doxorubicin and etoposide (Yoon et al., 2001).
Cisplatin exposure markedly increased p53 expression
in parental cells but not in NCI-H460CIS; without drug
treatment, Bcl-2 and Bax were expressed in NCI-
H460CIS cells, but not in parental cells (Yoon et al.,
2001). These data suggest that p53 function is abrogated
and Bax and Bcl-2 are up-regulated in NCI-H460CIS
cells, thus providing an explanation of cisplatin resis-
tance (Yoon et al., 2001). The protective role of Bcl-2
family members in cisplatin-induced cytotoxicity is fur-
ther confirmed by the evidence that stable expression of
Bcl-2 and Bcl-xL increases clonogenic survival of cells
treated with cisplatin from 18% to 47–51%, suppresses
cytochrome c release from mitochondria, caspase-8 acti-
vation, and occurrence of apoptosis by cisplatin treat-
ment in the NCI-H460 NSCLC cell line (Ferreira et al.,
2000a). Further confirmation of the importance of Bcl-2
in drug resistance against cisplatin has also been ob-
tained in SCLC cell lines (Sartorius and Krammer,
2002). In addition to this, overexpression of Bcl-2 and
p21Waf1/Cip1 in human A549 cells induces resistance to
cisplatin (Zhang et al., 1999). In vitro selection with
camptothecin generates the human NSCLC cell line
A549CPT, which is resistant to drug-induced apoptosis
by virtue of attenuation of caspase-3-like protease
activity, as compared with parental A549 cells (Zhang
et al., 1999). Likewise, transfection of either Bcl-2 or
p21Waf1/Cip1 cDNA into parental A549 cells resulted in
resistance to apoptosis, while treatment with Bcl-2
and p21Waf1/Cip1 antisense oligodeoxynucleotides re-
stored drug susceptibility in A549CPT cells (Zhang et al.,
1999). These results indicate that coinduction of Bcl-2
and p21Waf1/Cip1 in A549CPT cells may be involved in
acquired drug resistance by inhibition of caspase-medi-
ated apoptosis (Zhang et al., 1999). Long-term exposure
of A549 cells to the protein kinase inhibitor 7-hydroxys-
taurosporine (UCN-01) selected cells (A549UCN) with
acquired resistance against UCN-01. A549UCN exhibited
a 14-fold resistance against cisplatin compared with the
parental A549 line, and resistant cells were character-
ized by overexpression of the CDK inhibitors p21 and
p27, and of cyclins D1 and E and of Bcl-2 (Sugiyama et
al., 1999). In contrast, cyclin A and B1, pRB, and CDK2
were apparently down-regulated, without changes in
CDK4/6. UCN-01 hardly affected the expression of cyclin
B1 and induced pRB dephosphorylation in both cell
types. In A549UCN cells, but not in the parental line,
UCN-01 induced down-regulation of cyclin A and CDK2
activity (Sugiyama et al., 1999). In a clinical study 27
NSCLC patients were treated with concomitant daily
low-dose cisplatin and radiotherapy with the aim of in-
vestigating whether biological factors related to radio-
sensitivity and chemosensitivity have prognostic rele-
vance (Van de Vaart et al., 2000). Tumor specimens were
analyzed for p53 and Bcl-2 expression, cell proliferation
(Ki-67), and the occurrence of apoptosis. In addition to
this, cisplatin-DNA adducts in epithelial cells of the oral
cavity were assessed immunocytochemically. Univariate
and multivariate analyses were performed to assess the
association between the biological factors and survival
over a median follow-up of 41 months, during which 21
patients (78%) died (Van de Vaart et al., 2000). In a
univariate analysis age, tumor stage, and cisplatin-DNA
adduct staining were the only factors significantly asso-
ciated with survival (P  0.05, log-rank test), while p53,
Bcl-2, Ki-67, and apoptosis showed no relationship with
outcome (Van de Vaart et al., 2000). Multivariate anal-
ysis revealed that cisplatin-DNA adduct staining re-
mained an independent prognostic factor (hazard ratio,
0.10), with shorter survival times for patients with low
cisplatin-DNA adduct staining (Van de Vaart et al.,
2000).
Experimental data on the influence of c-MYC expres-
sion/amplification on chemotherapeutic activity of plat-
inum compounds in NSCLC are lacking. A few studies
have examined the chemosensitivity of SCLC and gen-
erally found that amplification of the c-MYC gene is
often correlated with poor prognosis and advanced, pre-
treated disease. A cisplatin-resistant SCLC subline,
GLC4CDDP, contains a c-MYC amplification; stable
transfection of the cell line with an antisense c-MYC
causes inhibition of cell proliferation, induces apoptosis,
reduces clonogenicity, and slightly increases sensitivity
to cisplatin in vitro (Van Waardenburg et al., 1996,
1997). The study of the effect of cisplatin exposure on the
degree of N-MYC amplification in two SCLC cell lines
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(H-69, SBC-4) demonstrated that the N-MYC gene was
amplified approximately 40- and 60-fold in SBC-4 and
H-69 cells, respectively, and these two cell lines were
more resistant to cisplatin than nine SCLC cell lines
without N-MYC amplification (Mizushima et al., 1996).
In 107 specimens (38 tumors and 69 tumor cell lines)
from 90 patients with SCLC, amplification of one of the
MYC family genes was found in 3 of 40 (8%) untreated
patients as compared to 19 of 67 (28%) treated subjects
(P  0.01) (Brennan et al., 1991). The MYC family DNA
amplification occurred in 17 of 54 (31%) tumor samples
from patients treated with cyclophosphamide-based
combinations and in 2 of 13 (15%) tissue specimens from
patients treated with etoposide/cisplatin (P  0.25). Fi-
nally, there were no prominent differences in the fre-
quency of amplification following treatment with vari-
ous chemotherapy regimens, and MYC family DNA
amplification was similar in tumors and cancer cell lines
obtained from the same patients (Brennan et al., 1991).
No data are available on the role of the MYC family on
carboplatin chemosensitivity.
Overexpression of the tyrosine kinase encoded by the
HER-2/neu gene, p185HER-2/neu, is a common alteration
in NSCLC and has been associated with poor prognosis
and drug-resistant phenotype. NSCLC cells that overex-
press HER-2/neu are less sensitive to cisplatin-induced
cytotoxicity in comparison to cells expressing low levels
of HER-2/neu (You et al., 1998). In agreement with this
evidence, the in vitro treatment of lung cancer cells with
the tyrosine kinase inhibitor CP127,374 and cisplatin
was more potent than cisplatin alone with respect to cell
growth inhibition and induction of apoptosis (You et al.,
1998). In addition to this, to examine whether the ty-
rosine kinase activity of p185HER-2/neu is required for
proliferation and resistance to chemotherapeutic drugs,
NSCLC cells overexpressing HER-2/neu were treated
with the tyrosine kinase inhibitor emodin alone and in
combination with cisplatin. Experimental results
showed that emodin preferentially suppressed the pro-
liferation of HER-2/neu-overexpressing NSCLC cells
and its combination with cisplatin resulted in synergis-
tic inhibition of lung cancer cell growth (Zhang and
Hung, 1996). These results indicate that tyrosine kinase
activity is required for the chemoresistant phenotype of
HER-2/neu-overexpressing NSCLC cells and that ty-
rosine kinase inhibitors can sensitize these cells to che-
motherapeutic drugs, including cisplatin (Zhang and
Hung, 1996). These data again support the relevant role
of HER-2/neu signaling in the regulatory balance
among cell proliferation, DNA repair, cell cycle check-
points, and apoptosis (You et al., 1998). Furthermore, in
a panel of 20 NSCLC cell lines established from previ-
ously untreated patients, high p185HER-2/neu expression
was correlated with chemoresistance, low S-phase frac-
tion, and long doubling times (Tsai et al., 1996b). By
contrast, cell lines expressing relatively low levels of
p185HER-2/neu were relatively chemosensitive and had
higher S-phase fraction and shorter doubling times.
Multivariate analysis revealed that the level of
p185HER-2/neu was the only independent predictor for
chemoresistance to cisplatin (Tsai et al., 1996b). Al-
though intrinsic resistance is likely to be a multifactorial
process, overexpression of p185HER-2/neu may be an im-
portant factor affecting drug sensitivity of NSCLC (Tsai
et al., 1996b). An additional reason for reduced cisplatin
sensitivity of cancer cells overexpressing HER-2/neu
may be the influence of these signaling pathways on
DNA repair activity, particularly through the nucleotide
excision repair (NER) system, which plays a major role
in the mechanism for repairing DNA damage by cispla-
tin. Indeed, the investigation of NER activity after cis-
platin-induced DNA lesions in a panel of 16 NSCLC cell
lines showed that high NER activity was closely corre-
lated with both cisplatin resistance and high expression
of p185HER-2/neu. On the contrary, high levels of EGFR
showed very little influence on the relationship between
p185HER-2/neu and cisplatin resistance, suggesting that
EGFR may be a secondary factor in modulating the
chemoresistance of NSCLC cells when compared with
HER-2/neu (Tsai et al., 2000). Moreover, the immuno-
histochemical analysis of HER-4 demonstrated its pres-
ence in 25% of NSCLC tissues; no response to gemcitab-
ine-cisplatin was documented in HER-4-positive
patients, while an objective response was seen in 11 of
15 (73%) HER-4-negative subjects, thus suggesting that
the lack of HER-4 expression significantly favored re-
sponse to chemotherapy (Merimsky et al., 2001).
No experimental findings are available in the litera-
ture on the role of FHIT in the chemosensitivity of
NSCLC. The only data are obtained in a human lung
cancer cell line (SCLC-R1) established from a metastatic
lesion of SCLC; in vitro, SCLC-R1 cells are sensitive to
cisplatin and carboplatin. The SCLC-R1 line is charac-
terized by a translocation involving chromosome 16 and
noticeable deletions in both the FHIT region in the short
arm of chromosome 3 [del(3)(p14)] and in the telomeric
region of the short arm of chromosome 12 [del(12)(p13)]
(Gasperi-Campani et al., 1998). No amplifications or
rearrangements were documented with respect to
c-MYC, L-MYC, N-MYC, int-2, HER-2/neu, RAS,
c-MOS, and hst-1 genes, while wild-type p53, pRB,
p21K-ras, and p21H-ras gene products were shown. The
neuron-specific enolase (NSE) level was much higher in
the cytosol of the cell line than in the serum of the
patient, and the cell line also had high expression of
chromogranin A and cytokeratin 19 (Gasperi-Campani
et al., 1998). Finally, overexpression of the excision re-
pair cross-complementing 1 (ERCC1) gene, which is cru-
cial in the repair of cisplatin-DNA adducts, is reported to
negatively influence the effectiveness of cisplatin-based
therapy and was found to be a predictive factor for
survival after cisplatin-gemcitabine administration in
advanced NSCLC (Lord et al., 2002).
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B. Taxanes
Paclitaxel and docetaxel (Fig. 2) are potent chemo-
therapeutic agents that interfere with mitotic spindle
function to block cells at G2/M, the most radiosensitive
phase of the cell cycle. Utilization of paclitaxel as a
radiation sensitizer in vivo to treat aggressive, locally
advanced neoplasms resulted in high response rates and
acceptable toxicity in patients with NSCLC (King et al.,
1999). Recent evidence suggests that paclitaxel is
unique in its ability to activate apoptosis in tumor cells
with TP53 mutations. To assess whether TP53 gene
therapy may enhance the effect of chemotherapy given
sequentially or concurrently with external beam radia-
tion, the combined effects of adenovirus-mediated wild-
type TP53 gene transfer, chemotherapy, and radiation
therapy on lung cancer growth in vitro and in vivo were
examined on human NSCLC cell lines A549, NCI-H460,
NCI-H322, and NCI-H1299. The combination of these
three therapeutic modalities, including paclitaxel, syn-
ergistically inhibited tumor cell growth at the 50% and
80% inhibitory effect levels in vitro (Nishizaki et al.,
2001). In a mouse model with NCI-H1299 and A549
xenografts, combined treatment synergistically inhib-
ited tumor growth in the absence of any apparent in-
crease in toxicity when compared with other treatments
and control groups. These findings suggest that a com-
bination of gene therapy, chemotherapy, and radiation
therapy may be an effective strategy for human cancer
treatment (Nishizaki et al., 2001). Wild-type TP53 gene
transfer by adenoviral vectors in the human NCI-H157
pulmonary squamous cancer cells and NCI-H1299 large
cell carcinoma cells induced a modest increase in the
anticancer efficacy of paclitaxel, and the analysis of the
interaction between paclitaxel and TP53 transduction
demonstrated an additive effect (Osaki et al., 2000).
However, it has been demonstrated that adenoviral
transfer of wild-type TP53 in seven NSCLC cell lines
with wild-type, deleted, or point-mutated TP53 syner-
gistically interacts with DNA-damaging agents in most
cell lines by enhancing apoptosis, but displays only ad-
ditive effects with paclitaxel and docetaxel (Horio et al.,
2000). In vitro and in vivo studies suggest that paclitaxel
may activate tumor cell apoptosis in the presence of
TP53 mutation and trigger tumor cell death by alternate
pathways. To assess whether this finding can be trans-
lated into the clinical setting, 30 patients with locally
advanced (stage III) NSCLC were treated with paclitax-
el/radiotherapy. Mutations in TP53 were found in 12 of
30 patients (40%). The objective response rate was 75%
for patients with tumors with p53 mutations, and 83%
for patients with wild-type p53, the difference being not
statistically significant. Therefore, in this study p53 mu-
tations do not predict the response of patients with
NSCLC to paclitaxel/radiotherapy, at variance with the
results obtained with other chemotherapeutic agents
and ionizing radiation (Safran et al., 1996). A similar
investigation was carried out in 25 patients with meta-
static NSCLC treated with single-agent paclitaxel. TP53
mutations in exons 5 through 8 were found in 8 of 25
patients (32%) and the response rates were 75% for
patients with TP53 mutations and 47% for patients with
wild-type TP53. The 1-year survival rates for patients
with and without TP53 mutations after treatment with
weekly paclitaxel were 63 and 53%, respectively, thus
confirming that TP53 mutations do not adversely affect
the response rate to paclitaxel as a single agent in met-
astatic NSCLC (King et al., 2000). Furthermore, ex vivo
chemosensitivity testing showed that TP53 mutations
did not correlate with the activity of paclitaxel/carbopla-
tin on cancer cells from primary NSCLCs (Vogt et al.,
2002). These findings are in agreement with the obser-
vation that the p53-null human NSCLC NCI-H358 cells
are sensitive to paclitaxel and that transfection with
wild-type TP53 slightly reduces the chemosensitivity to
the taxane (Ling et al., 2000). Indeed, treatment of NCI-
H358 cells with paclitaxel blocks cell-cycle progression
at the G2/M phase and increases cyclin B1 and cdc2
expression. On the contrary, the same treatment
slightly arrests the cell cycle at the G2/M phase and
elevates cyclin B1 expression in cells transfected with
wild-type TP53, which appeared to be blocked in the G1
phase of the cell cycle (Ling et al., 2000). These findings
suggest that transduction of cells with wild-type TP53
triggers the senescence program, which is responsible,
at least in part, for the reduced sensitivity to paclitaxel
(Ling et al., 2000). Other studies, however, demon-
strated that the infection of an adenoviral vector carry-
ing the wild-type TP53 into the human lung cancer cell
lines, NCI-H1299 (deleted p53), RERF-LC-OK (mutant
p53), and A549 (wild-type p53), synergistically increased
the sensitivity to several anticancer agents, including
docetaxel, regardless of the cellular p53 status (Inoue et
al., 2000). Finally, TP53 gene therapy was examined in
25 patients undergoing first-line chemotherapy for ad-
vanced NSCLC, including carboplatin at AUC6 plus pac-
litaxel 175 mg/m2 (day 1), or cisplatin 100 mg/m2 (day 1)
plus vinorelbine 25 mg/m2 (days 1, 8, 15, and 22) in
combination with intratumoral injection on day 1 of
7.5  1012 particles of SCH 58500, a recombinant ade-
novirus carrying wild-type TP53. No difference was ob-
served between the response rate of lesions treated with
TP53 gene therapy in addition to chemotherapy (52%
objective responses) and tumors treated with chemo-
therapy alone (48% objective responses) (Schuler et al.,
2001). Subgroup analysis according to the chemotherapy
regimens did not reveal evidence for increased local tu-
mor regressions in response to TP53 gene therapy in
patients receiving carboplatin plus paclitaxel (Schuler et
al., 2001).
Inhibition of p21ras activation by FTI-2148, which
prevents p21ras conjugation with farnesyl moiety, sup-
pressed the growth of the human lung adenocarcinoma
A549 cells in nude mice, and combination therapy of
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FTI-2148 with paclitaxel resulted in a greater antitumor
efficacy than monotherapy (Sun et al., 1999), thus pro-
viding indirect evidence of the possible influence of
p21ras biological activation on the response to pacli-
taxel.
Previous reports have demonstrated that reconstitu-
tion of p16INK4a has marked effects on the proliferative
capacity of tumor cell lines both in vitro and in vivo, and
that p16INK4a expression causes resistance to some che-
motherapeutic agents. The transduction of p16INK4a
with the recombinant adenovirus Adp16 to the p16INK4a-
negative, pRB-positive bladder cancer cell line EJ
caused a profound inhibition of cell proliferation medi-
ated by arrest in the G1 phase of the cell cycle. In
contrast, the p16INK4a-positive, pRB-negative cell line
J82 was unaffected by this treatment (Grim et al., 1997).
However, when adenovirally mediated p16INK4a replace-
ment was combined with the chemotherapeutic agent
paclitaxel, a marked chemoresistance was observed in
genetically engineered cells (Grim et al., 1997), an effect
likely to be dependent on the reconstitution of effective
G1 checkpoint block and reduction of the fraction of cells
progressing to the paclitaxel-sensitive G2/M phase
(Grim et al., 1997). The interaction of genetic profile and
mutational status of key tumor-suppressor genes with
paclitaxel in combination with other agents commonly
used in NSCLC was examined in the human NSCLC cell
lines A549 (p16INK4a deleted, p53 wild-type, and pRB
wild-type), Calu-1 (p16INK4a deleted, p53 deleted, and
pRB wild-type), and NCI-H596 (p16INK4a wild-type, p53
mutated, and pRB deleted) (Edelman et al., 2001). The
IC50 of paclitaxel was similar on the A549 and NCI-
H596 cell lines (1.8 and 1.4 nM), albeit it was higher (6
nM) on the Calu-1 cell line (Edelman et al., 2001). Al-
though the authors did not evaluate the statistical rel-
evance of these findings and their possible link with the
genetic pattern of cell lines being used, the data appear
to indicate that the loss of two major tumor-suppressor
genes, i.e., p16INK4a and p53, may adversely affect the
chemosensitivity of cells to paclitaxel, although pacli-
taxel is not a DNA-damaging agent.
The protective effect of Bcl-2 against apoptosis is lost
if the protein is phosphorylated; indeed, Bcl-2 phosphor-
ylation can be induced by agents that affect microtubule
depolymerization or prevent microtubule assembly, in-
cluding taxanes and cryptophycins. The human NCI-
H460 NSCLC cells express high levels of Bcl-2 and, after
a 4-h exposure to paclitaxel 50 nM, Bcl-2 phosphoryla-
tion was demonstrated by Western blot analysis (Lu et
al., 2001). In NCI-H460 cells, 90% cell killing was ob-
tained after 24 h of exposure to 20 nM paclitaxel, while
in the Bcl-2-negative Calu-6 NSCLC cells the same ef-
fect was obtained with a lower drug concentration (11
nM) (Lu et al., 2001). Thus, paclitaxel is an inducer of
Bcl-2 phosphorylation and can be active also in cells
with Bcl-2 overexpression, although the concentrations
required to exert its effect are higher in Bcl-2-negative
than in Bcl-2-positive cells (Lu et al., 2001). The in vivo
efficacy of paclitaxel 60 mg/kg i.v. every 3 weeks was
characterized in heterotransplanted human NSCLC tu-
mors characterized with respect to MRP, HER-2/neu,
EGFR, Bax, and Bcl-2, and p53 (Perez-Soler et al., 2000).
The response rate to paclitaxel was 21%, a percentage
similar to that reported in phase II studies in patients
with advanced NSCLC and treated with single-agent
paclitaxel. Tumor parameters significantly associated
with response were HER-2/neu and Bcl-2 expression; in
particular, all responding tumors were HER-2/neu ()
and Bcl-2 (), while 48% of nonresponding tumors were
HER-2/neu () and 43% were Bcl-2 () (Perez-Soler et
al., 2000). There was a trend toward a higher response
rate in Bax-positive tumors and MRP- and EGFR-nega-
tive tumors, but it was not statistically significant. The
response rate was independent of baseline p53 status
and mitotic index. Responding tumors had a higher Bax/
Bcl-2 ratio 24 h after therapy, but the difference was
only marginally significant (2.8 for responding tumors
versus. 1.1 for nonresponding tumors, P  0.07) (Perez-
Soler et al., 2000). The combination of two microtubule-
active agents, docetaxel and vinorelbine, is able to inac-
tivate the proto-oncogene Bcl-2 through protein
phosphorylation. Indeed, the administration of do-
cetaxel (60 mg/m2) and vinorelbine (45 mg/m2) every 2
weeks to chemotherapy-naive patients with advanced
NSCLC was associated with a major objective response
rate of 51%, a median survival time of 14 months, and
1-year survival rate of 60%, suggesting that this drug
combination is highly active for the treatment of ad-
vanced NSCLC (Miller et al., 2000).
The cytotoxic activity of paclitaxel is dependent on the
interaction with microtubules, which are heterodimers
of - and -tubulin; both of them are guanosine triphos-
phate (GTP)-binding proteins and -tubulin is a GT-
Pase, whereas -tubulin has no enzyme activity. Bind-
ing sites for paclitaxel have been demonstrated on the
-tubulin subunit that has six isotypes. The increased
expression of the brain-specific human class III -tubu-
lin isotype, encoded by the H4 gene, is associated with
paclitaxel resistance in ovarian tumors and NSCLC cell
lines (Kavallaris et al., 1999). The treatment of paclitax-
el-resistant A549-T24 NSCLC cells, which display a
4-fold increase in H4 expression compared to parental
A549 cells, with 1 M antisense oligodeoxynucleotides
targeted against various regions of the H4 gene re-
duced mRNA expression by 40 to 50%, and the abun-
dance of the class III -tubulin isotype corresponded to a
39% increase in sensitivity to paclitaxel. These findings
support the role of H4 and class III -tubulin expres-
sion in paclitaxel resistance and have potential implica-
tions for the treatment of paclitaxel-resistant tumors
(Kavallaris et al., 1999). An additional mechanism of
paclitaxel resistance might involve mutations in GTP-
and paclitaxel-binding domains of -tubulin in tumor
cells. -Tubulin mutations in exons 1 and 4 were ob-
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served in the DNA isolated from biopsy specimens of 16
patients (33%) of a cohort of 49 subjects with advanced
or metastatic NSCLC (Monzo et al., 1999). Patients were
treated with two schedules of paclitaxel, 210 mg/m2 over
3 h and 200 mg/m2 over 24 h, and none of the patients
with -tubulin mutations had an objective response,
whereas 39.4% of patients without -tubulin mutations
had complete or partial responses (Monzo et al., 1999).
Median survival was 3 months for the 16 patients with
-tubulin mutations and 10 months for the 33 patients
without -tubulin mutations, the difference being highly
statistically significant (Monzo et al., 1999). The analy-
sis of 20 lung cancer cell lines and 22 specimens from
NSCLC patients showed silent mutations at codon 180
of the -tubulin gene, which encodes the GTP-binding
site of the protein, and at codons 195 and 217 (Tsurutani
et al., 2002). However, neither missense nor nonsense
mutations within or near the GTP-binding site of the
-tubulin gene were detected. These results indicate
that -tubulin gene mutations might not play a major
role in the mechanism of resistance to paclitaxel in this
selected patient population (Tsurutani et al., 2002).
Acquired resistance to paclitaxel can be mediated by
several mechanisms, including overexpression of P-gp,
altered expression of -tubulin isotypes, intrinsic or ac-
quired mutations in -tubulin, and expression of novel
genes. -Tubulin mutations were recently identified in
33% of 49 NSCLC patients, none of whom had an objec-
tive response to paclitaxel treatment (Rosell and Felip,
2001). Cisplatin resistance is associated with several
molecular alterations, including overexpression of me-
tallothionein and the mRNA level of the excision repair
cross-complementing (ERCC1) gene. Early detection of
circulating cancer cells in peripheral blood and the anal-
ysis of DNA abnormalities may be used to monitor the
effects of therapy. In particular, serum DNA can be used
as a surrogate for detecting genetic abnormalities and as
a potential guide for customizing treatment. Indeed,
-tubulin mutations in serum DNA were detected in
42% of 131 NSCLC patients and in none of the healthy
individuals (Rosell and Felip, 2001).
Overexpression of P-gp by tumors results in multi-
drug resistance to structurally unrelated chemothera-
peutic agents including vinca alkaloids, anthracyclines,
taxanes, and epipodophyllotoxins, and this type of resis-
tance may be reverted by P-gp antagonists; one such
agent, LY335979, fully restored sensitivity to paclitaxel
in CEM/VLB100 leukemia cells at 0.1 M (Dantzig et
al., 1996). LY335979 blocked [3H]azidopine photoaffin-
ity labeling of P-gp in CEM/VLB100 plasma membranes
and competitively inhibited equilibrium binding of
[3H]vinblastine to P-gp, with a Ki value of approximately
0.06 M. Furthermore, the inhibition of P-gp activity
enhanced the antitumor activity of paclitaxel in a model
of a human NSCLC nude mouse xenograft (Dantzig et
al., 1996). On the basis of the crucial importance of P-gp
in modulating the therapeutic response to paclitaxel, in
vivo imaging of P-gp has been attempted to assess the
likelihood of response of tumors to P-gp-transportable
drugs, including paclitaxel. For this purpose, 99mTc-
tetrofosmin was administered to 20 patients with stage
III or IV NSCLC before chemotherapy with paclitaxel
and tumor-to-normal lung ratios, and retention indices
were calculated by chest imaging to assess the expres-
sion of P-gp in NSCLC (Kao et al., 2001). The early and
delayed mean tumor-to-normal lung ratios were 1.59 	
0.25 and 1.50 	 0.25, respectively, for 10 patients with a
good response to paclitaxel and 1.09 	 0.09 and 1.03 	
0.05, respectively, for 10 patients with a poor response
(P  0.001). On the contrary, retention index was not a
predictive factor of response to paclitaxel as other prog-
nostic factors, including age, sex, tumor size, stage, and
cell type. Therefore, in vivo imaging of P-gp may be
useful in predicting the chemotherapeutic response to
paclitaxel (Kao et al., 2001; Shiau et al., 2001).
C. Gemcitabine
Gemcitabine (Fig. 2) is a cytidine analog that is intra-
cellularly phosphorylated by deoxycytidine kinase to
gain cytotoxic activity that is dependent on inhibition of
ribonucleotide reductase and drug incorporation into the
DNA during the S phase. Deoxycytidine kinase is a
rate-limiting enzyme required for the activation of the
pyrimidine analog cytarabine (Beausejour et al., 2002),
the most widely used agent for the chemotherapy of
hematological malignancies. Deoxycytidine kinase also
plays an important role in the activation of several new
agents for the treatment of leukemia, such as the purine
analogs 2-chloro-deoxyadenosine and fludarabine. Gem-
citabine has remarkable therapeutic activity as a single
agent against several solid malignancies, such as
NSCLC, suggesting that deoxycytidine kinase is a
widely distributed important target for the activation of
antimetabolites in solid tumors. Studies on the regula-
tion of deoxycytidine kinase have shown that the en-
zyme has a complex regulation since it undergoes feed-
back inhibition by intracellular nucleotides (Singhal et
al., 1992). In addition to this, there is an inverse rela-
tionship between doubling time and deoxycytidine ki-
nase activity in cancer cell lines, with rapidly growing
cells (doubling time of approximately 20 h) showing the
highest activity, and slower-growing cells (doubling time
of approximately 60 h) showing the lowest enzyme ac-
tivity (Singhal et al., 1992). In the human NSCLC cell
line SW1573, 5 M cortisol and 100 nM dexamethasone
decreased the sensitivity of cancer cells to gemcitabine,
cortisol reduced deoxycytidine kinase activity in
SW1573 cells, while dexamethasone decreased, in the
same cells, the activity of thymidine kinase 2, an enzyme
involved in the salvage pathway of gemcitabine (Berg-
man et al., 2001b). These data provide evidence that the
interference of drugs on metabolic pathways of gemcit-
abine might be clinically relevant, particularly with ste-
roids such as dexamethasone, which are frequently used
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to treat side effects of cytotoxic therapy (Bergman et al.,
2001b). Furthermore, a high level of resistance to gem-
citabine in human lung carcinoma SW-1573 cells is as-
sociated with deoxycytidine kinase deficiency at mRNA
and protein levels; sensitivity to other antitumor drugs
was not altered, except for cytarabine (van Bree et al.,
2002). Cytosolic 5-nucleotidase is responsible for deac-
tivation of nucleotides; solid tumors, such as adenocar-
cinomas of the lung, are frequently hypoxic and are,
therefore, likely to exhibit increased nucleotide break-
down through the 5-nucleotidase pathway (Blay et al.,
1997). 5-Nucleotidase activity is likely to play an im-
portant role in tumor resistance to nucleoside analogs;
although this hypothesis has not been investigated in
lung cancer, data are presented in the literature dem-
onstrating that increased enzyme activity is likely to be
responsible for the decreased amount of ribonucleotides
and deoxyribonucleotides in leukemia cells resistant to
2-chloro-deoxyadenosine and cytarabine (Lotfi et al.,
2001). Cytidine deaminase irreversibly inactivates gem-
citabine to the metabolite difluoro-deoxyuridine
(Beausejour et al., 2002); the enzyme is widely distrib-
uted within tissues and its activity was found to be high
in tissues from various types of human cancers, includ-
ing NSCLC (Miwa et al., 1998). Indeed, gemcitabine was
less effective against tumors xenotransplanted to ani-
mals with high levels of cytidine deaminase in cancer
cells (Miwa et al., 1998). Of note, NCI-H69DAU, a dauno-
rubicin-resistant variant of NCI-H69 with overexpres-
sion of P-gp, and NYHVM, a teniposide-resistant variant
of NYH with an altered topoisomerase II target, were
more sensitive to gemcitabine than the parental cell
lines because of a 4.3- and 2-fold increased activity of
deoxycytidine kinase, respectively (Bergman et al.,
2001a). Furthermore, cytidine deaminase was 9-fold
lower in NCI-H69DAU cells (Bergman et al., 2001a).
However, recent results obtained in the human A549
NSCLC cells transduced with deoxycytidine kinase dem-
onstrated that difluoro-deoxyuridine was cytotoxic to
the A549dCK cells, but not to the wild-type cells, possibly
as a result of the activity of the mitochondrial thymidine
kinase, an important modulator of gemcitabine-induced
cell toxicity (Beausejour et al., 2002).
To explore the level of expression of genes encoding
enzymes of nucleoside metabolism, a recent study pro-
vided evidence of heterogeneous expression of deoxycy-
tidine kinase, 5-nucleotidase, and cytidine deaminase
in tumor tissue from 42 untreated patients with NSCLC
(De Braud et al., 2001), suggesting the possible use of
gene expression profiling of drug-metabolizing enzymes
to predict chemosensitivity to gemcitabine (Fig. 3). Gem-
citabine and paclitaxel are active agents in the treat-
ment of NSCLC; their simultaneous or sequential com-
bination in the NSCLC cell lines NCI-H460, NCI-H322,
and Lewis Lung resulted in comparable cytotoxicity,
varying from additivity to antagonism. Gemcitabine
caused an S (48%) and G1 (64%) arrest at IC50 and
10-fold the IC50, respectively (Kroep et al., 2000). Pacli-
taxel induced G2/M arrest (70%) which was maximal
within 24 h at 10-fold the IC50. Apoptosis was more
pronounced when paclitaxel preceded gemcitabine, as
compared to the reverse sequence. In NCI-H460 cells,
paclitaxel increased the accumulation of the active
triphosphate metabolite of gemcitabine 2-fold in con-
trast to NCI-H322 cells (Kroep et al., 2000). Paclitaxel
did not affect deoxycytidine kinase, but nucleotide levels
increased, possibly explaining the high concentrations of
the active triphosphate metabolite of gemcitabine
reached within cells; moreover, gemcitabine incorpora-
tion into the RNA was enhanced (Kroep et al., 2000).
Gemcitabine almost completely suppressed DNA syn-
thesis in cell lines (70–89%), while paclitaxel had a
minor effect and did not enhance the inhibitory effect of
gemcitabine on DNA synthesis (Kroep et al., 2000).
Therefore, gemcitabine-paclitaxel did not show se-
quence-dependent cytotoxic effects and all combinations
were not more than additive. However, since paclitaxel
increased active triphosphate metabolite accumulation,
gemcitabine incorporation into RNA, and apoptotic in-
dex, the administration of paclitaxel before gemcitabine
may be preferred compared to the reverse sequence
(Kroep et al., 2000). Indeed, a clinical study in which the
sequence of paclitaxel followed by gemcitabine was ad-
ministered on a weekly basis to chemotherapy-naive
FIG 3. Intracellular metabolism of gemcitabine (dFdC) to difluorode-
oxyuridine (dFdU), and to mono- (dFdCMP), di- (dFdCDP) and triphos-
phate (dFdCTP) metabolites. Phosphorylation of gemcitabine by deoxy-
cytidine kinase (dCK), inhibition of ribonucleotide reductase (RR) by
dFdCDP and incorporation of dFdCTP into DNA are associated with
cytotoxicity and tumor response. On the contrary, deamination of gem-
citabine by cytidine deaminase (CdA) to produce dFdU and dFdCMP
dephosphorylation by 5-nucleotidase is associated with drug inactivation
and tumor resistance. Deoxycytidine kinase may be up-regulated as a
consequence of ribonucleotide reductase inhibition; in addition to this,
DNA repair may induce dCK activity.
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patients with stage III-IV NSCLC demonstrated objec-
tive responses at all dose levels, with an overall response
rate of 43% in 30 evaluable patients (De Pas et al., 2000).
Hematological toxicity included grade 4 neutropenia,
grade 3 thrombocytopenia, and febrile neutropenia. The
worst nonhematological toxicity was grade 3 elevation in
serum transaminases and grade 2 neurosensory toxicity
in 8% and 5% of cycles, respectively. This study demon-
strated that the weekly administration of paclitaxel and
gemcitabine is well tolerated, and has promising antitu-
mor activity in NSCLC at the recommended dose of 100
mg/m2 paclitaxel and 1500 mg/m2 gemcitabine (De Pas
et al., 2000).
Gemcitabine induces apoptosis in drug-sensitive cells;
therefore, the involvement of Bcl-2 superfamily mem-
bers was investigated. Previous studies have demon-
strated that several splice variants are derived from
both the caspase 9 and Bcl-x genes in which the Bcl-x
splice variant, Bcl-xL, and the caspase 9 splice variant,
caspase 9b, inhibit apoptosis in contrast to the pro-
apoptotic splice variants, Bcl-xS and caspase 9 (Chalfant
et al., 2002). Treatment of A549 NSCLC cells with gem-
citabine down-regulated the levels of anti-apoptotic
Bcl-xL and caspase 9b mRNA with a concomitant in-
crease in the mRNA levels of pro-apoptotic Bcl-xS and
caspase 9 (Chalfant et al., 2002). In addition to this, the
Fas/FasL system in lung cancer cells was examined
upon exposure to gemcitabine. All lung cancer cell lines
(NCI-H460, NCI-H322, GLC4, GLC4/ADR, NCI-H187,
and N417) expressed Fas and FasL at RNA and protein
levels, and apoptosis could be induced in 4 of 6 cell lines
upon exposure to the Fas agonist monoclonal antibody
CLB-CD95/15 (Ferreira et al., 2000b). After gemcitabine
exposure no significant FasL upregulation was ob-
served, whereas Fas expression was increased in the
wild-type p53 cell line NCI-H460, but not in cells with
mutant p53 (Ferreira et al., 2000b). Moreover, no corre-
lation was observed in lung cancer cell lines between
sensitivity to gemcitabine and to the antibody CLB-
CD95/15; in addition to this, preincubation of cells with
either the Fas-antagonist antibody CLB-CD95/2 or a
FasL-neutralizing antibody did not protect from drug-
induced apoptosis. Finally, caspase-8 activation was ob-
served upon drug exposure independently from Fas/
FasL signaling. Taken together, these observations
provide evidence against a role of the Fas/FasL signaling
pathway in drug-induced apoptosis in lung cancer cells
(Ferreira et al., 2000b).
The effects of gemcitabine on expression of p53 and
p21, cell proliferation and induction of apoptosis, and
cell cycle distribution were evaluated in the human lung
cancer cell lines NCI-H460 and NCI-H322. Gemcitabine
inhibited cell growth and induced apoptosis in a concen-
tration- and time-dependent manner; flow-cytometry
analysis of DNA at 4, 24, 48, and 72 h after treatment
with gemcitabine at IC80 demonstrated the accumula-
tion of cells in the G1 phase (Tolis et al., 1999). Gemcit-
abine induced p53 and p21 expression in the p53 wild-
type NCI-H460 cell line but not in the p53 mutant NCI-
H322 cell line; the percentage of cells expressing p53
was highest after treatment with drug concentrations
corresponding to IC80, whereas the highest percentage
of p21-positive cells could be induced by treatment with
gemcitabine at IC50 (Tolis et al., 1999). These findings
suggest that low concentrations of gemcitabine induce
cell cycle arrest through the activity of p53 and p21,
whereas higher drug concentrations induce p53-medi-
ated apoptosis (Tolis et al., 1999), thus providing evi-
dence of the importance of wild-type p53 expression in
the chemosensitivity to gemcitabine. To evaluate
whether the major tumor-suppressor genes are involved
in the response of NSCLC cells in vitro to gemcitabine,
the human cell lines A549 (p16INK4a deleted, p53 wild-
type, and pRB wild-type), Calu-1 (p16INK4a deleted, p53
deleted, and pRB wild-type), and NCI-H596 (p16INK4a
wild-type, p53 mutated, and pRB deleted) were evalu-
ated with respect to gemcitabine alone and in combina-
tion with carboplatin and paclitaxel (Edelman et al.,
2001). The IC50 of gemcitabine was similar in the A549
and NCI-H596 cell lines (11 and 10 nM), albeit some-
what higher (18 nM) on the Calu-1 cell line (Edelman et
al., 2001), again indicating that the integrity of at least
p16INK4a or p53 tumor-suppressor genes renders cells
more sensitive to growth inhibition by the nucleoside
analog. In the A549 cell line all combinations of gemcit-
abine with carboplatin and paclitaxel demonstrated an-
tagonism at lower fractions affected and synergism at
higher fractions affected. On the contrary, the NCI-
H596 cell line displayed the highest sensitivity to all
drug combinations, while in Calu-1, bearing a deletion
in both p16INK4a and p53, the simultaneous administra-
tion of gemcitabine and carboplatin was borderline ad-
ditive or antagonistic (Edelman et al., 2001). Overall,
p16INK4a and p53 appear important determinants of
chemosensitivity of cancer cells to gemcitabine.
Inhibition of p21ras activation by FTI-2148 sup-
pressed the growth of the human lung adenocarcinoma
A-549 cells in nude mice and combination therapy of
FTI-2148 with gemcitabine resulted in a more enhanced
antitumor efficacy than monotherapy (Sun et al., 1999),
thus suggesting a potential negative role of p21ras acti-
vation by mutation or overexpression on the activity of
gemcitabine. Furthermore, transfection of the NCI-
H460 human NSCLC cell line with the anti-apoptotic
genes Bcl-2 or Bcl-xL was associated with increased
clonogenic survival of cells treated with gemcitabine
from 15% to 50–54%, thus indicating that the cytotoxic
effect of gemcitabine is antagonized by Bcl-2 and Bcl-xL
(Ferreira et al., 2000a).
The intrinsic resistance of lung cancer cells against
gemcitabine does not correlate with the level of HER-2/
neu expression, although a modest reduction in the che-
mosensitivity to the nucleoside analog is seen in cells
with high p185HER-2/neu levels (Tsai et al., 1996a). In
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addition to this, the combination of gemcitabine with
DNA-damaging agents, including cisplatin, may be ac-
tive against NSCLC cells overexpressing HER-2/neu,
because p185HER-2/neu up-regulation is associated with a
more effective DNA repair ability, thus attenuating the
lethal effects of chemotherapeutic agents. Furthermore,
the comparison of the interaction among gemcitabine-
cisplatin, gemcitabine-etoposide, and cisplatin-etoposide
in a panel of 12 NSCLC cell lines and the analysis of the
correlations between the level of p185HER-2/neu and drug
cytotoxicity demonstrated little cross-resistance of gem-
citabine to either etoposide or cisplatin (Tsai et al.,
1996a). Furthermore, gemcitabine-containing combina-
tions demonstrated equivalent or superior activity com-
pared to cisplatin-etoposide, with gemcitabine-cisplatin
showing a greater synergistic activity (Tsai et al.,
1996a). The effect of cisplatin-etoposide was not related
to p185HER-2/neu expression, whereas gemcitabine-con-
taining regimens, especially gemcitabine-cisplatin, had
a greater cytotoxicity against cells with high levels of
p185HER-2/neu (Tsai et al., 1996a). These findings indi-
cate that the gemcitabine-cisplatin combination is more
active than etoposide-cisplatin, particularly in cells with
enhanced expression of the HER-2/neu gene (Tsai et al.,
1996a).
D. Epipodophyllotoxins
Epipodophyllotoxins are tight-binding inhibitors of to-
poisomerases II, and etoposide (Fig. 2) is the epipodo-
phyllotoxin most widely used in NSCLC. A study exam-
ined the effect of introducing a mutant TP53 gene into
the NCI-H460 cell line, which carries a wild-type TP53
gene, and the wild-type TP53 gene into the NCI-H1437,
NCI-H727, NCI-H441, and NCI-H1299 cells carrying a
p53 protein mutated at amino acid residues 143, 175,
248, and 273, respectively, on the chemosensitivity to
several anticancer agents, including etoposide (Lai et
al., 2000). The representative cell line NCI-H1437 cells
transfected with wild-type TP53 genes showed a dra-
matic increase in the susceptibility to etoposide com-
pared to untransfected NCI-H1437. An increase in che-
mosensitivity to etoposide was also observed in wild-
type TP53 transfectants of NCI-H727, NCI-H441, and
NCI-H1299 cells (Lai et al., 2000). In contrast, loss of
cytotoxicity by etoposide and a lack of p53-mediated cell
death were observed in NCI-H460 cells transfected with
mutant TP53. These observations suggest that TP53
gene status modulates the degree of chemosensitivity
and induction of apoptosis by etoposide in NSCLC cells
(Lai et al., 2000). Using a panel of 7 NSCLC cell lines
with wild-type, deleted, or point-mutated TP53, the in
vitro cytotoxicity of etoposide was examined in combina-
tion treatment with a TP53 transduction by an adeno-
viral vector. Gene transduction and etoposide showed
synergistic effects in 6 of 7 cell lines and additive effects
against a p53-mutated cell line (Horio et al., 2000). Flow
cytometry and DNA fragmentation analysis revealed
that TP53 transduction enhanced the apoptotic death
induced by etoposide in 6 of 7 cell lines (Horio et al.,
2000). These results suggest that wild-type TP53 plays
an important role in cell response to etoposide and gene
transduction may synergistically enhance the chemo-
sensitivity of the majority of NSCLC cells to DNA-dam-
aging agents due to the enhancement of apoptosis (Horio
et al., 2000). Additional studies provided evidence that
TP53 transduction by an adenoviral vector into the
NSCLC cell lines NCI-H1299 (p53 deleted), RERF-
LC-OK (p53 mutated), and A549 (wild-type p53) in-
creased the sensitivity to etoposide regardless of the
baseline TP53 status, and a synergism between gene-
therapy and etoposide was confirmed (Inoue et al.,
2000). The immunohistochemical analysis of p53 in 146
surgically resected specimens of NSCLC demonstrated
that 65 of 146 samples (45%) showed abnormal p53
protein accumulation in 10% of cancer cells within the
tumor tissue (p53), whereas 81 (55%) were p53, in
which no or less than 10% positive cancer cells were
detected (Higashiyama et al., 1998). In vitro chemosen-
sitivity testing on surgical samples to several anticancer
agents, including etoposide, was then performed by a
collagen gel-droplet embedded culture system. Although
it was demonstrated that p53-negative tumors were sig-
nificantly more sensitive to some anticancer agents, in-
cluding 5-fluorouracil, than p53-positive samples, the
same finding was not observed with etoposide (Higash-
iyama et al., 1998). To investigate whether TP53 affects
the expression of MRP, one of the major factors for
non-P-gp-mediated multidrug resistance in lung cancer,
107 NSCLCs were examined by immunohistochemistry
and it was shown that 43.9% were positive for MRP
(Oshika et al., 1998). In addition to this, NSCLC speci-
mens with mutant p53 showed a significant correlation
with MRP upregulation and coexpression of MRP and
p53 in the same NSCLC cells was also demonstrated
(Oshika et al., 1998). Twenty-six patients with MRP-
positive tumors who underwent postoperative chemo-
therapy with MRP-transportable anticancer drugs, such
as etoposide, had significantly poorer prognosis than did
those with MRP-negative tumors (Oshika et al., 1998).
In addition to this, NSCLC patients with coexpression of
MRP and p53 showed poorer clinical course than did
those without MRP and p53 (P  0.014). These results
suggest that MRP overexpression is affected by mutant
p53 and this combination adversely influences the prog-
nosis of NSCLC (Oshika et al., 1998). Finally, etoposide
treatment of TP53-mutated SCLC H69 and GLC4 cell
lines is not associated with the increase in the p53-
target gene p21Waf1/Cip1; thus the progression of cells
through the G2/M phase is allowed and apoptosis may
occur (Liu et al., 2002).
Activation of the HER-2/neu gene is frequently en-
countered in NSCLCs and has been linked to shortened
survival. The analysis of chemosensitivity of 20 NSCLC
cell lines established from untreated patients demon-
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strated that mutation of the TP53 gene was a common
event (18 of 20 lines); there was no relationship, how-
ever, between mutations at any specific codon and che-
moresistance. On the contrary, multivariate analysis
revealed that the expression of HER-2/neu was the only
independent predictor for chemoresistance to etoposide
(Tsai et al., 1996b). Further investigation of the role of
the HER-2/neu-encoded tyrosine kinase p185HER-2/neu
on the chemosensitivity and drug-induced cell cycle
changes of NSCLC cell lines demonstrated that high-
p185HER-2/neu-expressing cells were more resistant to
etoposide, but displayed enhanced chemosensitivity to tyr-
phostin AG825, a preferential inhibitor of p185HER-2/neu,
which may be used in combination chemotherapy to
sensitize tumor cells to the activity of etoposide (Tsai et
al., 1996c). A study on the effect of HER-2/neu overex-
pression and RAS point mutations on the chemosensi-
tivity to several anticancer agents, including etoposide,
on 20 NSCLC cell lines established from untreated pa-
tients was in agreement with other studies on this issue
and demonstrated a significant direct correlation be-
tween the IC50 values for all drugs and the degree of
HER-2/neu gene expression in all 20 NSCLC cell lines
(Tsai et al., 1993). The IC50 values for etoposide in cells
with RAS mutations were slightly lower than in those
without RAS mutations (borderline significance, P 
0.031). Interestingly, HER-2/neu expression in cell lines
with RAS mutations was lower than in those without
RAS mutations, although the difference was not signif-
icant. These findings confirm that overexpression of
HER-2/neu is a marker for intrinsic multidrug resis-
tance and of therapeutic failure in NSCLC (Tsai et al.,
1993).
The relationships between chemoresistance and the
presence of RAS point mutations in 20 NSCLC cell lines
established from untreated patients demonstrated that
RAS mutations do not adversely affect the activity of
etoposide in NSCLC (Tsai et al., 1993). According to this
finding, H-ras transduction in the NCI-H82 SCLC cells
(NCI-H82Hras) resulted in a phenotypic change toward
NSCLC with no change in etoposide sensitivity (Kauf-
mann et al., 1995). This observation was further con-
firmed by a study in patients affected by NSCLC; sub-
jects were treated with chemotherapy including mesna,
ifosfamide, carboplatin, and etoposide, and stratification
on the basis of K-RAS mutational status showed that the
response rate and progression-free and overall survival
were not affected by K-RAS mutation in the primary
tumor (Rodenhuis et al., 1997).
The analysis of the relationship between pRB expres-
sion levels and cytotoxicity of etoposide in a panel of
NSCLC cell lines with wild-type pRB provided evidence
of a significant direct correlation between chemosensi-
tivity and high levels of pRB expression (P  0.049)
(Yamamoto et al., 1998). The analysis of the effect of
etoposide on pRB status and cell cycle distribution of the
NSCLC cell lines Ma-12, the most sensitive, and Ma-31,
the most resistant, showed that etoposide, after a 24-h
exposure at 0.1–10 M, suppressed pRB expression and
induced pRB dephosphorylation and accumulation of
Ma-12 cells in the G2/M phase of the cell cycle
(Yamamoto et al., 1998). On the contrary, etoposide ex-
posure was associated with phosphorylation of pRB and
no changes in pRB expression and cell cycle distribution
in Ma-31 cells (Yamamoto et al., 1998). Despite these in
vitro findings, the analysis of pRB expression in clinical
specimens was not correlated with clinical outcome. In-
deed, absent or aberrant pRB expression was detected in
12 of 80 NSCLC specimens (Shimizu et al., 1994). A
stable, hypophosphorylated mutant pRB was detected in
three NSCLC samples. Analysis of the matched clinical
data showed no associations between pRB status and
age, sex, extent of disease, performance status, smoking
history, and previous treatment (Shimizu et al., 1994).
Retrospective analysis showed no correlation of pRB
expression with best clinical response, overall survival,
or in vitro chemotherapeutic drug sensitivity (Shimizu
et al., 1994). An investigation was carried out to study
the relationship between the immunocytochemical ex-
pression of topoisomerases II and II, MRP, p53, p21,
and Bcl-2 in primary tumor samples from 93 patients
who were then treated with etoposide-based chemother-
apeutic regimens (Dingemans et al., 1999). High levels
of topoisomerases II and II were associated with
shorter survival and lower complete response rate, re-
spectively. In addition to this, multivariate analysis
demonstrated that high expression of topoisomerase II
and Bcl-2 were predictive for shorter survival (Dinge-
mans et al., 1999). Therefore, high expression of topo-
isomerases II and II and Bcl-2 adversely affects the
efficacy of etoposide-based chemotherapy (Dingemans et
al., 1999). No data are reported in the literature on the
influence of c-MYC on chemoresponsiveness to etopo-
side. The available data are obtained in SCLC, in which
a dysregulation of both c-MYC gene expression and ret-
inoid signaling pathways commonly occurs. Preclinical
data provide evidence that all-trans-retinoic acid inhib-
its SCLC in vitro growth and affects c-MYC expression
(Kalemkerian et al., 1998). The administration of com-
bination chemotherapy with etoposide (120 mg/m2 i.v.
on days 1–3), cisplatin (60 mg/m2 i.v. on day 1), and
all-trans-retinoic acid (150 mg/m2/day p.o. for up to 1
year) in patients with SCLC induced 1 complete re-
sponse and 9 partial responses in 22 assessable patients,
for an overall response rate of 45% (Kalemkerian et al.,
1998). The median survival was 10.9 months and the
1-year survival was 41%, being similar to treatment
with cisplatin and etoposide alone (Kalemkerian et al.,
1998). These data indirectly argue against a major role
of c-MYC expression in tumor cell sensitivity to etopo-
side. To characterize the mechanisms associated with
chemoresistance in NSCLC, the expression of P-gp,
MRP, and LRP was examined using the A549 cell line
selected for resistance to etoposide. The wild-type A549
88 DANESI ET AL.
cells strongly express LRP, while the MRP protein is
expressed at a moderate level and P-gp is not detected
(Trussardi et al., 1998). Induction of resistance to etopo-
side paralleled an increase in the expression of the MRP
gene and a decrease in LRP. These results indicate that
NSCLC cells exhibit a complex pattern of drug-resis-
tance proteins, still susceptible to evolve under treat-
ment (Trussardi et al., 1998). In an additional study,
MRP gene expression was examined by reverse tran-
scriptase-polymerase chain reaction (RT-PCR) and pro-
tein immunoblotting in 15 unselected cell lines, and it
was found that MRP was frequently expressed in
NSCLC, with markedly varying intensity (Berger et al.,
1997). Two cell lines expressed high MRP levels without
amplification of the MRP gene. Using daunomycin as
MRP substrate and verapamil as MRP modulator,
transporting activity of MRP was related to its gene
expression (Berger et al., 1997). Moreover, a significant
correlation between MRP expression and chemoresis-
tance against a number of anticancer agents, including
etoposide, was observed (Berger et al., 1997). A clear
relationship between MRP gene expression and sensi-
tivity to etoposide was also observed in vitro in nine lung
cancer cell lines not expressing the MDR1 gene. In one
cell line, drug resistance was related with high expres-
sion of DNA topoisomerase II (Narasaki et al., 1997).
Furthermore, a positive correlation between MRP gene
expression in three cell lines and the modulatory effect
of verapamil on etoposide was demonstrated. These data
were not confirmed in SCLC cells, thus suggesting that
MRP is likely to be involved in intrinsic multidrug re-
sistance in NSCLC rather than in SCLC (Narasaki et
al., 1997). As a matter of fact, NSCLC and SCLC differ
in their clinical response to topoisomerase II-directed
drugs, such as etoposide and teniposide, as NSCLC is
virtually insensitive to single-agent therapy, while
SCLC responds in two-thirds of cases (Kreisholt et al.,
1998). Preclinical studies demonstrated that resistance
to topoisomerase II inhibitors depends on enzyme con-
tent and activity as well as on P-gp and MRP. Immuno-
cytochemical analysis of untreated tumor tissue from 27
cases of NSCLC and 29 cases of SCLC demonstrated
that NSCLC had significantly less topoisomerase II
than SCLC, as only 5 of 27 NSCLC cases had more than
5% positive cells compared with 28 of 29 SCLC, and 0 of
27 NSCLC had more than 25% positive cells compared
with 26 of 29 SCLC tissue specimens (Kreisholt et al.,
1998). P-gp was detected in more than 5% of cells in only
3 of 27 NSCLC and 6 of 29 SCLC, and MRP in 5 of 27
NSCLC and 9 of 29 SCLC. After treatment of patients
with either etoposide or teniposide there was a signifi-
cant increase in MRP and P-gp expression in SCLC,
while topoisomerase II decreased (Kreisholt et al.,
1998). In conclusion, the major difference between
NSCLC and SCLC was in topoisomerase II content,
which is in turn related to the clinical activity of etopo-
side (Kreisholt et al., 1998).
E. Vinca Alkaloids
Vinorelbine is a semisynthetic vinca alkaloid in which
the catharanthine moiety contains an eight-membered
ring in place of the nine-membered ring that is present
in all naturally occurring compounds of the vinblastine
group (Fig. 2). This modification selectively reduces the
interaction with anoxal versus mitotic microtubules and
may account for the lower neurotoxicity with improved
antitumor activity observed in clinical trials in patients
with NSCLC. Vinorelbine leads to phosphorylation of
Bcl-2 on serine residues, leading to inactivation of this
protein and facilitating the unopposed action of the pro-
apoptotic protein Bax (Haldar et al., 1997). This mech-
anism of action is also possessed by docetaxel; indeed,
preclinical in vitro data on the reciprocal enhancement
of chemotherapeutic activity of vinorelbine and do-
cetaxel provided evidence that the combination of two
microtubule-active agents is active (Aoe et al., 1999; Zoli
et al., 1999) due to the distinct drug targets on tubulin,
yet converging on Bcl-2/Bax balance that ultimately re-
sults in the triggering of apoptosis (Wang et al., 1999).
These findings are in agreement with the results of a
clinical trial on the combination of vinorelbine 45 mg/m2
by i.v. bolus injection followed by docetaxel 60 mg/m2 as
a 1-h i.v. infusion given every 2 weeks in 35 chemother-
apy-naive patients with advanced NSCLC (Miller et al.,
2000). The objective response rate was 51%; with a me-
dian follow-up of 14 months, the predicted median sur-
vival time was 14 months, and the 1-year survival rate
was 60%. Febrile neutropenia occurred in five patients
and symptomatic onycholysis and excessive lacrimation
were observed after several months of therapy, while no
dose-limiting neurotoxicity occurred. Thus, the do-
cetaxel and vinorelbine combination is an active regi-
men for the treatment of advanced NSCLC (Miller et al.,
2000). In vitro chemosensitivity testing by a collagen
gel-droplet embedded culture system on 146 surgically
resected specimens of NSCLC, with 45% of them show-
ing abnormal p53 accumulation in 10% of cancer cells
(p53) and 55% showing 10% positive cancer cells
(p53), demonstrated no relationship between p53 pro-
tein status and in vitro chemosensitivity to the vinca
alkaloid vindesine (Higashiyama et al., 1998). This re-
sult is not unexpected in view of the effect of vinca
alkaloids on the cell cycle, which is dependent on the
interference with mitotic spindle function to block cells
at the G2/M phase; therefore, cell death occurs in a
p53-independent way. The investigation of the clinical
efficacy of combination chemotherapy with p53 gene
therapy has nonetheless attracted great interest for the
role of p53 in the cell death induced by other antitumor
drugs, including alkylating agents. For these reasons,
studies aimed at restoring normal p53 function by
means of adenovirus-expressing wild-type p53 in tumors
with deleted or mutated p53 have been carried out. In a
phase II study gene therapy was complemented with
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simultaneous cisplatin and vinorelbine treatment (Bou-
lay et al., 2000). The efficiency of gene transduction was
monitored by biopsies of neoplastic tissue obtained from
all treated patients before and 24 to 48 h after gene
therapy. In most of the cases the p53 target gene
p21Waf1/Cip1 was upregulated, especially when the injec-
tion of higher doses of p53-expressing adenovirus was
combined with simultaneous chemotherapy (Boulay et
al., 2000). Interestingly, a clear p21Waf1/Cip1 gene re-
sponse was observed only in tumors showing stabiliza-
tion or regression. Hence, p21Waf1/Cip1 appears to be
upregulated after adenovirus-mediated p53 gene trans-
fer, and it is apparently the most sensitive marker
tested for biological response to gene therapy in NSCLC
(Boulay et al., 2000). However, the benefit of p53 gene
therapy has yet to be fully demonstrated because a re-
cent phase II study on 25 patients with unresectable
NSCLC failed to provide a clear additional benefit from
intratumoral p53 delivery compared to the effect that
can be achieved by effective first-line chemotherapy.
Indeed, patients received three cycles of carboplatin
(AUC 6; day 1) plus paclitaxel (175 mg/m2, day 1), or
cisplatin (100 mg/m2, day 1) plus vinorelbine (25 mg/m2,
days 1, 8, 15, and 22) in combination with intratumoral
injection on day 1 of 7.5  1012 particles of the recom-
binant adenoviral vector SCH 58500 carrying a wild-
type p53 (Schuler et al., 2001). There was no difference
between the response rate of lesions treated with p53
gene therapy in addition to chemotherapy (52% objective
responses) and lesions treated with chemotherapy alone
(48% objective responses) (Schuler et al., 2001). Sub-
group analysis according to the chemotherapy regimens
revealed evidence for increased mean local tumor re-
gressions in response to additional p53 gene therapy in
patients receiving cisplatin-vinorelbine, but not in pa-
tients receiving carboplatin-paclitaxel (Schuler et al.,
2001). There was no survival difference between the two
chemotherapy regimens, and the median survival of the
cohort was 10.5 months (1-year survival, 44%). Efficient
p53 transduction was confirmed in tumor samples from
68% of patients, and toxicities attributable to gene ther-
apy were mild to moderate (Schuler et al., 2001). Possi-
ble explanations to the findings of this study are the
following: 1) the enhancement of cytotoxic activity fol-
lowing p53 transduction is expected from the alkylating
agents cisplatin and carboplatin, not from drugs, such as
paclitaxel and vinorelbine, acting on the p53-indepen-
dent G2/M phase of the cell cycle; 2) efficient wild-type
p53 transduction may reduce the fraction of cells that
progress to the G2/M phase of the cell cycle, which is
sensitive to microtubule-active anticancer drugs; and 3)
adenoviral infection of deep portions of the tumor mass
may be negligible, thus preventing efficient TP53 gene
delivery.
A possible advantage in restoring normal p53 function
may be explained by the correlation observed between
p53 and MRP in NSCLC. Indeed, the analysis of 107
NSCLCs for MRP and p53 expression by immunohisto-
chemistry demonstrated that 43.9% specimens were
positive for MRP, and tumor tissues with mutant p53
showed a significant correlation with MRP overexpres-
sion (Oshika et al., 1998). Twenty-six patients with
MRP-positive tumors who underwent postoperative che-
motherapy with MRP-related anticancer drugs, includ-
ing vindesine, had significantly poorer prognoses than
did those with MRP-negative tumors (P  0.017). This
correlation between MRP expression and prognosis was
also seen in stage III patients (P 0.022) and in patients
with squamous cell carcinoma (P 0.062) (Oshika et al.,
1998). NSCLC patients with coexpression of MRP and
p53 showed poorer prognoses than did those without
MRP and p53 (P  0.014) (Oshika et al., 1998). These
results suggest that MRP overexpression affected by
mutant p53 has a significant effect on prognosis through
non-P-gp-mediated multidrug resistance in NSCLC (Os-
hika et al., 1998).
In addition to the mechanism of drug resistance to
vinca alkaloids, including vinorelbine, vindesine, vin-
cristine, and vinblastine, mediated by MRP, P-gp also
represents an important drug transport system that
plays a relevant role in the limitation of cytotoxic activ-
ity of vinca alkaloids. Despite the chemical modification
of vinorelbine, the drug is a P-gp substrate and displays
cross-resistance with other drugs transported by P-gp.
Indeed, vinorelbine-resistant, murine P388 leukemia
cells were cross-resistant to P-gp-transportable drugs,
including vinblastine and vincristine, but not to the
alkylating agents cyclophosphamide, carmustine, and
cisplatin or to the antimetabolites 5-fluorouracil and
methotrexate (Adams and Knick, 1995). Cellular resis-
tance to vinorelbine was stable without drug exposure
during continuous passage in vivo for more than 10
weeks and in vitro for at least 5 weeks. P388-resistant
cells exhibited increased expression of P-gp and a 30-fold
level of resistance of vinorelbine in vitro, which was
completely reversible with verapamil (Adams and
Knick, 1995). Therefore, enhanced expression of the
MDR1 gene renders cells cross-resistant to several cyto-
toxic agents and antagonizes the antitumor effect of
vinca alkaloids, including vinorelbine. For these rea-
sons, P-gp antagonists have been developed to revert the
drug-resistant phenotype to drug sensitivity. First-gen-
eration P-gp antagonists were characterized by low po-
tency and occurrence of adverse effects (i.e., verapamil);
on the contrary, the more recent compounds showed
enhanced activity and ability to chemosensitize cells to
several cytotoxic agents. In particular, GF120918, at
250 ng/ml, increased the sensitivity of a multidrug-re-
sistant SCLC cell line (H69/LX4) to the P-gp substrates
paclitaxel, taxotere, vinblastine, vinorelbine, and etopo-
side to levels that were either greater (in the case of
etoposide) or close to that of the parent cell line (Myer et
al., 1999). This was achieved despite the remarkable
variation in the levels of resistance of the cell line for
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various anticancer drugs tested, and even in the case of
high levels of resistance, as was the case for paclitaxel
and taxotere (Myer et al., 1999).
No data are available on the effect of c-MYC expres-
sion on the chemotherapeutic activity of vinorelbine.
The inhibition of c-MYC gene expression by an inducible
antisense expression vector in the SCLC cell line
GLC4cDDP, containing c-MYC gene amplification and
resistant to cisplatin, did not result in modification in
the pattern of cell chemosensitivity to vincristine, thus
suggesting a limited impact of c-MYC gene function on
cytotoxicity by vinca alkaloids (Van Waardenburg et al.,
1997).
F. Ifosfamide and Cyclophosphamide
Ifosfamide (Fig. 2) and cyclophosphamide are alkylat-
ing agents widely used for the treatment of solid tumors
and hematological malignancies including NSCLC,
breast cancer, and lymphomas. Although studies ad-
dressing the influence of MYC amplification on the che-
motherapeutic effect of ifosfamide or cyclophosphamide
are not available in the literature, a study of 90 patients
with SCLC demonstrated that amplification of one of the
MYC family genes was detected in 3 of 40 (8%) untreated
patient specimens compared to 19 of 67 (28%) samples
from treated subjects, the difference being statistically
significant (P  0.01) (Brennan et al., 1991). In addition
to this, the amplification of MYC DNA copy number
occurred in 17 of 54 (31%) of the specimens from patients
treated with chemotherapeutic combinations including
cyclophosphamide (Brennan et al., 1991). These results
demonstrate that MYC family DNA amplification occurs
more commonly in specimens from treated than un-
treated patients, thus suggesting that chemotherapy ex-
erts a selective pressure to the development of cells with
amplified MYC genes.
Ex vivo chemosensitivity of human NSCLC obtained
from 28 cases of primary tumors showed that TP53
mutations were associated with resistance to cyclophos-
phamide-etoposide-epirubicin (Vogt et al., 2002). Fur-
thermore, wild-type TP53 gene transfer by adenoviral
vectors in the human NCI-H157 squamous cell lung
carcinoma, and the human NCI-H1299 large cell lung
cancer, induced a modest increase in the anticancer
efficacy of cyclophosphamide in vitro and the analysis of
interaction demonstrated an additive effect between cy-
clophosphamide and wild-type TP53 transduction
(Osaki et al., 2000).
Mutated K-RAS constitutes an adverse prognostic fac-
tor in stage I or II lung cancer and has been linked to
resistance to ionizing radiations and some therapeutic
agents. For these reasons, its inclusion in the staging
system of lung cancer, together with TNM classification,
has been proposed (Rosell et al., 1995). To determine
whether the clinical course and the response to chemo-
therapy of patients with advanced adenocarcinoma of
the lung depends on the presence or absence of a K-RAS
mutation, patients with advanced adenocarcinoma of
the lung were treated with ifosfamide, carboplatin, and
etoposide, and genotypical analysis of their tumor sam-
ples was performed to demonstrate the presence of K-
RAS gene mutations (Rodenhuis et al., 1997). K-RAS
mutations could be established in 69 of 83 patients
(83%); chemotherapy with ifosfamide, carboplatin, and
etoposide was administered to 62 patients, 16 of whom
were shown to have a K-RAS mutation-positive tumor
(Rodenhuis et al., 1997). The patterns of metastases,
response, and survival were similar between the K-RAS
mutation-positive and K-RAS mutation-negative groups
(Rodenhuis et al., 1997). Therefore, patients with ad-
vanced lung adenocarcinoma who harbor a K-RAS mu-
tation may have major responses to chemotherapy and
have similar progression-free and overall survival as
patients with K-RAS mutation-negative tumors (Roden-
huis et al., 1997). At variance with these data, a study in
40 patients with stage III NSCLC who underwent tumor
resection after neoadjuvant treatment with ifosfamide,
carboplatin, and etoposide and subsequent radio-chemo-
therapy with carboplatin and vindesine demonstrated
that K-RAS codon 12-point mutations were found in 13
of 28 resection specimens (46%) and, even after complete
resection, the presence of a K-RAS mutation was a sig-
nificant predictor for a poor progression-free survival
(Broermann et al., 2002).
G. Novel Agents
1. Topoisomerase I Inhibitors. Topotecan and irino-
tecan (Fig. 4) are semisynthetic derivatives of campto-
thecin with potent topoisomerase I inhibitory activity
and a wide range of antitumor efficacy in vitro and in
vivo. Topotecan and irinotecan, like other DNA-damag-
ing agents, arrests or delays cell cycle progression dur-
ing S and G2 phases in a wide variety of tumor-derived
cell lines. Particularly, the G2 arrest gives time for the
cell to repair DNA lesions before starting a new cell
cycle. For these reasons, the control of these restriction
points plays a relevant role in the modulation of anti-
cancer effect by topoisomerase I inhibitors. A study ex-
amined the effect of the introduction of mutant TP53
gene into the NCI-H460 cell line, which carries a wild-
type TP53 gene, and the introduction of wild-type TP53
gene into NCI-H1437, NCI-H727, NCI-H441, and NCI-
H1299 cells, which carry a p53 mutated at amino acid
residues 143, 175, 248, and 273, respectively (Lai et al.,
2000). The representative cell line NCI-H1437 cells
transfected with wild-type TP53 gene showed a dra-
matic increase in the susceptibility to camptothecin. An
increase in chemosensitivity was also observed in wild-
type TP53 transfectants of NCI-H727, NCI-H441, and
NCI-H1299 cells (Lai et al., 2000). In contrast, loss of
chemosensitivity and a lack of p53-mediated DNA deg-
radation in response to anticancer agents were observed
in NCI-H460 cells transfected with mutant TP53. These
observations suggest that TP53 gene status modulates
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the extent of chemosensitivity and the induction of ap-
optosis by different anticancer agents in NSCLC cells,
including the topoisomerase I inhibitor camptothecin
(Lai et al., 2000). Wild-type TP53 gene transfer in a
human pulmonary squamous cell carcinoma, the NCI-
H157 cell line, and a human pulmonary large cell carci-
noma, the NCI-H1299 cell line, enhanced in a supra-
additive manner the effectiveness of 7-ethyl-10-hydroxy-
camptothecin (SN-38), the active metabolite of
irinotecan on NCI-H157 cells, while an additive effect
was observed on NCI-H1299 cells (Osaki et al., 2000).
These findings suggest that irinotecan may thus be use-
ful as a possible anticancer agent in a combination ther-
apy regimen using wild-type TP53 gene transfer (Osaki
et al., 2000). In line with these observations, the com-
bined treatment of human lung cancer cell lines, NCI-
H1299 (deleted p53), RERF-LC-OK (mutant p53), and
A549 (wild-type p53), with anticancer drugs, including
irinotecan, and a recombinant adenoviral vector ex-
pressing wild-type TP53 cDNA, increased the sensitivity
to the drug, regardless of the cellular TP53 status, and a
synergism was observed by the isobologram analysis
(Inoue et al., 2000). The study of the interaction between
topotecan and the G2/M-active agent etoposide in the
TP53-mutated NCI-H23 NSCLC cell line demonstrated
that short-term sequential topotecan3etoposide treat-
ment was effective in inducing cytotoxicity in cancer
cells (Taron et al., 2000). Detailed analysis of results
evidenced that: 1) sequential topotecan3etoposide was
synergistic when drug administration overlapped the
maximum percentage of topotecan-induced G2/M phase
cell arrest interval; and 2) the reverse sequential sched-
ule (etoposide3topotecan) was only additive, thus pro-
viding evidence of sequence-dependent effects of anti-
cancer treatment (Taron et al., 2000). Using a panel of 7
NSCLC cell lines with wild-type (2 cell lines) or abnor-
mal (2 null and 3 point-mutated cell lines) TP53, it was
demonstrated that the in vitro combined effects of the
DNA-damaging agent SN-38 and the adenoviral vector
carrying wild-type TP53 was synergistic with respect to
cytotoxicity on six of seven cell lines and additive against
a p53-mutated cell line (Horio et al., 2000). Flow cyto-
metric and DNA fragmentation analyses revealed that a
sublethal dose of TP53-adenoviral vector augmented the
apoptotic response induced by SN-38 in six of seven cell
lines, thus demonstrating that wild-type TP53 transduc-
tion may enhance the chemosensitivity of NSCLCs to
DNA-damaging agents (Horio et al., 2000). Topotecan
displays potent growth inhibitory activity on the human
lung cancer cell lines NCI-H460 (wild-type p53) and
NCI-H322 (mutant p53). Induction of apoptosis after
treatment is concentration- and time-dependent, and
treatment with topotecan at IC80 was most effective in
triggering DNA fragmentation (Tolis et al., 1999). DNA
analysis by flow-cytometry indicates that topotecan at
IC80 causes accumulation of cells in S and G2/M phases
and induces the expression of both p53 and p53-related
target p21Waf1/Cip1 in the NCI-H460 cell line but not in
NCI-H322, which carries a mutant p53 (Tolis et al.,
1999). The percentage of cells expressing p53 is highest
at IC80 values, whereas the highest percentage of
p21Waf1/Cip1 positive cells could be induced by in vitro
FIG 4. Chemical structures of investigational agents for the treatment of NSCLC.
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treatment at IC50 values, suggesting that p53 induces
cell cycle arrest at low drug concentrations and apopto-
sis at higher concentrations (Tolis et al., 1999). These
findings provide evidence of the important role of p53
and related targets, including p21Waf1/Cip1, on the re-
sponse of NSCLC cells to topoisomerase I inhibitors.
Preliminary findings indicate that CDKN2A
(p16INK4a) enhanced the cytotoxicity of topoisomerase I
inhibitors in NSCLC cells (Nishio et al., 1997). Indeed,
gene transduction provided evidence that the sensitivity
of p16INK4a-transfected A549 cells was increased by up
to 9.1-fold with respect to irinotecan and SN-38, as com-
pared with parental, p16INK4a deleted A549 cells
(Fukuoka et al., 1997). Furthermore, the topoisomerase
I-mediated DNA relaxation activity in p16INK4a-trans-
duced cells was approximately five times higher than
those of the parental A549 cells (Fukuoka et al., 1997).
RNA and protein analyses indicated that increased to-
poisomerase I activity of p16INK4-transduced cells was
dependent on increased enzyme mRNA and protein lev-
els (Fukuoka et al., 1997). Thus, p16INK4a transduction
is able to restore the chemosensitivity to topoisomerase
I inhibitors by means of the increment in topoisomerase
I mRNA level, protein content, and activity in cells pre-
viously lacking functional p16INK4a (Fukuoka et al.,
1997). Further analysis of the effect of p16INK4a trans-
duction on the in vitro chemosensitivity of A549 NSCLC
cells to the topoisomerase I inhibitor irinotecan showed
that transfected cells were more prone to undergo apo-
ptosis with respect to p16INK4a-deleted parental A549
(Fukuoka et al., 2000). Apoptosis was suppressed by
inhibitors of interleukin-1-converting enzyme (ICE/
caspase-1) or ICE-like proteases, as determined by DNA
fragmentation and proteolytic cleavage of poly(ADP-ri-
bose) polymerase, a natural substrate for caspase-3
(Fukuoka et al., 2000). In CDKN2A-transfected A549
cells, cytosolic peptidase activities increased during iri-
notecan-induced apoptosis and were suppressed by the
highly specific caspase-3 and caspase-3-like inhibitor,
Z-DEVD-fluoromethyl-ketone (Fukuoka et al., 2000).
These findings indicate that p16INK4a is involved in the
activation pathway of caspase-3 induced by irinotecan,
in addition to its regulatory activity on topoisomerase I
levels (Fukuoka et al., 2000). Furthermore, a delay in
S-phase progression and induction of apoptosis were
observed after treatment with irinotecan in CDKN2A-
transduced A549 cells, which also displayed down-regu-
lation of cyclin A, whereas cyclin B, cdk2, and cdc2
protein levels were unaffected (Fukuoka et al., 2000).
Recent findings demonstrate that overexpression of
Bcl-2 and p21Waf1/Cip1 in the human A549 NSCLC cell
line induces resistance to apoptosis to a variety of anti-
cancer drugs, including camptothecin (Zhang et al.,
1999). The multidrug-resistant cell line A549CPT was
established by in vitro selection with camptothecin, and
A549CPT cells were resistant to drug-induced apoptosis
because of remarkable attenuation of caspase-3-like pro-
tease activity compared with parental A549 cells (Zhang
et al., 1999). The main mechanisms associated with re-
sistance to apoptosis in A549CPT cells were overexpres-
sion of anti-apoptotic Bcl-2 and p21Waf1/Cip1 (Zhang et
al., 1999). Transfection of either Bcl-2 or p21Waf1/Cip1
cDNA into parental A549 cells resulted in resistance to
apoptosis, and the cotreatment of p21Waf1/Cip1 and Bcl-2
antisense oligodeoxynucleotides restored drug suscepti-
bility in A549CPT cells more effectively than either one of
them alone (Zhang et al., 1999). These results indicate
that coinduction of Bcl-2 and p21Waf1/Cip1 in A549CPT
cells may be involved in acquired drug resistance
against anticancer agents, such as topoisomerase I poi-
sons, by inhibiting caspase-mediated apoptosis (Zhang
et al., 1999). In addition to this, transfection of the
NCI-H460 human NSCLC cell line with the anti-apop-
totic genes Bcl-2 or Bcl-xL is associated with increased
clonogenic survival of cells treated with topotecan, from
16% to 45–46%, thus confirming that the cytotoxic effect
of topotecan is antagonized by Bcl-2 and Bcl-xL (Fer-
reira et al., 2000a). Finally, resistance to irinotecan has
been observed in a Bcl-2-transfected human SCLC cell
line, SBC-3Bcl-2, as compared with the parental line
SBC-3, while there was no difference in sensitivity to
cisplatin and paclitaxel between SBC-3 and SBC-3Bcl-2
(Ohmori et al., 1993).
The overexpression of the MDR1 gene encoding P-gp
is associated with a drug-resistant phenotype against
topotecan, as shown in KB-V1 cells, selected for vinblas-
tine resistance, and in NIH3T3 cells, transfected with a
plasmid expressing P-gp (NIH-MDR-G185) (Hoki et al.,
1997). However, NIH-MDR-G185 cells displayed no sig-
nificant resistance to other topoisomerase I inhibitors,
such as 9-aminocamptothecin, camptothecin, and SN-
38, while KB-V1 cells were cross-resistant to these com-
pounds (Hoki et al., 1997). The expression of the drug
transport systems P-gp and MRP1 and 2 do not seem to
play a relevant role in drug resistance to camptothecin
and SN-38 (Cummings et al., 2002b); therefore, addi-
tional mechanisms, including enhanced clearance by
glucuronidation from cancer cells (Cummings et al.,
2002a), mutation of the topoisomerase I gene (Urasaki et
al., 2001), and reduced levels of topoisomerase I, result-
ing in decreased enzyme activity (Pommier et al., 1999)
are likely to be implicated. The clinical relevance of
these findings remains to be demonstrated, however,
since topotecan does not apparently induce P-gp expres-
sion, and multidrug-resistant tumors are usually not
resistant to topotecan (Houghton et al., 1995). The study
of the cytotoxic effects of SN-38 on multidrug-resistant
human glioblastoma GB-1 cells and nondrug-resistant
human glioblastoma U87-MG cells demonstrated that
SN-38 is significantly more active against GB-1 and
U-87MG cells than camptothecin (Nakatsu et al., 1997).
Furthermore, DNA analysis showed that SN-38 induced
apoptosis in these tumors, thus suggesting that SN-38
has significant cytotoxic activity on malignant glioma
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cells regardless of the expression of drug-resistant mech-
anisms (Nakatsu et al., 1997). Additional studies on the
role of P-gp in drug resistance against topoisomerase I
inhibitors demonstrated that camptothecin produced
equivalent amounts of cell growth inhibition and/or
DNA single-strand breaks in the drug-sensitive (AuxB1)
and multidrug-resistant (CHRC5) Chinese hamster
ovary cells, while topotecan, SN-38, and 9-aminocamp-
tothecin were up to 12-fold less toxic to the multidrug-
resistant cells than to the wild-type cells (Mattern et al.,
1993). These findings are consistent with differences in
yields of DNA single-strand breaks produced in AuxB1
and CHRC5 cells by treatments with the various com-
pounds (Mattern et al., 1993). The resistance ratios of
the topoisomerase I inhibitors were approximately one-
tenth those of drugs known to be substrates of P-gp;
thus, cells that overexpress P-gp have the potential to
develop some level of cross-resistance to the topoisomer-
ase I inhibitors (Mattern et al., 1993). Nonetheless, to-
potecan has a substantial therapeutic effect on B6D2F1
mice implanted with multidrug-resistant sublines of
P388 leukemia compared with its effect on mice im-
planted with wild-type P388 cells (Mattern et al., 1993).
Limited data are available in the literature concern-
ing the role of the activated RAS oncogene in cellular
responses to topoisomerase I inhibitors. The transduc-
tion of the viral H-RAS oncogene in NCI-H82 human
SCLC was associated with a 2-fold increase in topoisom-
erase I activity and a 1.7-fold decrease in the IC50 for
camptothecin (Kaufmann et al., 1995). These changes
resulted in 30-fold lower survival of NCI-H82rasH cells
compared with parental NCI-H82 cells at camptothecin
concentrations as low as 10 nM (Kaufmann et al., 1995).
Although these data were obtained by gene transduction
in a SCLC cell line, it may be speculated that in NSCLC
cells bearing an isolated RAS mutation the increase in
topoisomerase I associated to DNA may facilitate the
occurrence of lethal strand breaks by topoisomerase I
inhibitors and cell death.
2. Epidermal Growth Factor Receptor Inhibi-
tors. ZD1839 (Iressa), OSI-774 (Fig. 4), and C225
(cetuximab) are agents that target the interaction be-
tween EGFR (ErbB-1) and EGF or block signal trans-
duction mediated by EGF (Ciardiello and Tortora, 2001).
The critical role of the EGF autocrine loop in cancer
progression has led to an extensive search for selective
inhibitors of the EGFR signaling pathway. The results of
a large body of preclinical studies and the early clinical
trials thus far conducted suggest that targeting the
EGFR could represent a significant contribution to can-
cer therapy (Ciardiello and Tortora, 2001). A variety of
different approaches are currently being used to inhibit
cell signaling through EGFR. The most promising strat-
egies in clinical development include monoclonal anti-
bodies to prevent EGF binding and small molecule in-
hibitors of the tyrosine kinase activity that inhibit
autophosphorylation and downstream intracellular sig-
naling (Ciardiello and Tortora, 2001). At least five block-
ing monoclonal antibodies have been developed against
the EGFR (ErbB-1). Among these, IMC-C225 (Cetux-
imab) is a chimeric human-mouse monoclonal IgG1 an-
tibody that has been the first anti-EGFR targeted ther-
apy to enter clinical evaluation in cancer patients, alone
or in combination with radiotherapy or chemotherapy. A
number of small molecule inhibitors of the EGFR ty-
rosine kinase enzymatic activity are also in develop-
ment. Preclinical and clinical findings indicate that
ZD1839 (Iressa) and OSI-774 are active against a broad
spectrum of tumors, particularly NSCLC, and have an
acceptable safety profile.
The comparison of mRNA expression of EGFR, HER-
2/neu, and survival in primary tumors and matching
nonmalignant tissues from 83 patients with NSCLC
demonstrated that EGFR and HER-2/neu mRNAs were
detectable in all specimens analyzed (Brabender et al.,
2001). Twenty-nine (34.9%) and 28 (33.7%) patients had
high HER-2/neu and EGFR expression, respectively.
High HER-2/neu and EGFR coexpression were detect-
able in 14 (16.9%) patients and were associated with
shorter survival (P  0.004), whereas high EGFR ex-
pression showed only a trend toward inferior survival
(P  0.176) (Brabender et al., 2001). The impact of
HER-2/neu and EGFR coexpression on patients’ sur-
vival was additive (P  0.003), and multivariate analy-
sis determined high HER-2/neu expression (P  0.041)
and high EGFR/HER-2/neu coexpression (P  0.030)
as significant and independent unfavorable prognostic
factors (Brabender et al., 2001). These findings indicate
that HER-2/neu and EGFR play a crucial role in the
biological behavior of NSCLC, and the high prevalence
of tumors with elevated EGFR expression justify the
targeting of the EGFR signal transduction to treat
NSCLC (Brabender et al., 2001). To study the prognostic
value of the expression of EGFR (ErbB-1), HER-2/neu
(ErbB-2), and p53, and the amplification of EGFR, HER-
2/neu, and HER-3 (ErbB-3) in NSCLC, tumor tissue
specimens from 118 patients with NSCLC were exam-
ined (Reinmuth et al., 2000). Most NSCLC tissue spec-
imens analyzed were aneuploid (81%), 14% showed pos-
itive staining for EGFR, 18% for p185HER-2/neu, and 41%
for p53. There were normal mean gene copy numbers in
86% for EGFR, 94% for HER-2/neu, and in 96% for
HER-3. No significant correlations were noted among
EGFR, p185HER-2/neu, and p53 expression, ploidy status
and tumor stage (Reinmuth et al., 2000). The molecular
analysis of 65 samples from normal lung and tumor
tissue demonstrated that lung tumors with abnormali-
ties of TP53 at exons 4–8 had a significantly higher
EGFR content (P  0.001), S phase fraction (P  0.007),
DNA index (P 0.017), and a lower proportion of cells in
G1/G0 phase (P  0.04) than lung tumors with no such
TP53 gene mutations (Lopez-Guerrero et al., 1998). In
normal lung the cellular growth fraction decreases sig-
nificantly with the intensity of p53 expression, and the
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lack of biologically functional p53 is apparently related
to fast-growing lung cancers (Lopez-Guerrero et al.,
1998). To determine the combined effect of growth factor
receptor and tumor-suppressor gene abnormalities on
the prognosis of NSCLC, 290 tumor specimens compris-
ing 155 cases of stage I, 30 cases of stage II, 96 cases of
stage III, and 9 cases of stage IV were examined by
immunohistochemical staining on formalin-fixed, paraf-
fin-embedded materials to detect EGFR and p53 in tu-
mor tissue (Ohsaki et al., 2000). Histological subtypes
included 142 adenocarcinomas, 127 squamous cell car-
cinomas, 17 large cell carcinomas, and 4 other types of
malignancy (Ohsaki et al., 2000). Positive staining for
EGFR was demonstrated in 124 (42.8%) cases; more
EGFR-positive cases were found in squamous cell carci-
nomas than in nonsquamous cell carcinomas (P 
0.0121). Staining for p53 protein was observed in 147
(50.7%) specimens (Ohsaki et al., 2000). Multivariate
proportional hazard modeling of data revealed that
EGFR protein expression was a risk factor (P  0.0240);
patients negative for both EGFR and p53 survived for a
longer period of time (P  0.0427) (Ohsaki et al., 2000).
Although the relationship between target expression
and therapeutic efficacy of EGFR inhibitors has not been
examined in these studies, it may be speculated that the
high incidence of tumors overexpressing EGFR is the
prerequisite for activity of inhibitors and that p53 ab-
normalities should not be relevant for the activity of
such inhibitors, since their mechanism of action does not
involve DNA damage and does not require the activation
of a p53-dependent apoptotic pathway to induce cell
death.
The study of the expression of ErbB-1, K-RAS gene
mutations and c-MYC gene amplification was performed
in tumor and normal lung tissues from 100 patients with
NSCLC. The amount of EGFR in 97 tumor and 82 nor-
mal tissues was 16.0 	 3.7 and 10.8 	 2.0 fmol/mg,
respectively (mean 	 S.D., P  0.015) (Sekine et al.,
1998). Overexpression of the EGF receptor was observed
in 6 (24.0%) of 25 squamous cell carcinomas, 16 (23.2%)
of 69 adenocarcinomas, and 23 (23.7%) of a total of 97
tumors. K-RAS mutations were observed in 9 of 100
tumors; of these, 5 (55.6%) mutations were in codon 12,
1 (11.1%) was in codon 22, and 3 (33.3%) were in codon
61 (Sekine et al., 1998). The patterns of the mutations
were GC transversions in three (33.3%) tumors, GC
transitions in two (22.2%), and AT transversions in four
(44.4%) tumors. There was no association between
EGFR overexpression and K-RAS mutation; c-MYC am-
plification was studied in 23 neoplastic tissues but was
not detected (mean number of copies  1.28 	 0.24)
(Sekine et al., 1998). Of note, the expression of c-MYC is
influenced strongly by the presence of growth factors,
such as EGF (Niklinski et al., 2001). For these reasons,
the mutual interaction between the c-MYC oncogene
and EGF might be disrupted by the use of EGFR inhib-
itors. The oncogenes c-MYC and TGF- are frequently
overexpressed in human bronchiolo-alveolar adenocarci-
nomas, and experiments in transgenic mice demonstrate
that c-MYC and EGF are directly involved and cooperate
with one another during formation of bronchiolo-alveo-
lar adenocarcinomas in the lung (Ehrhardt et al., 2001),
thus providing additional evidence on the role of c-MYC
and growth factors in NSCLC tumorigenesis. In addition
to this, Southern blot analysis revealed coamplification
of ErbB-1 (7p12) and c-MYC (8q24) (Taguchi et al.,
1997). In a group of 81 human squamous cell carcinomas
of the lung, overexpression of ErbB-1 oncoprotein
(EGFR) was detected in 79% of the tumors, HER-2/neu
in 35%, and c-MYC in 48%; patients with ErbB-1 posi-
tive tumors had a poor prognosis (Volm et al., 1992). In
addition, these tumors were more frequently drug-resis-
tant; therefore, EGFRs may serve as prognostic factors
for the aggressiveness of squamous cell carcinomas of
the lung and for the response of these tumors to chemo-
therapy (Volm et al., 1992).
3. Folic Acid Analogs. The pyrrolopyrimidine-based
antifolate pemetrexed (LY231514, Fig. 4) is a multitar-
geted folate analog in which a pyrrole ring replaces the
pyrazine moiety of the pterine portion of folic acid and a
methylene group replaces the benzylic nitrogen in the
bridging portion of the molecule (Mendelsohn et al.,
1999). While this compound inhibits thymidylate syn-
thase, it also inhibits other folate-dependent enzymes
including dihydrofolate reductase, aminoimidazole car-
boxamide ribonucleotide formyltransferase, and glyci-
namide ribonucleotide formyltransferase (Mendelsohn
et al., 1999). Like other folic acid analogs, it is a sub-
strate of folylpolyglutamate synthase; the drug is effi-
ciently metabolized to highly polyglutamated active spe-
cies by this enzyme and utilizes the reduced folate
carrier for entry into the cell to exert its antitumor
activity (Mendelsohn et al., 1999). Pemetrexed has
shown a broad spectrum of anticancer activity, including
NSCLC in humans (Rusthoven et al., 1999). The admin-
istration of pemetrexed 600 mg/m2 every 3 weeks to 59
chemotherapy-naive patients with surgically incurable
NSCLC was associated with an overall response rate of
15.8%; the median duration of response was 4.9 months,
and the median survival was 7.2 months. The principal
toxicities were myelosuppression and rash (Clarke et al.,
2002).
The analysis of cytotoxicity by novel folic acid antag-
onists on the NCI-H69/P SCLC cell line and its multi-
drug-resistant subline NCI-H69/LX4, which overex-
presses MDR1, as well as on COR-L23/P large cell line
and its subline COR-L23/R overexpressing MRP, dem-
onstrated that H69/LX4 and COR-L23/R sublines both
showed clear cross-resistance to a number of folic acid
antagonists associated with a marked reduction in cel-
lular drug accumulation (Robson et al., 1998). Vera-
pamil, as a drug-resistance modifier, showed little activ-
ity, whereas cyclosporin A was more active and partially
restored drug accumulation in H69/LX4 overexpressing
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P-gp. Hence, novel antifolates appear to be substrates
for both the P-gp and MRP resistance mechanisms (Rob-
son et al., 1998).
VII. Integrated Analysis of Drug Activity:
Pharmacoproteomics and Pharmacogenomics
Proteins are the key mediators of cellular behavior,
and understanding how proteins direct cellular changes
from normal to malignant phenotype and the process of
adaptation and resistance to toxicity induced by antican-
cer agents is of key importance to control these changes
and improve treatments. Along with the growing knowl-
edge of genomics, substantial efforts are underway to
understand the encoded information, a challenge mainly
conceived as proteomics (Naaby-Hansen et al., 2001;
Whitelegge and Le Coutre, 2001). Proteomics is a newly
coined term that refers to the study of the proteome, the
protein products of the genome (Wasinger and Corthals,
2002). The opportunities offered by proteomics are not
limited to a list of all the proteins; indeed, the scientific
target of proteomics is to characterize the flow of infor-
mation within the cell, which is mediated by networks of
proteins that organize in discrete signal transduction
pathways (Liotta et al., 2001). The critical issues of
anticancer drug sensitivity and toxicity, treatment opti-
mization, and drug target identification are analyzed at
the genomic and proteomic levels by pharmacogenomics
and pharmacoproteomics, two distinct disciplines that
provide separate and complementary classes of informa-
tion. Direct analysis of tumor tissues offers obvious ad-
vantages since genomic and proteomic analysis of cul-
tured cell lines, when compared with microdissected
cells from the same patient, revealed a significant lack of
correlation in expression patterns (Liotta et al., 2001).
While this was not unexpected, it emphasizes the need
for the development of microtechnologies to analyze the
proteomic profile in small tumor samples obtained from
clinical specimens. Laser capture microdissection pro-
vides access to cells directly from tissue specimens; how-
ever, the limited availability of patient material urges
scientists to develop new highly sensitive methodologies
for proteomic profiling of human malignancies. The lim-
itations of two-dimensional gel electrophoresis, the
mainstay of most proteomic analysis, are being over-
come by new approaches to protein characterization,
including high-density protein arrays, antibody arrays,
and small molecular arrays (Liotta et al., 2001). Surface-
enhanced laser desorption/ionization time-of-flight
(SELDI-TOF) mass spectrometry is a novel approach to
protein analysis that combines chromatography and
mass spectrometry. One of the key features of SELDI-
TOF mass spectrometry is its ability to provide a rapid
protein expression profile from a variety of biological
and clinical samples, and it has been used for biomarker
identification and for the study of protein-protein and
protein-DNA interaction (Issaq et al., 2002).
The application of protein research to the response
of tumors to drugs led to valuable advances in the
understanding of pharmacodynamics of anticancer
agents. The study of the effect of butyrate, a fatty acid
that causes growth arrest and apoptosis of cancer
cells, using two-dimensional gel electrophoresis and
matrix-assisted laser desorption/ionization time-of-
flight (MALDI-TOF) mass spectrometry, evidenced
that drug treatment resulted in alterations in the
proteome of HT-29 cells (Tan et al., 2002). These
changes included components of the ubiquitin-protea-
some system, and both pro-apoptotic (caspase-4 and
cathepsin D) and anti-apoptotic proteins (hsp27, anti-
oxidant protein-2, and pyruvate dehydrogenase E1)
were up-regulated in butyrate-treated cells, some of
them (cathepsin D and hsp27) showing a time-depen-
dent increase in expression (Tan et al., 2002). Treat-
ment with 5-azacytidine leads to a decrease in cell
growth of lymphoma cell line DG 75 with an arrest at
the G0/G1 phase of the cell cycle and increased expres-
sion of p16INK4a because of promoter demethylation.
Proteomic study evidenced that 5-azacytidine treat-
ment affected protein expression; some of the up-reg-
ulated proteins appeared related to the energy metab-
olism, cytoskeleton organization, cell viability, and
protein synthesis (Poirier et al., 2001). The analysis of
quantitative changes in the protein composition of the
CEM T-lymphoblasts after treatment with a cyclin-
dependent kinase inhibitor demonstrated significant
down-regulation of -enolase, triosephosphate isomer-
ase, eukaryotic initiation factor 5A, and - and -sub-
units of Rho GDP-dissociation inhibitor 1. These pro-
teins are known to play an important role in cellular
functions such as glycolysis, protein biosynthesis, and
cytoskeleton rearrangement (Kovarova et al., 2000).
One additional application of proteome research is
the study of the multidrug resistance phenotype in
cancer cells, which results from protein-mediated
drug detoxification, cellular drug transport, and DNA
replication and repair mechanisms (Hutter and Sinha,
2001). Protein analysis has been applied to the study
of drug-resistant phenotype toward daunorubicin, mi-
toxantrone, etoposide, cisplatin, fotemustine, and vin-
desine (Poland et al., 2002). Finally, proteomic profile
analysis appears to be a valuable tool for identifica-
tion of proteins that may serve as cancer-specific bi-
omarkers for early detection and biologic profiling.
Using the approach of laser capture microdissection
followed by separation by two-dimensional gel electro-
phoresis and analysis by mass spectrometry, the 52-
kDa FK506 binding protein, Rho G-protein dissocia-
tion inhibitor, and glyoxalase I were found to be
selectively overexpressed in invasive human ovarian
cancer with respect to tumors with low malignant
potential (Jones et al., 2002).
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VIII. Concluding Remarks
Lung cancer is the most common cause of cancer death
worldwide. There is a continued search for novel screen-
ing methods and evaluation of molecular events or in-
termediate biomarkers, not only to detect those subjects
at higher risk of developing the disease, but also to
assess the likelihood of response to chemotherapeutic
treatments and select novel targets for improved thera-
pies (Rosell et al., 2001). In this context, the application
of pharmacogenetics and postgenomic techniques has
the potential to improve the management of patients
with lung cancer, particularly by providing the molecu-
lar basis for choosing among the increasing number of
chemotherapeutic agents available for the treatment of
NSCLC.
Most of the scientific literature available thus far
deals with the analysis of few, if not just one, genetic
markers of the disease, and this has been the limitation
of translational studies on genetics of NSCLC. Genome-
wide expression profiling is an important tool for func-
tional genomic studies and represents a unique oppor-
tunity to speed up the process of identifying correlations
between genotype and clinical course in individual pa-
tients. Automated technology allows high-throughput
gene activity monitoring by analysis of complex expres-
sion patterns, resulting in fingerprints of diseased ver-
sus normal or developmentally distinct tissues. Differ-
ential gene expression can be most efficiently monitored
by DNA hybridization on arrays of oligonucleotides or
cDNA clones. Starting from high-density filter mem-
branes, cDNA microarrays have recently been devised in
chip format to make gene expression profiling a useful
tool for the identification of genetic abnormalities ame-
nable for anticancer drug development (Johnson, 2001).
The same cDNA libraries can be used for high-through-
put protein expression and antibody screening on high-
density filters and microarrays. These libraries connect
recombinant proteins to clones identified by DNA hy-
bridization or sequencing, hence creating a direct link
between genes and functional proteins. Clone libraries
become amenable to database integration including all
steps from DNA sequencing to functional assays of gene
products (Bu¨ssow et al., 2001). In the future, pharma-
coproteomics will represent a distinct scientific field ded-
icated to the analysis of the interaction between drugs
and protein targets for drug discovery and treatment
optimization. This novel technology will allow avoiding
the problem of the frequent lack of concordance between
gene expression, as evidenced by mRNA levels within
the cell, and protein accumulation (Anderson and Seil-
hamer, 1997). Although most practical proteomics is
being done with bidimensional gels and mass spectrom-
etry, including specialized techniques such as matrix-
assisted laser desorption/ionization time-of-flight mass
spectrometry for high-throughput screening, there are
protein chip technologies under development. One of the
first is surface-enhanced laser desorption ionization,
which is showing the potential for discovery of novel
cancer biomarkers (Vastag, 2000).
Finally, pharmacogenomics, owing to the continuous
development of technology and bioinformatics, has the
potential to enhance the ability of pharmacologists to
increase knowledge of the mechanism of action of drugs
and the interaction with the genetic background of indi-
vidual subjects, and clinicians to use anticancer agents
in a safer and more effective manner.
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